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Thesis summary 
Myoclonus dystonia (MD) is a neurogenic movement disorder that can be caused by 
mutations in the SGCE gene encoding ε-sarcoglycan. ε-sarcoglycan belongs to the 
sarcoglycan family of cell surface-localised, single-pass transmembrane proteins originally 
identified in muscle where they form a heterotetrameric subcomplex of the dystrophin-
associated glycoprotein complex (DGC). Mutations in the SGCA, SGCB, SGCG and SGCD 
genes encoding α-, β-, γ- and δ-sarcoglycan cause limb-girdle muscular dystrophy (LGMD). 
There is no phenotypic overlap between MD and LGMD. LGMD-associated sarcoglycan 
mutations impair trafficking of the entire sarcoglycan complex to the cell surface and 
destabilise the DGC in muscle, while MD-associated mutations typically result in loss of ε-
sarcoglycan from the cell surface. This suggests cell surface ε-sarcoglycan but not other 
sarcoglycans is required for normal brain function. To gain insight into ε-sarcoglycan’s 
function(s) in the brain, immunoaffinity purification was used to identify ε-sarcoglycan-
interacting proteins. Ubiquitous and brain-specific ε-sarcoglycan isoforms co-purified with 
three other sarcoglycans including ζ-sarcoglycan (encoded by SGCZ) from the brain. 
Incorporation of an LGMD-associated β-sarcoglycan mutant into the brain sarcoglycan 
complex impaired the formation of the βδ-sarcoglycan core but failed to abrogate the 
association and trafficking of ε- and ζ-sarcoglycan in heterologous cells. Both ε-sarcoglycan 
isoforms also co-purified with β-dystroglycan, indicating inclusion in DGC-like complexes. 
Additionally, the brain-specific ε-sarcoglycan isoform co-purified with the perineuronal net 
component tenascin-R, potentially suggesting a unique function for this isoform in 
modulating synapses. In common with SGCE, transcripts from the genes encoding α-, β-, δ-, 
γ- and ζ-sarcoglycans were found to undergo extensive alternative splicing, in some cases 
producing novel isoforms that affected assembly and trafficking of the sarcoglycan complex. 
In summary, data presented herein show that alternatively spliced sarcoglycan isoforms are 
part of the DGC in brain. These data contribute to our understanding of MD pathophysiology 
and the role of the sarcoglycan protein family. 
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Chapter 1: General introduction 
1.1. Introduction 
Dystonia is a movement disorder characterised by involuntary, abnormal muscle contractions 
leading to abnormal postures and/or movements. It was first described in 1911 by Hermann 
Oppenheim as “dystonia musculorum deformans” (Albanese et al., 2013). Though for many 
years regarded as a psychogenic condition, it is now commonly accepted that dystonia arises 
from neurological dysfunction (Frucht, 2013). It can occur in a number of contexts including 
neurological trauma, infection, metabolic disease and as part of a genetic disorder (Geyer and 
Bressman, 2006).  
This chapter will provide an overview of dystonia with particular emphasis on the monogenic 
dystonias. The focus of this thesis is on Myoclonus Dystonia (MD), 20-80% of cases of 
which are caused by mutations in SGCE encoding ε-sarcoglycan (Asmus et al., 2009, Gerrits 
et al., 2006, Nardocci et al., 2008, Peall et al., 2013, Ritz et al., 2009, Tezenas du Montcel et 
al., 2006). Therefore, MD and the sarcoglycans will be discussed in detail. Thesis aims will 
be outlined at the end of the chapter. 
1.2. Overview of dystonia 
The abnormal movements and postures seen in patients with dystonia are generated by 
simultaneous activation of both agonist and antagonist muscles. Dystonic movements tend to 
be patterned, can display motor overflow into adjacent muscles, and involve the same group 
of muscles each time. Voluntary movements may exacerbate or trigger dystonic movements 
(Albanese et al., 2013, Geyer and Bressman, 2006, Phukan et al., 2011, Sitburana et al., 
2009). Some patients find that a sensory trick (“geste antagoniste”) such as a light touch to  
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the affected area can temporarily 
ameliorate dystonia (Kagi et al., 
2013, Poisson et al., 2012, 
Ramos et al., 2014). Most cases 
of dystonia are not associated 
with gross structural 
abnormalities on cerebral 
imaging, and therefore dystonia 
is typically regarded as a 
disorder of neurofunction 
(Breakefield et al., 2008, Geyer 
and Bressman, 2006).  
1.2.1. Classification of 
dystonia 
The most recent consensus on 
dystonia phenomenology and 
classification subdivides 
dystonia along two principal 
axes: clinical features and 
aetiology, as summarised in 
table 1.1 (Albanese et al., 2013).  
Axis I. Clinical characteristics 
 
Age at onset Infancy (birth-2yrs) 
Childhood (3-12yrs) 
Adolescence (13-20yrs) 
Early adulthood (21-40yrs) 
Late adulthood (>40yrs) 
Body 
distribution 
Focal 
Segmental 
Multifocal 
Generalised 
Hemidystonia 
Temporal 
pattern 
Disease 
course 
Static 
Progressive 
Day-to-
day 
Persistent 
Diurnal 
Action-specific 
Paroxysmal 
Associated 
features 
Isolated (dystonia and tremor 
only) 
Combined with other movement 
disorder(s) 
Additional neurological/systemic 
features 
Axis II. Aetiology 
 
Origin Inherited Autosomal dominant 
Autosomal recessive 
X-linked recessive 
Mitochondrial 
Acquired Brain injury 
Vascular 
Neoplastic 
Perinatal brain injury 
Toxin 
Drug 
Infection 
Psychogenic 
Idiopathic Sporadic 
Familial 
Neuropathology Neurodegeneration 
Structural lesions 
Neither 
Table 1.1 Classification of dystonia according to (Albanese et al., 2013). 
Under the most recent consensus update on dystonia classification, dystonia 
can be divided along two axes: clinical characteristics and aetiology. This 
table provides the complete proposed system for classifying dystonia. 
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1.2.1.1. Axis I: clinical features 
A major clinical classification is by distribution of dystonia-affected body parts. Focal 
dystonias affect a single region of the body, and include cervical dystonia, blepharospasm, 
writer’s cramp or hand dystonia, and spasmodic dysphonia or laryngeal dystonia. If dystonia 
affects multiple contiguous muscle groups it is referred to as segmental, in contrast to 
multifocal dystonia where multiple non-contiguous muscle groups are affected. Hemidystonia 
involves multiple muscle groups on one side of the body only, while generalised dystonia 
involves the trunk and at least two other body regions.   
Age at onset is grouped into five classes: infancy (0-2 years at onset), childhood (3-12 years), 
adolescence (13-20 years), early adulthood (21-40 years) or late adulthood (>40 years) 
(Albanese et al., 2013). Early onset typically correlates with a more severe phenotype that is 
more likely to progress with time (Albanese et al., 2013). However, a substantial delay 
between onset and diagnosis can complicate determining age at onset (Phukan et al., 2011).  
Dystonia may also be subdivided by whether it occurs in isolation (only dystonia is present) 
or in combination with other movement disorder(s) (combined dystonia) (Albanese et al., 
2013, Balint and Bhatia, 2014). The isolated dystonias include syndromes featuring dystonia 
and tremor only, whereas combined dystonias can feature other movement disorders such as 
myoclonus, parkinsonism or spasticity (Albanese et al., 2013). In combined dystonias, the 
non-dystonic movement disorder(s) may be more prominent and/or the presenting feature 
(Albanese et al., 2013, Balint and Bhatia, 2014, Fung et al., 2013).  
1.2.1.2. Axis II: aetiology 
Within the aetiology axis, the principle division is between inherited, acquired and idiopathic 
dystonias (Albanese et al., 2013). Acquired dystonias stem from known insults to the central 
nervous system (CNS), while inherited dystonias have a defined genetic cause. Idiopathic 
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dystonias currently have no known cause, but may be reassigned to one of the other two 
categories with further study.  
1.2.2. Neuroanatomy 
Multiple brain regions have been implicated in the pathogenesis of dystonia. Originally, the 
basal ganglia were regarded as the principal brain region involved in dystonia as basal 
ganglia lesions were frequently observed in association with dystonia in both humans and 
animal models (Bhatia and Marsden, 1994, Lehéricy et al., 2013, Neychev et al., 2011, 
Wilson and Hess, 2013). However, lesional studies have also implicated other regions 
including the cerebellum, cortex and brainstem in dystonia (LeDoux and Brady, 2003, 
Matsumura et al., 1992, Matsumura et al., 1991, Neychev et al., 2011, Prudente et al., 2013). 
Notably, subtle cerebellar alterations such as reduced Purkinje cell numbers have been 
identified in some patients with dystonia, while specific disruption of cerebellar function can 
produce dystonia in model animals (LeDoux and Brady, 2003, Ma et al., 2012, Pizoli et al., 
2002, Prudente et al., 2013, Raike et al., 2013).  
Neuroimaging studies have also implicated multiple regions in dystonia. Case-control 
analyses using voxel-based morphometry, positron emission tomography (PET), and 
functional magnetic resonance imaging (fMRI) have consistently demonstrated differences in 
the basal ganglia, cortex, cerebellum and thalamus of patients with dystonia compared to 
healthy controls (Carbon et al., 2009, Carbon et al., 2004, Draganski et al., 2009, Egger et al., 
2007, Lehéricy et al., 2013, Suzuki et al., 2007). Diffusion tensor imaging (DTI) examines 
water movement in the brain, which is influenced by the white matter microstructure; DTI 
studies of patients with dystonia have found altered connectivity between motor control 
regions including the cerebellum and basal ganglia (Argyelan et al., 2009, Carbon et al., 
2008, Carbon et al., 2004, Cheng et al., 2012).  
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Animal models also implicate multiple brain regions in dystonia. Lesions and administration 
of stimulants or inhibitors to the basal ganglia, cerebellum, pre-motor cortex, motor cortex, 
and thalamus can all induce dystonia in animal models (Neychev et al., 2011). Cell type-
specific knockout of genes including Atp1a3, Itpr1, and Sgce (section 1.2.4) in the 
cerebellum or striatum can also produce dystonic phenotypes (Fremont et al., 2015, Hisatsune 
et al., 2013, Yokoi et al., 2012a, Yokoi et al., 2012b). Additionally, dystonia in the dt rat 
(Atcay mutation) and Tottering mouse (Cacna1a mutation) can be prevented by ablation of 
the cerebellum, cerebellar outputs, or the cerebellar Purkinje cells alone (Campbell et al., 
1999, LeDoux, 2011, LeDoux et al., 1993, LeDoux et al., 1995, Neychev et al., 2008).  
1.2.3. Neurophysiological abnormalities in dystonia 
The general neurophysiological abnormalities observed in dystonia can be grouped into three 
broad themes: loss of inhibition, sensory dysfunction, and abnormal neural plasticity 
(Quartarone and Hallett, 2013).  
1.2.3.1. Loss of inhibition 
Normal movements are thought to involve both activation of the required muscle(s) and 
surround inhibition of other muscles to ensure movement specificity. Failure of surround 
inhibition would cause movement overflow into unintended muscles, as seen in dystonia 
(Hallett, 2011, Quartarone and Hallett, 2013). Reduced surround inhibition has been 
demonstrated for several dystonias including focal hand, cervical, blepharospasm, segmental 
and generalised dystonias (Berardelli et al., 1985, Nakashima et al., 1989, Quartarone et al., 
2005, Ridding et al., 1995, Rona et al., 1998, Tisch et al., 2006a, Tisch et al., 2006b). 
GABAergic signalling may be involved in surround inhibition, since injecting the GABA-A 
antagonist bicuculline into the motor or pre-motor cortex of monkeys results in increased 
neuronal activity and co-contraction of antagonist muscles during movement (Matsumura et 
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al., 1992, Matsumura et al., 1991). Subsequent PET, magnetic resonance spectroscopy (MRS) 
and MRI studies have provided mixed support for GABA abnormalities in the basal ganglia 
and cortex of dystonia patients compared to healthy controls (Garibotto et al., 2011, Herath et 
al., 2010, Levy and Hallett, 2002).  
1.2.3.2. Impaired sensorimotor integration 
Although dystonia can appear a “pure” motor disorder, sensory symptoms have been reported 
in many forms of dystonia: pain is associated with cervical dystonia, while blepharospasm 
patients often report photosensitivity and other ocular symptoms (Patel et al., 2014). Sensory 
input can modify dystonia as demonstrated by symptom reduction with sensory tricks, 
reduced dystonic movements after topical anaesthetic application, and worsening of dystonia 
by vibration (Kaji et al., 1995). Patients with dystonia also have difficulty in discriminating 
between temporally or spatially separated stimuli (Bara-Jimenez et al., 2000a, Bara-Jimenez 
et al., 2000b, Molloy et al., 2003, Scontrini et al., 2009). These deficits might relate to the 
disorganisation of somatotopic representation reported in both humans with dystonia and 
primate models of dystonia (Patel et al., 2014, Quartarone and Hallett, 2013). This suggests a 
defect of integration between sensory input and motor control in dystonia. 
1.2.3.3. Maladaptive neural plasticity 
Neural plasticity allows the brain to remodel connections in response to changes in input and 
desired output, but abnormal plasticity is thought to erode motor control and so contribute to 
dystonia (Neychev et al., 2011, Quartarone and Hallett, 2013, Sadnicka et al., 2014). Several 
studies have used transcranial magnetic stimulation (TMS) to identify enhanced plasticity of 
multiple regions in patients with different types of focal dystonia (Meunier et al., 2012, 
Quartarone et al., 2003, Quartarone et al., 2008, Weise et al., 2011, Weise et al., 2006). A 
similar study of individuals with dystonia-associated TOR1A mutations (section 1.2.4.1) 
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identified enhanced plasticity in individuals with dystonia but reduced plasticity in non-
manifesting carriers, suggesting a protective effect of reduced plasticity (Edwards et al., 
2006). This supports abnormal plasticity as a driver of dystonia rather than a consequence.  
1.2.4. The monogenic dystonias: insights into the molecular aetiology of dystonia 
Since the late 1990s, substantial progress has been made in identifying the genes responsible 
for inherited dystonias. There are approximately 21 genetically defined dystonic disorders at 
the time of writing, although evidence for some of these is still preliminary (table 2.1).    
1.2.4.1. Isolated dystonias 
TOR1A: DYT1 early-onset generalised dystonia 
The most extensively researched heritable form of isolated dystonia is DYT1 early-onset 
generalised dystonia caused by autosomal dominant mutations in TOR1A. This severe 
dystonic disorder typically begins in early life (5-28 years) with focal limb dystonia that then 
spreads, usually sparing the craniocervical region (Bressman et al., 2000). It has a penetrance 
of 30-40%, in part due to a missense SNP that complements pathogenic mutations (Bressman 
et al., 1989, Risch et al., 1990, Risch et al., 2007). The most common TOR1A mutation is 
deletion of a GAG trinucleotide (ΔGAG), which removes a glutamate residue from the 
encoded torsinA protein to produce torsinA ΔE (Ozelius et al., 1997, Vulinovic et al., 2014).  
TOR1 is broadly expressed throughout the adult CNS with localisation of torsinA protein to 
the endoplasmic reticulum (ER) lumen, nuclear envelope (NE) and synaptic vesicles in 
neurons (Augood et al., 1999, Augood et al., 1998, Konakova et al., 2001, Konakova and 
Pulst, 2001, Naismith et al., 2004, Shashidharan et al., 2000). In heterotetrameric complexes 
with either NE-localised lamina-associated polypeptide 1 (LAP1) or ER-localised luminal 
domain like LAP1 (LULL1), torsinA becomes a functional AAA+ ATPase  
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DYT 
designation 
Disorder Gene Encoded protein Inheritance Status 
Isolated dystonia 
    
 
DYT1 Early-onset generalised dystonia TOR1A TorsinA ADom Confirmed  
DYT6 Adolescent-onset dystonia of mixed type THAP1 Thanatos-associated protein domain-
containing apoptosis-associated protein 1 
ADom Confirmed 
 
DYT25 Adult onset cranial-cervical dystonia GNAL Gαolf ADom Confirmed  
DYT4 Spasmodic/"whispering" dysphonia TUBB4A β-tubulin 4A ADom Confirmed  
DYT23 Adult onset cranial-cervical dystonia CIZ1 Cdkn1A-interacting zinc finger protein 1 ADom Unconfirmed  
DYT24 Adult onset cranial-cervical dystonia ANO3 Anoctamin-3/TMEM16C ADom Unconfirmed  
- Primary isolated dystonia HPCA Hippocalcin AR Novel  
DYT27 Isolated dystonia COL6A3 Collagen alpha-3 (VI) chain AR Dubious 
Combined dystonia 
    
 
DYT3 X-linked dystonia-parkinsonism, "lubag" TAF1 Transcription initiation factor TFIID subunit 1 XR Confirmed  
DYT5 
Dopa-responsive dystonia, Segawa 
syndrome 
GCH1 GTP cyclohydrolase 1 ADom Confirmed 
 
Dopa-responsive dystonia, Segawa 
syndrome 
TH Tyrosine hydroxylase AR Confirmed 
 
Dopa-responsive dystonia SPR Sepiapterin reductase AR Confirmed  
DYT8 Paroxysmal nonkinesigenic dyskinesia 1 MR1 Myofibrillogenesis regulator 1 ADom Confirmed  
DYT9/ 
DYT18 
Paroxysmal choreoathetosis with episodic 
ataxia and spasticity/Paroxysmal 
exertion-induced dyskinesia 
SLC2A1 Glucose transporter 1 ADom Confirmed 
 
DYT10 Paroxysmal kinesigenic dyskinesia and 
infantile convulsions 
PRRT2 Proline-rich transmembrane protein 2 ADom Confirmed 
 
DYT11 Myoclonus dystonia SGCE ε-sarcoglycan ADom 
(imprinted) 
Confirmed 
 
DYT12 Rapid-onset dystonia-parkinsonism ATP1A3 Sodium/potassium-transporting ATPase 
subunit alpha-3 
ADom Confirmed 
 
DYT16 Young-onset dystonia-parkinsonism PRKRA Interferon-inducible double-stranded RNA-
dependent protein kinase activator A 
AR Confirmed 
Chapter 1: General introduction 
 
[9] 
 
 
- Myoclonus dystonia-like CACNA1B Voltage-dependent N-type calcium channel 
subunit alpha-1B 
ADom Novel 
 
- Myoclonus dystonia RELN Reelin ADom Novel  
- Myoclonus dystonia KCTD17 BTB/POZ domain-containing protein KCTD17 ADom Novel 
Table 1.2 The monogenic dystonias. After Klein 2014. A complete list of the current genetically defined inherited dystonias. These are split by associated features in isolated dystonias 
(dystonia and tremor only) and combined dystonias (dystonia plus other signs). Disorders are marked as confirmed if they have been independently described by 2 different groups. Novel 
disorders were identified too recently for confirmation. COL6A3 is marked as dubious due to recent evidence that mutations in this gene may be common in healthy controls. Abbreviations: 
ADom, autosomal dominant; AR, autosomal recessive, XR, X-linked recessive.
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(Brown et al., 2014, Shashidharan et al., 2000, Sosa et al., 2014, Vander Heyden et al., 2009, 
Zhao et al., 2013a). NE TorsinA-LAP1 complexes rapidly induce structural reorganisation 
through LINC complex component displacement, implicating torsinA in nuclear envelope 
structure (Nery et al., 2008, Vander Heyden et al., 2009). In the ER, torsinA co-localises with 
known ER-associated protein degradation (ERAD) proteins and its absence inhibits 
degradation of specific ERAD targets (Nery et al., 2011). Consequently, torsinA is thought to 
contribute to the degradation of misfolded proteins and therefore inhibit stress responses. In 
keeping with this, overexpression of a TOR1A paralogue in C.elegans inhibits ER stress 
response onset while mouse fibroblasts deficient in torsinA have an increased stress response; 
torsinA expression can also reduce protein aggregates in cell and C.elegans models (Caldwell 
et al., 2003, Chen et al., 2010, McLean et al., 2002). Finally, torsinA interacts directly with 
the vesicle exocytosis protein snapin and motor complex component kinesin light chain 1 
(KLC1), and promotes endocytosis of polytopic membrane proteins (Granata et al., 2008, 
Kamm et al., 2004, Torres et al., 2004). TorsinA also inhibits neurite outgrowth, possibly 
through interactions with the cytoskeletal proteins vimentin and tubulin (Ferrari-Toninelli et 
al., 2004, Hewett et al., 2006). 
The ΔE mutation disrupts many of these interactions. TorsinA ΔE demonstrates enhanced 
translocation to the NE, but even in complex with LAP1 or LULL1 cannot hydrolyse ATP 
and therefore only slowly induces remodelling of the NE (Gonzalez-Alegre and Paulson, 
2004, Goodchild and Dauer, 2004, Naismith et al., 2009, Vander Heyden et al., 2009, Zhao et 
al., 2013a). In addition, torsinA ΔE cannot suppress protein aggregation and reduces ERAD 
efficiency compared to the wild-type protein (Caldwell et al., 2003, Nery et al., 2011). This is 
hypothesized to lead to toxic accumulation in neurons that compromises their function, 
potentially resulting in dystonia alongside disrupted NE structure (Nery et al., 2011).  
THAP1: DYT6 adolescent-onset dystonia of mixed type 
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The second dystonia gene identified was THAP1, partially penetrant dominant mutations in 
which cause an adolescent-onset dystonia that is typically craniocervical or upper limb at first 
with subsequent progression to segmental or generalised dystonia (Blanchard et al., 2011, 
Fuchs et al., 2009, Houlden et al., 2010, Xiromerisiou et al., 2012). THAP1 is expressed 
throughout the brain with temporal and regional regulation, and encodes Thanatos-associated 
protein domain-containing, apoptosis-associated protein 1 (THAP1) (Cayrol et al., 2007, 
Zhao et al., 2013b). Dimeric THAP1 binds specific 11-nucleotide DNA sequences and is 
thought to function primarily as a transcription factor regulating cell cycle progression 
(Bessiere et al., 2008, Blanchard et al., 2011, Cayrol et al., 2007, Clouaire et al., 2005, 
Roussigne et al., 2003, Sabogal et al., 2010, Sengel et al., 2011). THAP1 also binds the 
TOR1A promoter, although evidence for regulation of TOR1A expression by THAP1 is 
conflicting (Gavarini et al., 2010, Kaiser et al., 2010). Dystonia-associated THAP1 mutations 
reduce THAP1 stability and/or functionality, implicating perturbed neuronal gene expression 
in dystonia (Blanchard et al., 2011, Campagne et al., 2012, Sengel et al., 2011).  
GNAL: DYT25 adult-onset cranial-cervical dystonia 
Incompletely penetrant dominant mutations in GNAL cause craniocervical dystonia with a 
mean age at onset of 26 years (Fuchs et al., 2013, Vemula et al., 2013). Dystonia typically 
begins in the cervical region, subsequently progressing to the cranial musculature and 
occasionally other regions (Dauer, 2014, Fuchs et al., 2013, Vemula et al., 2013). GNAL 
encodes Gαolf, a G protein α subunit originally identified in olfactory neurons and paralogous 
to Gαs but specifically enriched in the cerebellar Purkinje cells and striatum where Gαs 
expression is low (Drinnan et al., 1991, Herve et al., 1993, Zhuang et al., 2000). Striatal D1 
dopamine receptors and adenosine A2A receptors therefore rely on Gαolf alone for intracellular 
signalling (Corvol et al., 2001, Herve et al., 2001, Kull et al., 2000, Zhuang et al., 2000). 
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Most dystonia-associated GNAL mutations are loss-of-function, so abnormal striatal response 
to dopaminergic input may underlie GNAL mutation-positive dystonia (Fuchs et al., 2013). 
CIZ1: DYT23 Adult-onset cervical dystonia 
Several CIZ1 mutations have been identified in patients showing cervical dystonia and tremor 
with a mean age at onset of 35 years, although the pathogenicity of some mutations has not 
yet been confirmed (Dufke et al., 2015, Uitti and Maraganore, 1993, Xiao et al., 2012). CIZ1 
is widely expressed in many tissues and encodes Cdkn1A-interacting zinc finger protein 1 
(Mitsui et al., 1999, Warder and Keherly, 2003). CIZ1 interacts with cell cycle regulatory 
proteins and nuclear matrix proteins through its N- and C-terminal regions respectively, and 
coordinates replication initiation at DNA replication origins (Ainscough et al., 2007, 
Copeland et al., 2010, Coverley et al., 2005, Liu et al., 2016). Correspondingly, CIZ1 
hyperphosphorylation inhibits the initiation of DNA replication (Copeland et al., 2015). How 
this might contribute to dystonia pathogenesis is currently unknown. 
ANO3: DYT24 craniocervical dystonia 
Mutations in ANO3 cause adult-onset tremor and focal craniocervical dystonia progressing to 
segmental (Charlesworth et al., 2012, Ma et al., 2015, Miltgen et al., 2016, Stamelou et al., 
2014, Zech et al., 2014b). ANO3 is predominantly expressed in the nervous system, and 
encodes a member of the anoctamin/TMEM16 calcium-activated multi-pass transmembrane 
protein family (Huang et al., 2013, Kunzelmann et al., 2016, Picollo et al., 2015). Although 
ANO1 and ANO2 are calcium-activated chloride channels, so far no channel activity has 
been described for ANO3 (Kunzelmann et al., 2016, Picollo et al., 2015, Suzuki et al., 2013). 
Although its function remains unknown, recent studies found that ANO3 modulates KCNT1 
sodium-activated potassium channel kinetics, and alters cell surface phospholipid distribution 
in heterologous cells (Huang et al., 2013, Picollo et al., 2015, Suzuki et al., 2013).  
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TUBB4A: DYT4 spasmodic “whispering” dysphonia 
Specific TUBB4A mutations cause spasmodic “whispering” dysphonia with a mean age at 
onset of 30 years that progresses to generalised dystonia (Hersheson et al., 2013, Lohmann et 
al., 2013, Wilcox et al., 2011). In addition to dystonia, patients often have a distinctive 
“hobby horse” gait with a thin facial appearance and body habitus (Lohmann et al., 2013, 
Wilcox et al., 2011). TUBB4A expression is mostly restricted to the brain, and other 
mutations cause hypomyelinating leukodystrophy with microcephaly (Romaniello et al., 
2015). Dystonia-associated TUBB4A mutations predominantly affect the autoregulatory 
region of the encoded β-tubulin 4A protein and appear to reduce total β-tubulin 4A levels 
(Hersheson et al., 2013, Lohmann et al., 2013). How this causes dystonia is unknown. 
HPCA: autosomal recessive early-onset dystonia 
Autosomal recessive HPCA mutations have been identified in two families with childhood-
onset focal lower limb dystonia progressing to segmental or generalised dystonia with tremor 
(Charlesworth et al., 2015, Khan et al., 2003). To date, no additional families with HPCA-
associated dystonia have been identified (Dobricic et al., 2016). HPCA encodes the neuronal 
calcium sensor hippocalcin and is expressed primarily in hippocampus principal cells, 
cerebellar Purkinje cells and the striatum (Amici et al., 2009, Paterlini et al., 2000, Saitoh et 
al., 1993). In its calcium-bound state hippocalcin activates a number of pathways including 
clathrin adaptor AP2-dependent endocytosis of NMDA and AMPA glutamate receptors (Jo et 
al., 2010, Kobayashi et al., 2005, Oh et al., 2006, Palmer et al., 2005). Hippocalcin also 
activates KCNQ potassium channels, contributing to slow afterhyperpolarisation (Kim et al., 
2012, Tzingounis et al., 2007). Hippocalcin is thus thought to be important for synaptic 
plasticity, which is defective in dystonia (section 1.2.3.3).   
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1.2.4.2. Combined dystonias 
GCH1, TH, SPR: DYT5, Dopa-responsive dystonia 
The dopa-responsive dystonias (DRDs) are a heterogeneous group of dystonias characterised 
by a distinct response of symptoms to treatment with levodopa. Onset is typically in 
childhood with lower limb dystonia progressing to generalised dystonia and demonstrating 
diurnal variation (Wijemanne and Jankovic, 2015). DRD can be caused by loss of function or 
dominant negative mutations in three genes: autosomal dominant (ADom) or recessive (AR) 
mutations in GCH1 encoding GTP cyclohydrolase 1, AR mutations in TH encoding tyrosine 
hydroxylase, and AR mutations in SPR encoding sepiapterin reductase (Wijemanne and 
Jankovic, 2015). All three genes encode proteins essential for dopamine synthesis, so 
mutations in these genes potentially disrupt basal ganglia dopaminergic neurotransmission 
(Furukawa et al., 2002, Furukawa et al., 1999, Wijemanne and Jankovic, 2015).  
ATP1A3: DYT12 rapid-onset dystonia parkinsonism 
Rapid-onset dystonia-parkinsonism (RDP) is one of a spectrum of disorders caused by highly 
penetrant mutations in ATP1A3, which encodes the α3 subunit of the Na+, K+ ATPase (de 
Carvalho Aguiar et al., 2004, Sweney et al., 2015). RDP is characterised by sudden onset of 
dystonia in a rostral-caudal (face, arms, then legs) pattern after a significant stressor such as 
fever or physical trauma during adolescence or adulthood. Parkinsonian features are also 
prominent (Brashear et al., 2007, Sweney et al., 2015). The Na+, K+ ATPase comprises α, β, 
and regulatory γ subunits, and helps maintain the plasma membrane electrochemical gradient; 
there are multiple isomers of each subunit (Bottger et al., 2011, DeAndrade et al., 2011). 
Mutant α3 has a reduced affinity for Na+, impairing ion transport (Blanco-Arias et al., 2009, 
Einholm et al., 2010, Rodacker et al., 2006, Toustrup-Jensen et al., 2014). Distinct neuronal 
subtypes express different α-subunit combinations, so hypomorphic α3 may preferentially 
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affect certain brain regions (McGrail et al., 1991). Indeed, in mice loss of α3 activity 
specifically in the cerebellum causes dystonia with abnormal Purkinje cell firing (DeAndrade 
et al., 2011, Fremont et al., 2014, Fremont et al., 2015, Ikeda et al., 2013, McGrail et al., 
1991, Sugimoto et al., 2014). Therefore cerebellar dysfunction may be central to RDP. 
PRKRA: DYT16 young onset dopa-responsive dystonia and parkinsonism 
Dopa-responsive dystonia and parkinsonism caused by PRKRA mutations is characterised by 
adolescence-onset dystonia progressing to generalised dystonia, with evidence of mild 
parkinsonism in some patients (Camargos et al., 2008, Quadri et al., 2016, Zech et al., 
2014a). Ubiquitously expressed PRKRA encodes interferon-inducible double-stranded RNA-
dependent protein kinase activator A or PACT, which is phosphorylated under stress 
conditions. It activates the latent kinase PKR to modulate gene expression and stop cell cycle 
progression (García et al., 2007, Patel et al., 2000, Peters et al., 2006, Singh et al., 2011). 
PACT also affects small RNA molecule biogenesis through interactions with Dicer and 
Argonaute-2 (Lee et al., 2006). Mutant PACT alters PKR activation in response to stress, 
implicating a defective stress response in dystonia (Vaughn et al., 2015).  
X-linked dystonia parkinsonism DYT3, “Lubag” 
X-linked recessive dystonia parkinsonism (XDP) or lubag is most common amongst Panay 
Islanders with a mean age at onset of 39 years; it presents with focal dystonia that usually 
generalises within 6 years, although a few patients present with parkinsonism (Domingo et 
al., 2015, Lee et al., 2002, Lee et al., 2011). Over time the parkinsonian features typically 
become more prominent and progressive atrophy of the basal ganglia can be seen on cerebral 
imaging (Goto et al., 2005, Lee et al., 2002, Lee et al., 2011, Rosales, 2010, Waters et al., 
1993). Although linkage analysis and disequilibrium studies have refined the XDP locus to 
427kb on Xq13.1, no mutations in protein-coding regions have been identified (Domingo et 
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al., 2015). However, five disease-specific single nucleotide changes, a 48bp deletion and a 
SVA retrotransposon insertion within the critical XDP region are inherited together as a 
single haploblock co-segregating with the disease (Deng et al., 2008, Domingo et al., 2015, 
Makino et al., 2007). These variants are in the vicinity of TAF1 encoding transcription 
initiation factor TFIID subunit 1 (Domingo et al., 2015, Herzfeld et al., 2007). The XDP 
haplotype is hypothesised to reduce expression of specific neuronal TAF1 isoforms and/or 
affect splicing patterns (Makino et al., 2007, Muller et al., 2007, Sako et al., 2011).  
MR-1: DYT8 paroxysmal nonkinesigenic dyskinesia 
Paroxysmal nonkinesigenic dyskinesia (PNKD) is a childhood-onset disorder characterised 
by episodes of dystonia, chorea and ballism that are precipitated by factors including alcohol, 
caffeine, exercise, heat, hunger, stress and fatigue (Bruno et al., 2007). Highly penetrant 
autosomal dominant mutations in MR-1 encoding the myofibrillogenesis regulator 1 protein 
have been identified in multiple families with PNKD (Ghezzi et al., 2015, Lee et al., 2004, 
Rainier et al., 2004). MR-1 may function as a detoxifying enzyme, though a more recent 
study showed that it also interacts with synaptic RIM proteins to regulate neurotransmitter 
exocytosis (Shen et al., 2015, Shen et al., 2011b). MR-1 mutations typically affect cleavage of 
the N-terminus and alter protein stability (Ghezzi et al., 2009, Shen et al., 2011b). Mice 
carrying an Mr1 knock-in mutation recapitulate the human PNKD phenotype and show 
abnormal basal ganglia dopaminergic signalling, suggesting MR-1 may be involved in 
monoaminergic neurotransmission (Lee et al., 2012b).  
SLC2A1: DYT9 and DYT18 paroxysmal exercise induced dystonia and episodic ataxia 
Paroxysmal exercise-induced dyskinesia (PED) is a rare childhood-onset disorder 
characterised by dyskinesia with dystonia, chorea, ballism and athetosis after exercise (Weber 
et al., 2008). Reduced penetrance mutations in SLC2A1, encoding the glucose transporter 
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GLUT1, have been identified in several families with PED, placing PED within the broad 
clinical spectrum of GLUT1 deficiency syndrome (Schneider et al., 2009, Suls et al., 2008, 
Weber et al., 2008). GLUT1 is the principle transporter for glucose uptake into neurons, 
astrocytes and erythrocytes (Pearson et al., 2013). PED-associated SLC2A1 mutations reduce 
GLUT1 capacity for glucose transport, compromising CNS metabolism during periods of 
high energy demand (Suls et al., 2008, Weber et al., 2011, Weber et al., 2008).  
PRRT2: DYT10 and DYT19 paroxysmal kinesigenic choreoathetosis 
Patients with paroxysmal kinesigenic dyskinesia (PKD) have childhood or early adolescent 
onset of brief, frequent attacks combining dystonia and chorea, typically triggered by sudden 
movement (Silveira-Moriyama et al., 2013, Tan et al., 2014). Highly penetrant, autosomal 
dominant mutations in PRRT2 have been identified in some PKD patients (Bhatia and 
Schneider, 2012, Wang et al., 2011). PRRT2 is widely expressed in the brain, and most PKD-
associated mutations prevent synthesis of the encoded transmembrane protein (Heron et al., 
2012, Lee et al., 2012a, Valente et al., 2016, Wu et al., 2014).  PRRT2 protein localises to the 
axonal plasma membrane where it interacts with neurotransmitter release SNARE proteins 
and the fast calcium sensor synaptotagmin to regulate calcium-stimulated neurotransmitter 
release (Lee et al., 2012a, Li et al., 2015, Valente et al., 2016, Wu et al., 2014).  
Myoclonus-dystonia 
This will be discussed in section 1.3. 
1.2.4.3. Insights from the monogenic dystonias 
Genes implicated in monogenic dystonias are involved in a variety of biological pathways, as 
shown in Figure 1.1. However, there are several points of convergence. Dopaminergic 
signalling to the striatum is repeatedly implicated, firstly by the dopamine-responsive 
dystonias arising from deficiencies in dopamine synthesis. Gαolf is required for downstream 
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signalling from striatal D1 dopamine receptors, linking GNAL mutation-positive dystonia to 
dopaminergic signalling (Corvol et al., 2001, Herve et al., 2001, Kull et al., 2000, Zhuang et 
al., 2000). Additionally, patients with TOR1A and THAP1 mutations have reduced striatal 
dopamine receptor availability on cerebral imaging; therefore these genes may also be 
involved in basal ganglia dopaminergic signalling (Carbon et al., 2009). Other monogenic 
dystonias implicate intracellular calcium signalling. ANO3 and PRRT2 both encode calcium-
sensitive proteins, while hippocalcin (HPCA) is itself a calcium sensor. Abnormal calcium 
homeostasis and/or response could contribute to neuronal dysfunction resulting in dystonia. 
Overall, however, the monogenic dystonias also provide strong support for the view of 
dystonia as a network disorder. While the above genes appear to predominantly affect the 
basal ganglia, ATP1A3 mutations specifically affect cerebellar Purkinje cells and PRRT2 has 
been linked to multiple sensorimotor brain regions. This supports involvement of multiple 
brain regions in dystonia. 
Figure 1.1 Overview of cell pathways implicated in dystonia by the monogenic dystonias, after (Lohmann and Klein, 
2013). The proteins encoded by dystonia-associated genes have been implicated in a number of cellular pathways. These are 
summarised here, but as research into the functions of these genes continues this list will likely require amendment. 
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1.3. Myoclonus-dystonia (MD) 
1.3.1. Overview of MD 
The focus of this thesis is specifically on the rare combined dystonia Myoclonus Dystonia 
(MD). MD typically begins in the first two decades of life and is characterised by 
predominantly upper body myoclonic jerks with or without dystonia affecting the neck and/or 
arms (Asmus et al., 2009, Kinugawa et al., 2009, Nardocci et al., 2008, Peall et al., 2014, 
Raymond et al., 2008, Ritz et al., 2009, Roze et al., 2008). The myoclonus tends to worsen 
with activity or posture maintenance, and improve with alcohol (Kojovic et al., 2011, Li et 
al., 2008, Marelli et al., 2008, Quinn, 1996, Roze et al., 2008). Psychiatric symptomology is 
also prominent, particularly in SGCE mutation-positive MD patients (section 1.3.2.1) 
(Carecchio et al., 2013, Peall et al., 2016, Peall et al., 2011).   
1.3.2. Mutations in SGCE cause MD 
1.3.2.1. SGCE mutation-positive MD 
Linkage analysis of several large MD families in the 1990s linked MD to a 3.2Mb region at 
7q21 (Asmus et al., 2001, Klein et al., 2000b, Nygaard et al., 1999, Vidailhet et al., 2001, 
Zimprich et al., 2001). Sequencing of the 15 genes within this region revealed mutations in 
SGCE in affected individuals from six different MD families (Zimprich et al., 2001). 
Subsequent studies have detected pathogenic SGCE mutations or deletions in 20-80% of MD 
patients (Asmus et al., 2009, Gerrits et al., 2006, Grunewald et al., 2008, Han et al., 2003, 
Nardocci et al., 2008, Peall et al., 2013, Ritz et al., 2009, Schule et al., 2004, Tezenas du 
Montcel et al., 2006). The SGCE locus is maternally imprinted, and therefore typically only 
paternally inherited mutations cause MD. Studies of mice and humans demonstrated 
exclusive expression of SGCE from the paternal allele (Grabowski et al., 2003, Muller et al., 
2002, Piras et al., 2000). Additionally, the human SGCE promoter CpG island is almost 
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entirely methylated on the maternal chromosome but unmethylated on the paternal 
chromosome (Grabowski et al., 2003, Muller et al., 2002). A few cases of apparently 
maternally inherited SGCE mutation-positive MD have been reported, although a loss of 
imprinting was not clearly demonstrated in any of these (Asmus et al., 2002, Beukers et al., 
2011, Grabowski et al., 2003).  
SGCE mutation-positive MD is distinguished by onset of the movement disorder within the 
first decade, and a higher than expected incidence of psychiatric disorders (Carecchio et al., 
2013, Gerrits et al., 2006, Nardocci et al., 2008, Peall et al., 2014, Tezenas du Montcel et al., 
2006). Approximately two-thirds of patients are symptomatic for at least one psychiatric 
disorder, a rate greater than that seen in either the general population or cohorts with other 
chronic, disabling movement disorders (Carecchio et al., 2013, Nardocci et al., 2008, Peall et 
al., 2016, Peall et al., 2014, Peall et al., 2013, van Tricht et al., 2012, Weissbach et al., 2013). 
Therefore psychiatric disorders are unlikely to be a secondary effect of the movement 
disorder. SGCE mutation-positive MD is associated with a distinct psychiatric phenotype 
characterised by primarily compulsive obsessive-compulsive disorder (OCD), and anxiety 
(Carecchio et al., 2013, Hess et al., 2007, Nardocci et al., 2008, Peall et al., 2016, Peall et al., 
2014, Peall et al., 2013, Saunders-Pullman et al., 2002, van Tricht et al., 2012, Weissbach et 
al., 2013). Social phobia, panic disorder, generalised anxiety disorder, agoraphobia, attention 
deficit/hyperactivity disorder, psychosis and anorexia nervosa have also been described in 
patients with MD (Dale et al., 2011, Nardocci et al., 2008, Peall et al., 2016, Peall et al., 
2013, Peall et al., 2011, van Tricht et al., 2012). Alcohol misuse is also common. Though 
initially considered secondary to alcohol’s therapeutic effect on the movement disorder, 
recent studies suggest alcohol misuse may actually be a core phenotype of SGCE mutation 
(Hess et al., 2007, Peall et al., 2016, Peall et al., 2013, Saunders-Pullman et al., 2002, 
Weissbach et al., 2013).  
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1.3.2.2. SGCE encodes ε-sarcoglycan 
SGCE was originally identified as a widely-expressed paralogue of the muscle-restricted 
SGCA gene (Ettinger et al., 1997, McNally et al., 1998). Expression of SGCE is highest in the 
brain, with particular enrichment in midbrain monoaminergic neurons, cerebellar Purkinje 
cells and the olfactory bulb (Chan et al., 2005, Nishiyama et al., 2004, Xiao and LeDoux, 
2003). SGCE encodes the transmembrane glycoprotein ε-sarcoglycan (SG), a member of the 
sarcoglycan family of proteins (section 1.4). Similar to its paralogue α-SG, ε-SG is a type I 
Figure 1.2 Genomic architecture, alternative splicing and isoforms of human SGCE encoding ε-SG. A) The genomic 
architecture of the human SGCE gene, not to scale. After Ritz et al., 2011. B) The splicing pattern for each of the three main 
SGCE transcripts is depicted against the basic genomic architecture. Lines connect exons included in the mature transcript. 
The polypeptide encoded by each transcript is illustrated below with major domains marked. Red shading marks the signal 
peptide, which is cleaved off to produce the mature protein; yellow marks the transmembrane domain; blue marks the 
peptide encoded by exon 8; purple or pink represent isoform-specific sequences; and the red N represents the N-linked 
glycosylation site. 
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transmembrane glycoprotein consisting of a posttranslationally cleaved N-terminal signal 
peptide, extracellular region with a single N-linked glycan, transmembrane domain, and short 
intracellular region as shown in Figure 1.2 (Esapa et al., 2007, Ettinger et al., 1997).  
SGCE pre-mRNA undergoes general and tissue-specific alternative splicing. The Alu 
element-derived cryptic exon 10 is rarely included in the mature transcript, as are several 
other exons identified through RNA sequencing (Figure 1.2a) (Nishiyama et al., 2004, Ritz et 
al., 2011). By contrast, exon 11b is incorporated into approximately 30% of human SGCE 
transcripts in the brain only; exon 11b+ transcripts encode ε-SG isoform 2 with an extended 
intracellular C-terminal tail compared to the more widespread ε-SG isoform 1 (Figure 1.2b) 
(Nishiyama et al., 2004, Ritz et al., 2011, Yokoi et al., 2005). Also, exon 8 is spliced out of 
some SGCE brain transcripts through the activity of RNA binding protein SAM68 (Chawla et 
al., 2009, Nishiyama et al., 2004, Paronetto et al., 2011, Ritz et al., 2011, Yokoi et al., 2005). 
Intriguingly, ε-SG isoforms 1 and 2 may differ in cell type and subcellular localisation in the 
brain. Fractionation analysis of mouse brain lysates has suggested that only isoform 1 is 
present in capillary endothelial cells and astrocytes, while isoforms 1 and 2 have differential 
synapse localisation in neurons (Chan et al., 2005, Nishiyama et al., 2004). The differences in 
intracellular C-terminal tail sequence and localisation between the two main ε-SG isoforms 
suggest that brain-specific ε-SG isoform 2 could have an as-yet unknown unique brain-
specific function. No effects of exon 8 inclusion/exclusion have been identified so far. 
While α-SG requires stabilisation by other sarcoglycan proteins to be retained at the plasma 
membrane, ε-SG stably localises to the plasma membrane with or without other sarcoglycans 
(Draviam et al., 2006b, Esapa et al., 2007). In smooth muscle, peripheral nerve, adipose 
tissue and cardiac muscle, ε-SG is a component of prototypical sarcoglycan complexes that 
are part of dystrophin-associated glycoprotein complexes (DGCs) and DGC-like complexes 
(section 1.4.2-3) (Cai et al., 2007, Durbeej and Campbell, 1999, Groh et al., 2009, Imamura 
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et al., 2000, Lancioni et al., 2011, Straub et al., 1999). However, ε-SG’s function at the 
plasma membrane with or without other sarcoglycans is unclear. 
1.3.2.3. SGCE mutations associated with MD 
Cell surface ε-SG appears to be essential for normal neural function. SGCE sequence changes 
that cause MD include missense and nonsense point mutations, small insertions/deletions, 
whole gene deletions, and larger genomic deletions covering multiple genes (Asmus et al., 
2007, Dale et al., 2011, DeBerardinis et al., 2003, Grunewald et al., 2008, Peall et al., 2014). 
The same SGCE mutation can lead to a variety of MD phenotypes even within the same 
family (Foncke et al., 2006, Nardocci et al., 2008, Tezenas du Montcel et al., 2006). Most 
pathogenic SGCE mutations result in total ε-SG deficiency, but even those retaining some ε-
SG expression result in absence of ε-SG from the cell surface (Esapa et al., 2007, Waite et al., 
2011). When expressed in heterologous cells, missense ε-SG mutants are usually localised to 
the ER, polyubiquitinated and degraded by the proteasome (Esapa et al., 2007, Waite et al., 
2011). This contrasts with the predominantly plasma membrane and Golgi localisation of 
wild-type ε-SG in those same cells (Esapa et al., 2007, Waite et al., 2011). Most mutant ε-SG 
not degraded by the proteasome is still retained in the ER, while a cell surface trafficking-
competent mutant was degraded by the endosomal-lysosomal system (Waite et al., 2011). 
Therefore, SGCE mutations causing MD lead to absence of ε-SG from the plasma 
membrane/cell surface. 
1.3.2.4. Mouse models of SGCE mutation-positive MD 
Several mouse Sgce mutants have been generated. The first knockout allele involved deletion 
of exon 4, and resulted in complete loss of Sgce expression when paternally inherited or 
homozygous (Yokoi et al., 2006, Yokoi et al., 2005). Knockout mice exhibited spontaneous 
myoclonus and motor abnormalities, plus increased striatal dopamine levels associated with 
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reduced striatal dopamine receptor 2 and abnormal dopaminergic signalling (Yokoi et al., 
2006, Zhang et al., 2012). These mice also had a behavioural phenotype suggestive of 
psychiatric abnormalities, including significantly higher scores on anxiety measures and a 
trend toward higher scores on measures of depression-like behaviour (Yokoi et al., 2006). If 
Sgce exon 4 loss is restricted to the striatum, mice had no overt myoclonus or dystonia but 
displayed deficits in motor learning, coordination and balance deficits (Yokoi et al., 2012b). 
By contrast, specific Sgce knockout in the cerebellar Purkinje cells resulted in mice with a 
slight motor learning deficit but no additional phenotypes (Yokoi et al., 2012a). This supports 
involvement of multiple brain regions in the Sgce deficiency phenotype. A second Sgce 
knockout allele replacing exons 6-9 with a cassette encoding neo and β-galactosidase has 
been produced, but not characterised beyond absence of ε-SG protein and normal muscle 
sarcoglycan complexes (Lancioni et al., 2011). 
1.3.3. Neuroanatomy and physiology 
Cerebral imaging studies of MD patients, particularly those with SGCE mutations, implicated 
several brain regions in MD pathogenesis. Several cerebral imaging techniques highlighted 
cerebellar dysfunction, including PET and fMRI demonstrating hypermetabolism and 
hyperactivity respectively (Beukers et al., 2010, Carbon et al., 2013, van der Salm et al., 
2013). In addition, cerebellum-controlled eye blink conditioning and saccadic eye movements 
are abnormal in SGCE mutation-positive MD patients (Hubsch et al., 2011, Popa et al., 
2014). The cortex has been implicated by fMRI studies demonstrating hyperresponsiveness 
of specific sensorimotor regions but overall reduced metabolism in MD patients compared to 
healthy controls (Beukers et al., 2010, Beukers et al., 2011, Carbon et al., 2013, Meunier et 
al., 2008, van der Salm et al., 2013, van der Salm et al., 2009). PET studies showed thalamus 
hypermetabolism also, in both manifesting and non-manifesting SGCE carriers though to a 
lesser degree in the latter (Carbon et al., 2013). White matter abnormalities have also been 
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described in MD patients, particularly in the region connecting the basal ganglia to the 
cerebellum (van der Meer et al., 2012). This was postulated to be a consequence of increased 
plasticity, resulting in changes to regional connections (van der Meer et al., 2012).  
1.3.4. MD: a genetically heterogeneous syndrome? 
Although SGCE remains the only gene definitively implicated in hereditary MD, mutations in 
a number of other genes have been linked to MD. 
1.3.4.1. DRD2 and TOR1A 
The first mutation identified as segregating with MD in a family was in a highly conserved 
region of DRD2 encoding the D2 dopamine receptor (Klein et al., 1999). However, 
examination of other MD families did not reveal further DRD2 mutations, and subsequent 
reassessment of the original DRD2-linked MD family identified a pathogenic SGCE mutation 
segregating with the MD phenotype (Durr et al., 2000, Klein et al., 2000a, Klein et al., 2002). 
Similarly, in another family MD appeared to co-segregate with a TOR1A mutation, but 
subsequent investigation identified a pathogenic SGCE mutation in all affected individuals 
(Doheny et al., 2002, Klein et al., 2002, Leung et al., 2001). Therefore, TOR1A and DRD2 are 
not believed to contribute to MD pathogenesis, though multigenic inheritance remains a 
possibility for some cases of SGCE mutation-negative MD. 
1.3.4.2. New genes associated with MD and MD-like phenotypes: RELN, 
CACNA1B, and KCTD17 
In the last two years, three new genes have been linked to MD or MD-like phenotypes in 
patients lacking SGCE mutations. A total of four distinct RELN mutations have been 
identified in three MD families and two sporadic MD patients with a classic MD phenotype 
involving upper body myoclonus, dystonia and anxiety- or depression-related disorders 
(Groen et al., 2015b). Age at onset was highly variable however, with adult onset in two 
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families and the sporadic cases but onset at 3-4 years in the final family (Groen et al., 2015b). 
RELN encodes the large glycoprotein reelin, an extracellular matrix (ECM) protein that binds 
to cell surface receptors including VLDLR, APOER2 and potentially α3β1 integrin (Folsom 
and Fatemi, 2013, Howell et al., 1999, Howell et al., 2000). This initiates an intracellular 
signalling cascade that regulates neuronal positioning and migration during development 
(Folsom and Fatemi, 2013). Correspondingly, reeler mice deficient in Reln and human 
patients with rare recessive RELN mutations or chromosomal rearrangements display 
disorganised brain structures or lissencephaly (Chang et al., 2007a, Folsom and Fatemi, 2013, 
Hong et al., 2000, Tissir and Goffinet, 2003, Zaki et al., 2007). Reelin also regulates 
neurotransmission, and contributes to formation and plasticity of the synapse (Folsom and 
Fatemi, 2013, Iafrati et al., 2014, Lakatosova and Ostatnikova, 2012). 
A family with an unusual MD-like syndrome linked to a point mutation in CACNA1B has 
also been identified (Groen et al., 2011, Groen et al., 2015a). Affected individuals had 
dystonia, progressive upper and lower limb myoclonus affecting gait and stability, painful 
cramps and cardiac arrhythmias (Groen et al., 2011, Groen et al., 2015a). As with SGCE 
mutation-positive MD, alcohol intake alleviates myoclonus in these patients (Groen et al., 
2011). CACNA1B encodes a pore-forming subunit of voltage-gated calcium channels, and in 
heterologous cells the R1389H mutation identified in the MD-like patients affected ion flow 
through the channel (Ament et al., 2015, Groen et al., 2015a). No additional CACNA1B 
mutations in MD patients have been identified to date, and the complex phenotype has raised 
questions regarding whether this clinical entity represents MD or an MD-like disorder (Groen 
et al., 2015a, Mencacci et al., 2015a).  
Finally, an autosomal dominant missense mutation in KCTD17 has been identified in two 
families with MD (Mencacci et al., 2015b). Affected individuals had onset of jerks or jerky 
tremor in the upper limbs between 5 and 20 years of age, with subsequent development of 
Chapter 1: General introduction 
 
[27] 
 
predominantly craniocervical and upper limb dystonia (Mencacci et al., 2015b). KCTD17 
encodes potassium channel tetramerisation domain-containing protein 17, a cytosolic 
BTB/POZ domain-containing protein (Mencacci et al., 2015b). Studies of MD patient 
fibroblasts implicated KCTD17 in calcium signalling, but there is also evidence the protein 
may be an ubiquitin ligase (Kasahara et al., 2014, Mencacci et al., 2015b).  
1.4. The sarcoglycans: a family of transmembrane glycoproteins 
ε-SG, encoded by SGCE and involved in the molecular pathogenesis of MD (section 1.3.2), 
belongs to the sarcoglycan protein family. This family of six transmembrane glycoproteins 
was originally identified in skeletal muscle as part of the dystrophin-associated glycoprotein 
complex (DGC), but has subsequently been detected in other tissues (Yoshida et al., 1994).  
1.4.1. Overview of the sarcoglycans 
SG Gene 
Genomic 
locus 
Amino 
acids 
Molecular 
weight 
N-linked 
glycans 
Disulphide 
bonds 
Associated 
disease 
α SGCA 17q21 387 50 2 0 LGMD 2D 
β SGCB 4q12 318 43 3 2 LGMD 2E 
δ SGCD 5q33 290 35 3 2 LGMD 2F 
γ SGCG 13q12 291 35 1 2 LGMD 2C 
ε SGCE 7q21 437 45 1 0 MD 
ζ SGCZ 8p22 312 35 2 1 none 
Table 1.3 The sarcoglycan protein family with associated diseases. Complete list of human sarcoglycan proteins with 
gene name, genomic locus, polypeptide size in amino acids, apparent molecular weight on SDS-PAGE, number of N-linked 
glycans, number of disulphide bonds, and the associated disease. Protein information obtained from UniProt database. 
Abbreviations: SG, sarcoglycan; LGMD, limb-girdle muscular dystrophy; MD, myoclonus dystonia. 
Sarcoglycans are single-pass transmembrane glycoproteins with a large glycosylated 
extracellular region, transmembrane domain, and short intracellular tail. The six sarcoglycans 
are α-SG encoded by SGCA, β-SG encoded by SGCB, δ-SG encoded by SGCD, γ-SG 
encoded by SGCG, ζ-SG encoded by SGCZ, and the previously discussed ε-SG encoded by 
SGCE (table 1.3). ε-SG and α-SG are paralogous type I transmembrane proteins with highly 
similar exon/intron borders, approximately 62% similarity and 45% identity at the amino acid 
level, and an extracellular cadherin/immunoglobulin superfamily domain similar to those 
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present in α-dystroglycan (Figure 1.3) (Bozic et al., 1998, De Rosa et al., 2011, Dickens et 
al., 2002, Ettinger et al., 1997, McNally et al., 1998). α-SG expression is restricted to muscle, 
whereas ε-SG is broadly expressed with particular enrichment in the brain (section 1.3.2.2).  
δ-SG, γ-SG and ζ-SG form another group of paralogues, with 74% similarity at the amino 
acid level but differential N-glycosylation (Jung et al., 1996, Shiga et al., 2006, Wheeler et 
al., 2002). These three sarcoglycans together with β-SG are type II transmembrane proteins 
with intracellular N-terminal regions and extracellular C-terminal regions containing 1-2 
Figure 1.3 Comparison of human sarcoglycan proteins. For each sarcoglycan protein, the full-length/canonical isoform 1 
is depicted. Transmembrane domains are marked in yellow, signal peptides marked in red, N marks an N-linked 
glycosylation site, and green lines represent disulphide bonds between cysteine residues. The intracellular and extracellular 
regions are marked against the polypeptide. Numbers at the C-terminus of each protein give the polypeptide length before 
processing. Polypeptides are approximately to scale. ε-SG and α-SG signal peptides are as reported in the Leiden Open 
Variation Database (Fokkema et al., 2011). 
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conserved disulphide bonds (Figure 1.3) (Chan et al., 1998, Shi et al., 2004, Wheeler et al., 
2002). γ-SG expression is muscle-specific, whereas ζ-SG is expressed more broadly with 
highest expression in the brain and lowest in skeletal muscle (Barresi et al., 2000b, Shiga et 
al., 2006, Yamamoto et al., 1994). Expression of β-SG and δ-SG is also widespread, though 
considerably greater in muscle compared to other tissues (Cheng et al., 2006, Jung et al., 
1996, Lim et al., 1995, Nigro et al., 1996). 
1.4.2. Synthesis and assembly of sarcoglycan complexes 
Immediately after synthesis, the sarcoglycans interact to form complexes containing 
equimolar quantities of each sarcoglycan and thought to be predominantly heterotetrameric 
(Holt and Campbell, 1998, Jung et al., 1996, Noguchi et al., 2000). With the exception of α- 
and ε-SG, sarcoglycans require heterotetramer assembly for cell surface trafficking (Noguchi 
et al., 2000). Paralogues α-SG and ε-SG are thought to be interchangeable in sarcoglycan 
complex assembly, as are γ-SG and ζ-SG (Cai et al., 2007, Liu and Engvall, 1999). 
Sarcoglycan heterotetramers composed of αβδγ-SG predominate in muscle, but εβδγ-SG 
heterotetramers have also been described in cardiac and smooth muscle (Duclos et al., 1998, 
Liu and Engvall, 1999, Straub et al., 1999, Yoshida et al., 1994). By contrast, Schwann cells 
and adipose tissue contain εβδζ-SG heterotetramers (Cai et al., 2007, Groh et al., 2009, 
Imamura et al., 2000). So far no functional differences between sarcoglycan complexes have 
been identified.  
Studies of sarcoglycan complex assembly in cultured myotubes, transiently transfected 
heterologous cells, and animal models of sarcoglycan deficiency (section 1.4.5) have 
highlighted the importance of β-SG, which appears to initiate sarcoglycan heterotetramer 
assembly by interacting strongly with δ-SG; this forms a βδ-SG “core” required for 
heterotetramer assembly and trafficking to the plasma membrane (Chan et al., 1998, Draviam 
et al., 2006a, Shi et al., 2004). Sequential deletion of the extracellular domain has narrowed 
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down the interaction between β-SG and δ-SG to the δ-SG extracellular juxtamembrane region 
between residues 57 and 92 (Chen et al., 2006). Co-immunoprecipitation (IP) experiments 
indicate that γ-SG/ζ-SG interacts strongly with the βδ-SG core via the more distal residues 
94-194 of γ-SG (Chan et al., 1998, Chen et al., 2006, Draviam et al., 2006a, Noguchi et al., 
2000, Shi et al., 2004, Yoshida et al., 1997, Yoshida et al., 1994). Based on further co-IP 
experiments, γ-SG/ζ-SG has been proposed to mediate a weaker interaction between α-SG/ε-
SG and the remainder of the complex, although in heterologous cells α-SG can interact 
directly with β-SG and δ-SG (Chan et al., 1998, Draviam et al., 2006a, Hack et al., 2000, 
Noguchi et al., 2000, Shi et al., 2004). Trafficking to the plasma membrane is thought to 
require normal N-linked glycosylation and disulphide bond formation in sarcoglycans plus 
the core interaction between β-SG and δ-SG (Chan et al., 1998, Chen et al., 2006, Draviam et 
al., 2006a, Shi et al., 2004). 
1.4.3. Sarcoglycans as part of the dystrophin-associated glycoprotein complex 
In muscle, the sarcoglycan complex forms a subcomplex of the dystrophin-associated 
glycoprotein complex (DGC) based on the cytosolic protein dystrophin (Figure 1.4a). This   
large multimeric complex can be biochemically subdivided into three subcomplexes: the 
sarcoglycan subcomplex containing the sarcoglycan complex (section 1.4.2) plus sarcospan; 
the dystroglycan subcomplex; and the cytosolic subcomplex of dystrophin, dystrobrevins and 
syntrophins (Yoshida et al., 1994)(Figure 1.4a). The dystroglycan subcomplex comprises 
single-pass transmembrane β-dystroglycan and heavily glycosylated extracellular α-
dystroglycan, both produced through proteolysis of a single precursor protein (Esapa et al., 
2003, Holt et al., 2000, Ibraghimov-Beskrovnaya et al., 1992). This complex connects ECM 
proteins that interact with α-dystroglycan (e.g. laminin) to dystrophin which interacts with the 
cytosolic region of β-dystroglycan and cytoskeletal structures (Allen et al., 2016, Chung and 
Campanelli, 1999, Prins et al., 2009, Way et al., 1992). Therefore the DGC connects the 
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cell’s cytoskeleton to the extracellular matrix, and is thought to protect the sarcolemma from 
mechanical stress (Allen et al., 2016, Petrof et al., 1993, Straub et al., 1997). Dystrophin is 
essential for DGC assembly; its absence due to DMD mutation in Duchenne and Becker 
muscular dystrophies results in secondary absence of all other DGC components from the 
muscle sarcolemma (Allen et al., 2016). 
 In addition to its structural function, the DGC is thought to influence signal transduction and 
calcium homeostasis by acting as a scaffold for recruitment of other proteins. Intracellular 
calcium levels are typically elevated with DGC dysfunction, which may be caused by 
dysregulation of calcium homeostasis or increased plasma membrane permeability (Allen et 
al., 2016). The cytosolic subcomplex comprising dystrophin, dystrobrevins and syntrophins 
Figure 1.4 Putative molecular organisation of the DGC in muscle and DGC-like complexes in the brain. Adapted 
from (Waite et al., 2009). Illustration of the basic organisation for the core DGC and DGC-like complexes in A) muscle, B) 
CNS neurons, and C) CNS glia. The muscle DGC has been determined through direct biochemical purification of the intact 
complex from tissue, whereas CNS DGC-like complexes have been inferred from protein interactions identified using a 
variety of protocols including yeast two-hybrid and co-immunoprecipitation from cultured cells and/or tissue. Only the basic 
structure and a subset of associated proteins are illustrated for each complex, and full details can be obtained in recent 
reviews (Allen et al., 2016, Waite et al., 2012, Waite et al., 2009). Arrows with question marks indicate putative but not 
confirmed protein interactions. Dystrobrevin and dystrophin are not to scale. Abbreviations: DGC, dystrophin-associated 
glycoprotein complex; DG, dystroglycan; SG, sarcoglycan; SGC, sarcoglycan complex; SSPN, sarcospan; nNOS, neuronal-
type nitric oxide synthase; SAST, syntrophin-associated serine/threonine kinase; ABD, actin binding domain; PH, plecstrin 
homology domain; PDZ, PSD-95 (postsynaptic density protein 95), discs_large and zonula occludens-1 domain; SU, 
syntrophin-unique region; Kir 4.1, inwardly rectifying potassium channel 4.1. 
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interacts with a number of signalling proteins, most notably neuronal-type nitric oxide 
synthase (nNOS) which is localised to the sarcolemma through its interactions with 
syntrophin and dystrophin (Adams et al., 2001, Allen et al., 2016, Brenman et al., 1996, Lai 
et al., 2013). Nitrous oxide (NO) produced by nNOS is a major signalling molecule in muscle 
that helps regulate functions such as glucose uptake and calcium release from intracellular 
stores (Allen et al., 2016). Syntrophin also helps recruit a number of cation channels and 
aquaporin to the vicinity of the DGC (Adams et al., 2001, Allen et al., 2016). In addition, 
environment- or activity-induced phosphorylation of β-dystroglycan and dystrophin regulates 
their interaction and interactions with other proteins (Ilsley et al., 2001, Sotgia et al., 2001, 
Swiderski et al., 2014). Similar phosphorylation has been described for other DGC 
components (Allen et al., 2016). In the ECM, the chondroitin sulphate proteoglycan biglycan 
interacts with α-dystroglycan to modulate expression and plasma membrane association of 
other DGC components (Bowe et al., 2000, Mercado et al., 2006, Rafii et al., 2006). Finally, 
integrin α7β1 interacts directly with sarcospan and is thought to contribute to both 
mechanical and signalling functions of the DGC (Allen et al., 2016, Marshall et al., 2012).  
The sarcoglycan heterotetramer is integrated into the DGC through several protein 
interactions, and may contribute both to DGC stability in the plasma membrane and to signal 
transduction. The βδ-SG core interacts with dystroglycan, while the extracellular domain of 
γ-SG interacts with and stabilises the tetraspanin protein sarcospan in the plasma membrane 
(Chan et al., 1998, Coral-Vazquez et al., 1999, Crosbie et al., 1997, Crosbie et al., 1999, 
Crosbie et al., 2000, Hayashi et al., 2006). The sarcoglycan heterotetramer may also interact 
with the N-terminal domain of dystrobrevin, although this is thought to be stronger with 
CNS-expressed β-dystrobrevin compared to muscle-expressed α-dystrobrevin (Blake et al., 
1998, Yoshida et al., 2000). Consequently, this interaction could be of greater importance in 
the CNS than in muscle (Blake et al., 1998). In vitro experiments identified an additional 
Chapter 1: General introduction 
 
[34] 
 
interaction between the βδ-SG core and the carboxyl terminus of dystrophin, though this has 
not been replicated in vivo (Chen et al., 2006). Finally, biglycan interacts with and modulates 
expression of α-SG and γ-SG (Rafii et al., 2006). Thus, in muscle the sarcoglycans form a 
heterotetrameric complex integrated into the wider DGC by multiple interactions. 
A number of DGC-like complexes have been described in the CNS (Figure 1.4b-c) (Blake et 
al., 1999). These can differ in dystrophin isoform (for example, Dp71 in glia), inclusion of α-
dystrobrevin-1 versus β-dystrobrevin in glia versus neurons, and the syntrophins incorporated 
(Blake et al., 1999, Blake et al., 1992, Blake et al., 1998, Tadayoni et al., 2012, Waite et al., 
2012). Brain DGC-like complexes have been inferred from protein interactions rather than 
through isolation of intact complexes, so the exact organisation of these complexes remains 
unknown. However, DGC-like complexes are clearly essential for normal neurological 
development and function. Dystroglycan glycosylation defects can result in severe brain 
structure abnormalities, while Duchenne/Becker muscular dystrophy patients commonly have 
cognitive impairment and neuropsychiatric disorders (Anderson et al., 2002, Snow et al., 
2013, Waite et al., 2012). Dystrophin, dystroglycan and dystrobrevin are all involved in the 
clustering of GABA-A and other neurotransmitter receptors clustering at the synapse, with 
disorganised postsynaptic regions in their absence although the mechanism behind this 
remains unknown (Brünig et al., 2002, Knuesel et al., 1999, Krasowska et al., 2014, Waite et 
al., 2012). In astrocytes, DGC-like complexes containing Dp71 are involved in localisation of 
aquaporin-4 and the Kir 4.1 inwardly rectifying potassium channel which help maintain the 
blood-brain barrier (Connors et al., 2004, Tadayoni et al., 2012, Waite et al., 2012). However, 
contributions of the sarcoglycans to these DGC-like complexes in brain remain unknown. 
1.4.4. The sarcoglycans in human disease 
Mutations in SGCA, SGCB, SGCD and SGCG cause autosomal recessive limb-girdle 
muscular dystrophy (LGMD), while mutations in SGCE cause MD (section 1.3.2). LGMD is 
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characterised by progressive degeneration of skeletal muscle, predominantly affecting the 
muscles around the pelvis and scapulae (Sandona and Betto, 2009). Patients with mutations 
in SGCB, SGCD or SGCG resulting in LGMD 2E, 2F and 2C respectively often develop 
cardiomyopathy in addition to skeletal muscle degeneration, though this is less common in 
patients with SGCA mutations, probably due to compensation for α-SG deficiency by ε-SG 
(Barresi et al., 2000a, Fayssoil, 2010, Lancioni et al., 2011, Politano et al., 2001, Sandona and 
Betto, 2009). LGMD can range from mild to severe even with the same sarcoglycan 
mutation, and is associated with partial or complete loss of the entire sarcoglycan complex 
from the sarcolemma in addition to deficiency of the mutated sarcoglycan (Draviam et al., 
2001, McNally et al., 1996, Sandona and Betto, 2009). In LGMD 2E or 2F, the entire 
sarcoglycan complex is typically reduced or lost from the sarcolemma with β-dystroglycan 
and dystrophin levels also reduced (Draviam et al., 2001, Klinge et al., 2008, Vainzof et al., 
1996). By contrast, SGCA or SGCG mutations typically result in a variable presence of 
residual sarcoglycans at the sarcolemma and no changes to β-dystroglycan or dystrophin 
(Klinge et al., 2008, Sandona and Betto, 2009). However, these are trends rather than firm 
differences and so cannot be used to differentiate between genotypes (Klinge et al., 2008). 
As with MD-associated SGCE mutations (section 1.3.2.3), most LGMD-associated 
sarcoglycan mutations result in sarcoglycan deficiency from the plasma membrane. Several 
LGMD-associated SGCA missense mutations have been shown to result in mutant α-SG 
proteins that are ubiquitinated and degraded by the proteasome (Gastaldello et al., 2008, 
Sandona and Betto, 2009). If the ER quality control pathway is inhibited, some of these 
mutant proteins can interact normally with other sarcoglycans and traffic to the plasma 
membrane, suggesting they retain at least partial functionality (Bartoli et al., 2008, Bianchini 
et al., 2014, Gastaldello et al., 2008, Soheili et al., 2012). Studies in heterologous cells have 
demonstrated that several LGMD-associated β-SG, δ-SG and γ-SG mutants impair assembly 
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of the sarcoglycan complex, while others interact with other sarcoglycans but reduce 
trafficking to the plasma membrane (Chen et al., 2006, Shi et al., 2004). Interestingly, one 
SGCD mutation was found to result in mislocalisation of the sarcoglycans to the NE in 
transgenic mice in addition to their absence from the sarcolemma (Heydemann et al., 2007).  
1.4.5. Animal models of sarcoglycan mutations 
In addition to the Sgce mutant mouse lines (section 1.3.2.4), rodent models of SGCA, SGCB, 
SGCD and SGCG deficiency have been generated. The first was the BIO14.6 strain of Syrian 
hamsters, which carries a spontaneous Sgcd exon 1 deletion (Nigro et al., 1997). BIO14.6 
hamsters develop muscular dystrophy plus cardiomyopathy associated with complete loss of 
the SGC and reduction of α-dystroglycan at the sarcolemma in skeletal and cardiac muscle 
(Ikeda et al., 2002, Roberds et al., 1993b, Straub et al., 1998). There are also several 
transgenic mouse lines with knock-in mutations or null alleles of Sgca, Sgcb, Sgcd and Sgcg. 
Mice homozygous for Sgca, Sgcb or Sgcd null alleles exhibit complete loss of the entire SGC 
from the skeletal muscle sarcolemma with severe muscular dystrophy (Araishi et al., 1999, 
Coral-Vazquez et al., 1999, Duclos et al., 1998, Durbeej et al., 2000). By contrast, Sgcg-
deficient mice have severe muscular dystrophy with loss of β-SG and δ-SG but residual α-SG 
at the sarcolemma (Hack et al., 1998). Sgcb, Sgcd and Sgcg null mice all develop 
cardiomyopathy but Sgca null mice do not, partially due to Sgce expression in cardiac muscle 
(Araishi et al., 1999, Coral-Vazquez et al., 1999, Duclos et al., 1998, Durbeej et al., 2000, 
Hack et al., 1998, Lancioni et al., 2011). Intriguingly, transgenic mice substantially 
overexpressing Sgcg also develop severe muscular dystrophy, with intracellular retention of 
γ-SG aggregates and upregulation of α- and β-SG (Zhu et al., 2001). This highlights the 
importance of appropriate levels of each sarcoglycan for normal muscle function.  
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1.4.6. Function(s) of the sarcoglycans 
Despite ongoing research, the precise function(s) of the sarcoglycan complex in muscle and 
in brain are unknown. In the muscle, the sarcoglycan complex is thought to help stabilise the 
wider DGC in the plasma membrane and thus support sarcolemma mechanical stability. 
However, there is increasing evidence for direct involvement of the sarcoglycans in calcium 
homeostasis and signal transduction. Sgcb and Sgcd null mice plus Sgcd null hamsters have 
abnormal calcium homeostasis in muscle despite residual DGCs at the sarcolemma (Fraysse 
et al., 2010, Iwata et al., 2003, Nakamura et al., 2001, Solares-Perez et al., 2010a, Solares-
Perez et al., 2010b). Genetically or chemically modulating calcium signalling in these rodents 
can improve the dystrophic phenotype (Iwata et al., 2005, Parsons et al., 2007). In Sgcb null 
mice, calcium leaking from intracellular storage through RyR1 channels in skeletal muscle 
was observed and may contribute to abnormal calcium homeostasis (Andersson et al., 2012). 
Increased calcium levels alone can cause muscular dystrophy in mice, possibly through 
activation of proteases that break down muscle (Iwata et al., 2005, Millay et al., 2009). 
Aberrant skeletal muscle calcium handling has also been described in an LGMD 2C patient, 
indicating this is not restricted to rodent LGMD models (Hassoni and Cullen, 1999).  
Several protein interactions implicate sarcoglycans in signal transduction. As previously 
described (section 1.4.3), the sarcoglycans interact with signalling scaffold protein 
dystrobrevin (Yoshida et al., 2000). Correspondingly, loss of the SGC in sarcoglycan-
deficient mice results in loss of nNOS from the sarcolemma with downstream effects on NO 
signalling (Crosbie et al., 2002, Heydemann et al., 2004). γ-SG and δ-SG specifically interact 
with two further proteins implicated in signal transduction: γ-filamin and the 16 kDa subunit 
of the vacuolar proton ATPase (16K) (Chen et al., 2007, Thompson et al., 2000). Filamins are 
involved in cytoskeletal remodelling after mechanotransduction through interaction with 
actin, and therefore may implicate sarcoglycans in mechanotransduction (Guyon et al., 2003, 
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Thompson et al., 2000). The contribution of the 16K protein is less clear, as in addition to its 
canonical role in the vacuolar ATPase it has been implicated in other functions including 
neurotransmitter exocytosis (Chen et al., 2007, Morel and Poea-Guyon, 2015). Both 16K and 
γ-filamin also interact with integrins, suggesting similar roles and/or bidirectional signalling 
between the integrins and sarcoglycans (Chen et al., 2007, Thompson et al., 2000).  
Several sarcoglycans also undergo tyrosine phosphorylation. In cultured myocytes, specific 
intracellular tyrosine residues in α-SG and γ-SG are phosphorylated during the formation of 
focal adhesions; these sarcoglycans also co-purify with adhesion proteins (Yoshida et al., 
1998). γ-SG is also phosphorylated in mouse skeletal muscle after contraction, and this 
phosphorylation is required for normal mechanotransduction (Barton, 2006, Barton, 2010). 
Sgcg null mice exhibit increased protein phosphorylation in skeletal muscle after contraction 
compared to wild-type mice (Barton, 2006). This also occurs in LGMD 2C patients and may 
relate to γ-SG’s interaction with archvillin, a stimulus-dependent scaffold for ERK1/2 and 
other signal transduction proteins (Spinazzola et al., 2015). In mouse muscle, the interaction 
between archvillin and phosphorylated ERK1/2 requires γ-SG (Spinazzola et al., 2015).  
The sarcoglycans could also contribute to signal transduction through interactions and 
activity in the extracellular space. α-SG and γ-SG interact with and are regulated by the ECM 
proteoglycan biglycan (section 1.4.3) (Rafii et al., 2006). In muscle biglycan modulates 
sarcolemmal localisation of the DGC, but it is also involved in numerous other processes 
including stabilising neuromuscular junction synapses (Amenta et al., 2012, Bowe et al., 
2000, Nastase et al., 2012, Rafii et al., 2006). Furthermore, α-SG’s extracellular region is an 
ecto-ATPase that can modulate extracellular ATP concentrations (Betto et al., 1999, Sandona 
et al., 2004). Therefore α-SG may modulate signalling via manipulation of extracellular ATP. 
However, all of the above protein interactions and possible functions for the sarcoglycans 
derive from studies performed on muscle, cultured myocytes, or heterologous cells. Several 
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sarcoglycans are known to be expressed in other tissues including the CNS, as previously 
discussed; however, their functions in those tissues remain largely unknown. 
1.5. Thesis aims 
Despite the well-established involvement of SGCE mutations in MD, at the start of this study 
very little was known about ε-SG and other sarcoglycans in the brain. Clues to a protein’s 
function can be obtained from the other proteins with which it interacts. Therefore, the 
overall aim of this study was to gain insight into the function(s) of ε-SG in the brain through 
identification of proteins with which it interacts.  
In pursuit of this aim, the study had three major objectives: 
1. To determine whether ε-SG interacts with other sarcoglycans and DGC components in 
the brain. A positive result would implicate DGC-like complexes in the molecular 
pathogenesis of MD (Chapter 3). 
2. To identify additional, non-DGC protein(s) with which ε-SG interacts in the brain 
(Chapter 3).  
3. To examine alternative splicing of SGCB, SGCD, SGCZ, SGCA and SGCG. 
Alternatively spliced transcripts encoding novel isoforms could contribute to 
heterogeneity of sarcoglycan complexes between tissues (Chapters 4 and 5). 
Finally, data presented in this thesis will be summarised and discussed in Chapter 6. 
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Chapter 2: Materials and methods 
All experiments used analytical grade chemicals from either Thermo Fisher Scientific or 
Sigma Aldrich unless otherwise indicated. 
2.1. Molecular Biology 
2.1.1. First strand synthesis from total RNAs 
Pre-extracted mouse whole brain total RNA was supplied by Dr Adrian Waite and used as a 
template for first strand cDNA synthesis. Pre-extracted control human cerebellum RNA from 
a study of neurological disorders in Wales (REC for Wales 09/MRE09/35) and total RNA 
from human skeletal muscle obtained from Clontech (item 636534) were used as templates 
for first strand cDNA synthesis. First strand cDNA from 1µg of RNA was synthesised with 
the Protoscript II First Strand cDNA Synthesis Kit (New England Biolabs) according to the 
manufacturer’s instructions and using the supplied poly-d(T)23VN primer to enrich for mature 
transcripts. First strand cDNA was stored at -20°C. 
2.1.2. Oligonucleotides (primers) 
All oligonucleotides (primers) are listed in appendix I. Primers were designed using a 
combination of Primer3 (Rozen and Skaletsky, 1999, Untergasser et al., 2012) and NCBI 
Primer-BLAST (Ye et al., 2012) using standard PCR design guidelines (Green and 
Sambrook, 2012). Primers were ordered from Sigma-Aldrich, re-suspended in molecular-
grade water at a concentration of 100µM and stored at -20°C. For each pair of primers, the 
optimal annealing temperature for polymerase chain reactions (PCRs) was determined by 
assessing PCR yield and specificity at a range of annealing temperatures from 56-63°C using 
the general PCR protocol with RedTaq polymerase (section 2.1.3.2). The highest annealing 
temperature with decent yield and the fewest amplified products visible on agarose gel 
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electrophoresis (section 2.1.4) was used for all subsequent PCRs with that primer pair (Green 
and Sambrook, 2012). 
2.1.3. Polymerase chain reaction 
All polymerase chain reactions (PCRs) were carried out using C1000/S1000 Thermal Cyclers 
(BioRad). For each PCR, the final reaction mixture contained 1X DNA polymerase buffer 
(1.5-2mM Mg2+ depending on enzyme), 0.2-0.5µM each forward and reverse primers, 0.16-
0.2mM deoxyribonucleotide mixture (0.16-0.2mM each dATP, dTTP, dGTP and dCTP), 
DNA polymerase, sterile molecular biology-grade water, and template DNA. Final PCR 
volume ranged from 10µl to 25µl depending on the DNA polymerase used and purpose of the 
reaction. For sequences with a high GC content, DMSO was added at a final concentration of 
5% to facilitate amplification (Green and Sambrook, 2012). The following DNA polymerase 
enzymes were used: 
 EasyA Hi-Fi Cloning enzyme (Agilent) for reverse transcription polymerase chain 
reaction (RT-PCR) from first strand cDNA 
 Q5 High-Fidelity DNA polymerase (New England Biolabs) for RT-PCR from first 
strand cDNA 
 RedTaq DNA polymerase (Sigma-Aldrich) for colony and routine PCRs 
 PfuUltra II Fusion DNA polymerase (Agilent) for site-directed mutagenesis (SDM) 
2.1.3.1. RT-PCR from first strand cDNA 
To amplify specific transcripts from first strand cDNA, either the EasyA Hi-Fi cloning 
enzyme (Agilent) or Q5 High-Fidelity DNA polymerase (New England Biolabs) was used. 
Using the EasyA Hi-Fi cloning enzyme, the typical PCR mixture was as follows: 
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Reagent Volume (µl) Final concentration 
10x EasyA reaction buffer 2.5 1x 
Deoxyribonucleotide mix 
(10mM) 
0.5 200µM 
Forward primer (10µM) 0.5 0.2µM 
Reverse primer (10µM) 0.5 0.2µM 
EasyA DNA polymerase 0.25 1.25 U/25µl 
Template 0.5-2 depending on 
application 
Depends on 
application 
Molecular grade water To 25 
 
 
Reaction mixtures using the Q5 High-Fidelity DNA Polymerase enzyme for RT-PCR were as 
follows: 
Reagent Volume (µl) Final concentration 
Q5 reaction buffer (5x) 5 1x 
Deoxyribonucleotide mix (10mM) 0.5 200µM 
Forward primer (10µM) 1.25 0.5µM 
Reverse primer (10µM) 1.25 0.5µM 
Q5 DNA polymerase 0.5 1 U/25µl 
Template 0.5-2 depending on 
application 
Depends on 
application 
Molecular grade water To 25  
 
For both cloning DNA polymerases, typical PCR cycling parameters were as follows: 
1. 95°C for 4min 
2. 95°C for 30s 
3. Optimised (section 2.1.2) annealing temperature for primers (usually 55-60°C), 30s 
4. 72°C for 1min/kb of product length 
5. Go to step 2, 20-30 times depending on the abundance of the target sequence and 
desired output quantity 
6. 72°C, 7min 
7. 8°C, hold. 
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PCR products were visualised by electrophoresis as described in section 2.1.4. 
2.1.3.2. General PCR 
For general PCRs using the RedTaq DNA polymerase system, the typical reaction mixture 
was as follows: 
Reagent Volume (µl) Final concentration 
10x RedTaq buffer 2 1x 
Deoxyribonucleotide mix (10mM) 0.32 160µM 
Forward primer (10µM) 0.8 0.4µM 
Reverse primer (10µM) 0.8 0.4µM 
RedTaq DNA polymerase 0.6 0.6 U/20µl 
Template 0.5-2 depending on 
application 
Depends on 
application 
Molecular grade water To 20  
 
The typical PCR cycling parameters and post-PCR analysis were as for the RT-PCRs. 
2.1.3.3. Colony PCR 
To screen bacterial colonies for plasmid inserts, individual bacterial colonies were picked 
using radiation-sterilised inoculation needles (Sarstedt/Fisher Scientific) and resuspended in 
30-40µl of sterile Lennox formulation (5g/l NaCl) Luria-Bertani (LB) broth or molecular 
biology grade water. A 2µl aliquot of the resuspended colony was used as the template in the 
following PCR reaction mixture with appropriate oligonucleotide primers: 
Reagent Volume (µl) Final concentration 
10x RedTaq buffer 2 1x 
Deoxyribonucleotide mix (10mM) 0.32 160µM 
Forward primer (10µM) 0.8 0.4µM 
Reverse primer (10µM) 0.8 0.4µM 
RedTaq DNA polymerase 0.6 0.6 U/20µl 
Template 2µl colony 
resuspension 
- 
Molecular grade water To 20  
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Typical thermal cycler parameters were as in section 2.1.3.1. PCR products were resolved by 
agarose gel electrophoresis as described in section 2.1.4.  
2.1.3.4. Site-directed mutagenesis 
Site-directed mutagenesis (SDM) was used to correct PCR errors and introduce mutations in 
cDNA plasmid constructs. The QuikChange (Aligent) mutatgenesis protocol using the 
PfuUltra high-fidelity DNA polymerase (Agilent) was employed for this as per the 
manufacturer’s protocol. The typical PCR mixture for SDM PCRs was as follows: 
Reagent Volume (µL) Final concentration 
10x PfuUltra reaction buffer 1 1x 
Deoxyribonucleotide mix (10mM) 0.2 200µM 
Forward primer (10µM) 0.2 0.2µM 
Reverse primer (10µM) 0.2 0.2µM 
PfuUltra DNA polymerase 0.2 1 U/10µl 
Plasmid template 1 - 
Molecular grade water To 10 - 
 
The PCR cycling protocol was as follows: 
1. 95°C for 30s 
2. 95°C for 30s 
3. 55°C for 1min 
4. 68°C for 15min 
5. Go to step 2 a total of 18 times 
6. 12°C hold 
1µl of the PCR product was analysed by agarose gel electrophoresis (section 2.1.4) to check 
that the reaction had been successful. DNA passaged through E.coli is methylated by 
deoxyadenosine methylase, so template DNA was removed from the SDM PCR product by 
adding 1µl of the methylated DNA-specific DpnI enzyme (New England Biolabs) and 
incubating this mixture at 37°C for 2h. The resultant product was used to transform 
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chemically competent XL1-Blue cells by heat shock (section 2.2.2); only E.coli transformed 
with intact (PCR product) plasmids would survive antibiotic selection. Plasmids from the 
resultant colonies were sequenced to verify that mutagenesis was successful. 
2.1.4. Agarose gel electrophoresis 
Agarose gels for resolving DNA fragments were made using 0.5-3% (w/v) agarose (ATGC) 
in 0.5x TBE (Fisher; 45mM Tris-borate, 1mM EDTA, pH 8.3). Agarose concentration was 
determined by the sizes of the DNA fragments to be resolved. Ethidium bromide was added 
to the gels at a final concentration of 100ng/ml to visualise DNA. DNA samples to be 
resolved were mixed with a suitable volume of 5x DNA loading buffer (30% (v/v) glycerol, 
20mM EDTA pH 8.0, 0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol in 
molecular grade water) before being loaded onto the gel. Samples were resolved by 
electrophoresis at 100-120V for 20-90min alongside a DNA fragment size standard, either 
the 1Kb Plus DNA Ladder (Life Technologies), or the Quick-Load 2-Log DNA Ladder (New 
England Biolabs).  UV transillumination of the gel was performed to visualise resolved, 
ethidium bromide-stained DNA (BioRad Gel Doc XR+ Imaging System). 
2.1.5. PCR product purification 
PCR products were purified using either the QIAGEN QIAquick Gel Extraction kit or the 
QIAGEN QIAquick PCR Purification kit as per the manufacturer’s instructions. Samples 
were eluted in 30-50µl of supplied elution buffer (EB) or molecular biology grade water 
depending on intended downstream use. 
2.1.6. Nucleic acid quantitation 
The concentration and purity of DNA and RNA samples were analysed using a NanoDrop 
8000 spectrophotometer (Thermo Scientific) according to the manufacturer’s instructions 
with the inclusion of an appropriate blank. 
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2.1.7. Cloning into plasmid vectors 
2.1.7.1. Vectors used and constructs produced 
Four different plasmid vectors were employed, depending on the qualities of the cDNA 
insert. All four plasmids were mammalian expression vectors, to facilitate expression of the 
inserted cDNA in cultured mammalian cells. These plasmids were: 
 pCI-neo (Promega) – standard expression vector with no included epitope tag; 
ampicillin selection in E.coli 
 pCMV-myc (Clontech) – expression of cDNA with an N-terminal c-Myc epitope tag; 
ampicillin selection in E.coli 
 pCMV-HA (Clontech) - expression of cDNA with an N-terminal human influenza 
haemagglutinin (HA) epitope tag; ampicillin selection in E.coli 
 pFUSE-hlgG2-F2 (Invivogen) – expression of cDNA with an N-terminal IL2 signal 
sequence for secretion; Zeocin selection in E.coli. 
The constructs produced are summarised in Table 2.1. c-Myc, HA and FLAG epitope tags 
were introduced into pCI-neo-based constructs by PCR. The c-Myc N-terminal tag was 
introduced into pFUSE-hlgG2-F2 constructs by PCR. 
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Encoded protein 
N-term 
epitope 
tag 
C-term 
epitope 
tag Species Plasmid vector 
5' RE 
site 
3' RE 
site 
ε-SG isoform 1 exon 8+ c-Myc - Human pFUSE-hlgG2-F2  NcoI NcoI 
ε-SG isoform 1 exon 8- c-Myc - Human pFUSE-hlgG2-F2  NcoI NcoI 
ε-SG isoform 2 exon 8+ c-Myc - Human pFUSE-hlgG2-F2  NcoI NcoI 
ε-SG isoform 2 exon 8- c-Myc - Human pFUSE-hlgG2-F2  NcoI NcoI 
α-SG isoform 1 - c-Myc Human pCI-neo SalI NotI 
α-SG isoform 3 (exon 6 
truncation) 
- c-Myc Human pCI-neo SalI NotI 
α-SG isoform 4 (Δ exon 9b) - c-Myc Human pCI-neo SalI NotI 
β-SG isoform 1 - FLAG Human pCI-neo SalI NotI 
β-SG isoform 2 - FLAG Human pCI-neo SalI NotI 
β-SG T182A - FLAG Human pCI-neo SalI NotI 
δ-SG isoform 1 (exon 9 
termination) 
- HA Human pCI-neo SalI NotI 
δ-SG isoform 2 (exon 8b 
termination) 
- HA Human pCI-neo SalI NotI 
δ-SG isoform 3 (Δ exon 7) - HA Human pCI-neo SalI NotI 
δ-SG isoform 1 exon 3 
truncation 
- HA Human pCI-neo SalI NotI 
δ-SG isoform 1 Δ exon 6 - HA Human pCI-neo SalI NotI 
ζ-SG isoform 1 c-Myc - Human pCMV-myc SalI NotI 
ζ-SG isoform 2 (Δ exon 3) c-Myc - Human pCMV-myc SalI NotI 
ζ-SG isoform 3 (Δ exon 5) c-Myc - Human pCMV-myc SalI NotI 
γ-SG isoform 1 c-Myc - Human pCMV-myc SalI NotI 
γ-SG isoform 2 (Δ exon 5) c-Myc - Human pCMV-myc SalI NotI 
γ-SG isoform 3 (exon 6b+) c-Myc - Human pCMV-myc SalI NotI 
Kcna3 c-Myc - Mouse pCMV-myc SalI NotI 
Tenascin-R (full-length isoform) - FLAG Mouse pCI-neo SalI NotI 
Table 2.1 Plasmid cDNA constructs for expression in mammalian cells. For each construct, the encoded protein, N-
terminal or C-terminal tag as appropriate, species of origin, vector and restriction enzyme sites used to produce the construct 
are provided. For novel sarcoglycan isoforms, the alternative splicing event responsible for that isoform is provided in 
parentheses. Abbreviations: 5’ RE site, restriction enzyme site at the 5’ end of the cDNA insert; 3’ RE site, restriction 
enzyme site at the 3’ end of the cDNA insert; C term, carboxyl terminus; N term, amine terminus. 
2.1.7.2. Restriction digest of DNA 
Plasmid vectors and PCR products were digested with restriction enzymes purchased from 
New England Biolabs (NEB). For single digests, the recommended NEB buffer was used; for 
double digests, either the recommended double digest buffer was used or sequential digests 
were performed. For a typical digest, 42.5µl of purified PCR product or 0.5-1µg of DNA was 
combined with 1x buffer, 1x bovine serum albumin (BSA), 5 units of each enzyme, and 
molecular grade water in a total volume of 50µl. This was incubated at 37°C for 3h to ensure 
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complete digestion of DNA. To prevent re-circularisation, digested plasmids were further 
incubated with 20 units of calf intestinal alkaline phosphatase (CIP; New England Biolabs) at 
37°C for an additional hour. This removed 5’ phosphate groups from the cut ends of the 
DNA. Digests were purified as described in section 2.1.5. 
2.1.7.3. Ligation of cohesive DNA fragment termini 
The termini of digested DNA fragments were ligated using the T4 DNA ligase (Promega). A 
typical reaction contained 1µl 10x ligase buffer, 1µl digested and purified plasmid vector (30-
100ng), 1µl (2U) of T4 ligase, 4µl of purified, digested PCR product, and molecular grade 
water to a total volume of 10µl. This reaction was thoroughly mixed and incubated at 4°C 
overnight to allow the ligation reaction to proceed to completion. For each preparation of 
linearised vector, a control reaction was also performed in which the insert DNA was 
omitted; this identified whether the vector had been fully linearised and dephosphorylated. 
Approximately 2-5µl of ligation reaction was used to transform cells of an appropriate E.coli 
strain (sections 2.2.2-4). 
2.2. Plasmid amplification and protein expression in E.coli 
2.2.1. Preparation of chemically competent E.coli XL1-Blue 
Chemically competent E.coli XL1-Blue cells (Agilent; genotype: recA1 endA1 gyrA96 thi-1 
hsdR17 supE44 relA1 lac [F’ proAB laclqZΔM15 Tn10 (Tetr)]) were prepared in-house using 
a slightly modified version of the calcium chloride protocol described in (Alexander, 1987). 
A single colony of XL1-Blue E.coli (Agilent) was used to inoculate 10ml of LB media 
containing 10µg/ml tetracycline to select for growth of only the tetracycline-resistant XL1-
Blue bacteria. This starter culture was incubated overnight at 37°C, 200rpm. The following 
morning, 5ml of the starter culture was used to inoculate 500ml of fresh, sterilised LB media 
and this culture was incubated at 30°C with shaking at 195rpm until the culture’s optical 
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density at 600nm (OD600) reached 0.45-0.55. The culture was then chilled on ice for 2h, and 
centrifuged at 2000rpm, 4°C for 20min. Harvested cells were resuspended gently in 24ml of 
ice-cold filter-sterilised salt solution (100mM CaCl2, 70mM MnCl2, 40mM sodium acetate 
(NaOAc), pH 5.5). After incubation on ice for another 45min, the cells were pelleted by 
centrifugation at 3500rpm, 4°C, for 10min. Cells were finally resuspended in 50ml of ice-
cold salt solution containing 15% (v/v) glycerol, aliquoted into sterile tubes at 200µl per tube, 
and stored at -80°C until use. Transformation efficiency was calculated by performing a set 
of standard heat-shock transformations (section 2.2.2) with known quantities of pUC18 
plasmid: 100pg, 50pg, 25pg, and 10pg. The number of bacterial colonies from these 
transformations were counted to determine the number of colony-forming units per 
microgram of DNA. 
2.2.2. Transformation of XL1-Blue cells using the heat-shock method 
In-house stocks of chemically competent XL1-Blue cells were transformed using a standard 
heat-shock method. For each transformation, 100µl of cells were combined with an 
appropriate volume of plasmid or ligation reaction in a thin-walled Falcon 2059 
polypropylene tube and incubated on ice for 20-30min. Cells were heat shocked at 42°C for 
45s, then placed on ice for 2min. To recover cells, 750µl of LB was added and the cells were 
incubated at 37°C for 45-60min. Cells were then plated on LB agar containing an appropriate 
antibiotic, and incubated at 37°C overnight before being checked for bacterial colony growth. 
2.2.3. Transformation of XL10-Gold cells using the heat-shock method 
XL10-Gold ultracompetent E.coli (Agilent; genotype: TetrΔ(mcrA)183 Δ(mcrCB-hsdSMR-
mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F´ proAB lacIqZDM15 Tn10 (Tetr) 
Amy Camr]) were used for situations requiring higher transformation efficiency, such as the 
generation of cDNA mini-libraries to be screened for alternatively spliced cDNA inserts. 
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Transformations were carried out using a scaled-down version of the manufacturer’s 
protocol: 2µl of the supplied 2-mercaptoethanol and 50µl of cells were mixed in a Falcon 
2059 tube, and incubated on ice for 10min with mixing approximately every 2min. To this 
mixture 2.5µl of ligation reaction or 1µl of a 1:50 plasmid dilution was added, and incubated 
on ice for 30min. Cells were heat shocked at 42°C for 30s and placed on ice for 2min. To 
recover cells, 750µl of LB broth was added and the cells were incubated at 37°C for 1h with 
shaking at 200rpm. Cells were spun down and re-suspended in a suitable volume of LB broth 
for plating of the entire transformation mixture on LB agar containing an appropriate 
antibiotic. Plates were incubated at 37°C overnight and checked for bacterial colony growth.  
2.2.4. Transformation of MAX Efficiency Stbl2 Competent cells using the heat-shock 
method 
MAX Efficiency Stbl2 competent cells (Life Technologies; genotype: F- mcrA Δ(mcrBC-
hsdRMS-mrr) recA1 endA1lon gyrA96 thi supE44 relA1 λ- Δ(lac-proAB)) were used for 
transformations of plasmids unstable in other E.coli strains. Transformations were carried out 
as per a scaled-down version of the manufacturer’s protocol: 3µl of plasmid plus 50µl cells 
were incubated on ice in a Falcon 2059 tube for 30min, then heat shocked at 42°C for 25s. 
After 2min on ice, cells were recovered by adding 750µl of the supplied SOC medium and 
incubated at 30°C for 60-90min with shaking at 225rpm. Cells were then spun down and 
resuspended in an appropriate volume of LB broth for plating on LB agar containing the 
appropriate antibiotic. Plates were incubated at 37°C overnight and then checked for bacterial 
colony growth. 
2.2.5. Preparation of plasmid DNA from E.coli 
Plasmid DNA was isolated from small (5-10ml), medium (50-100ml) or large-scale (150-
250ml) E.coli cultures. QIAGEN Spin Miniprep, Spin or Filter Midiprep, or Spin Maxiprep 
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kits were used to isolate DNA from these cultures respectively as per the manufacturer’s 
protocol. 
2.2.6. Expression of recombinant murine Thx-ε-SG C-terminus fusion protein in E.coli 
using the pET-32 system 
Recombinant His-tagged Thx-ε-SG isoform 1 C-terminus fusion protein was expressed in 
E.coli strain BL21 (DE3) (Agilent; genotype: E.coli B F- dcm ompT hsdS(rB
- mB
-) gal 
λ(DE3)). The fusion protein consisted of thioredoxin (Thx) plus the last 98 amino acids of 
mouse ε-SG isoform 1 (Esapa et al., 2007, Waite et al., 2011). The BL21 (DE3) strain is 
deficient in the ompT and lon proteases, which can reduce recombinant protein stability. A 
glycerol stock of BL21 (DE3) strain E.coli transformed with the fusion protein expression 
plasmid (supplied by A. Waite) was used to inoculate 10ml of LB containing an appropriate 
antibiotic, and this was incubated overnight at 37°C, 200rpm. A 2ml aliquot of the overnight 
culture was used to inoculate 250ml of LB containing an appropriate antibiotic and incubated 
at 37°C, 200rpm for about 2h until an OD600 of 0.6 was reached. Isopropyl β-ᴅ-1-
thiogalactopyranoside (IPTG) was added to the culture at a final concentration of 1mM to 
induce expression of the recombinant protein. The culture was incubated at 37°C, 200rpm for 
3h to permit protein synthesis. Cells were harvested from the culture by centrifugation at 
8000rpm, 4°C for 20 minutes. Samples (1ml) of bacterial culture were taken immediately 
before and after induction then analysed by SDS-PAGE and Coomassie blue staining 
(sections 2.5.1-2.5.3) to determine the level of protein induction.  
2.2.7. Purification of recombinant murine Thx-ε-SG isoform 1 C-terminus fusion 
protein from E.coli 
During purification of the recombinant murine Thx-ε-SG isoform 1 C-terminus fusion 
protein, buffers containing 2M urea were used to obtain denatured protein. First, the cell 
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pellet from 2.2.6 was resuspended in 15ml of sonication buffer (20mM Tris pH 8.0, 100mM 
NaCL, 2M urea) and sonicated thoroughly using a Vibra-Cell Ultrasonic Processor (Sonics) 
in 30s pulses at 50W with chilling on ice between sonication pulses. The sample was then 
centrifuged again at 13000rpm, 4°C for 20min to pellet cell debris and insoluble material. 
His-tagged Thx-ε-SG isoform 1 C-terminus fusion protein is soluble, so was purified from 
the supernatant (Esapa et al., 2007, Waite et al., 2011). In order to purify the fusion protein 
from the supernatant, an Econo-Pac® disposable chromatography column (Bio-Rad) was 
packed with 2ml of TALON® Resin (Clontech). The resin was washed once with molecular 
biology-grade water, and then equilibrated in 20ml sonication buffer containing 2M urea. The 
supernatant containing fusion protein was added to the capped column, and incubated at room 
temperature for 30min with rotation. The column was then drained of supernatant and 
unbound protein, and washed three times in sonication buffer. The column was washed once 
more, with 10ml sonication buffer containing 5mM imidazole. Recombinant protein was 
eluted from the column in 3 elutions of sonication buffer containing 100mM imidazole to 
displace His-tagged protein from the TALON resin: elution 1 was 1.8ml, elution 2 was 4ml, 
and elution 3 was 2ml. Aliquots from the resuspended cell pellet, supernatant, and elutions 
were processed for SDS-PAGE and stained with Coomassie blue (sections 2.5.1-2.5.3) to 
assess protein purification. Most of the purified protein was present in the second elution. 
2.3. Antibody preparation 
2.3.1. Generation of ε-SG isoform 2-specific antibodies 
To obtain antibodies specific to isoform 2 of ε-SG, rabbit polyclonal antibodies against the 
unique intracellular C-terminus of human ε-SG isoform 2 were generated. Two New Zealand 
white rabbits were immunised with a keyhole limpet haemocyanin-fused synthetic peptide 
corresponding to the human ε-SG isoform 2 C-terminus unique peptide NH2-C-
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QRFEVNGIPEERKLTEAMSL-COOH by CovaLab according to their standard 
immunisation protocols. Polyclonal antibodies against this peptide were purified from 
terminal bleed antiserum as described in section 2.3.2.2. 
2.3.2. Preparation of peptide immunogen affinity chromatography column 
The polyclonal rabbit antibodies against the ε-SG isoform 2-specific peptide immunogen 
were purified from terminal bleed antiserum by affinity chromatography with the immunogen 
peptide. Peptide immunogen affinity chromatography columns were produced by first filling 
an Econo-Pac® disposable chromatography column (Bio-Rad) with 2ml packed SulfoLink 
coupling resin (Thermo Scientific). This was equilibrated in 20ml coupling buffer without 
urea (50mM Tris pH 8.5, 5mM EDTA). The column was then capped before adding 2mg 
peptide immunogen (NH2-C-QRFEVNGIPEERKLTEAMSL-COOH) in 5ml coupling buffer; 
this was incubated at room temperature with rotation for 15min. The column was removed 
from the tube rotator and allowed to stand at room temperature for a further 30min. After the 
column was washed with 10ml coupling buffer, free iodoacetyl groups on the Sulfolink resin 
were blocked by incubating the column with 3ml filter-sterilised 50mM L-cysteine in 
coupling buffer for 15min at room temperature with rotation. The column was then allowed 
to stand at room temperature for a further 30 minutes before being washed with 20ml 1M 
NaCl. After the column was washed with phosphate-buffered saline (PBS; 0.1M phosphate 
buffer, 0.0027M potassium chloride, and 0.137M sodium chloride, pH 7.4), a frit was added 
and the column was ready for use. Columns were stored at 4°C with the resin equilibrated in 
PBS containing 0.025% (w/v) sodium azide. 
2.3.3. Preparation of denatured fusion protein affinity chromatography column 
Generating a fusion protein affinity chromatography column using purified denatured Thx-ε-
SG isoform 1 C-terminus fusion protein (section 2.2.7) required reduced protein. To 
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accomplish this, the protein was first desalted from sonication buffer into reduction buffer 
containing urea (0.1M sodium phosphate, 5mM EDTA, 2M urea) by running 3ml of protein 
purification elution 2 (section 2.2.7) over an Econo-Pac® 10DG desalting column (Bio-Rad) 
that had previously been equilibrated in reduction buffer. Protein was eluted in 4ml reduction 
buffer, and dithiothreitol (DTT, Sigma) was added to a final concentration of 25mM. This 
was incubated at 37°C for 90min in the dark to reduce the fusion protein. To the reduced 
protein, 2ml of coupling buffer (50mM Tris pH 8.5, 5mM EDTA, 2M urea) was added. This 
was passed over a fresh Econo-Pac® 10DG desalting column equilibrated in coupling buffer 
in two aliquots of 3ml each, with protein eluted from the column after each aliquot using 4ml 
coupling buffer. Once desalted into coupling buffer, the reduced fusion protein was incubated 
with 2ml packed coupling buffer equilibrated SulfoLink coupling resin (Thermo Scientific) 
for 15min at room temperature with rotation in an Econo-Pac® disposable chromatograph 
column (Bio-Rad). The column was then allowed to stand for 30min at room temperature 
before being drained and washed once with coupling buffer. To block remaining free 
iodoacetyl groups on the SulfoLink resin (Thermo Scientific), the column was incubated with 
2ml of 50mM L-cysteine at room temperature for 15min with rotation, and then allowed to 
stand for 30min at room temperature. The column was drained and washed once with 1M 
NaCl, then once with PBS. A frit was added, and the column was stored at 4°C with the resin 
equilibrated in PBS containing 0.025% (w/v) sodium azide.  
2.3.4. Antibody purification 
2.3.4.1. Purification of polyclonal antibodies from terminal bleed serum 
Antibodies were purified from rabbit terminal bleed antiserum using previously prepared 
affinity chromatography columns with the immunogen used to produce each antibody. For 
the esg3790 antibody the denatured Thx-ε-SG isoform 1 carboxyl terminus column (section 
2.3.3) was used, while for esg2-1355 and esg2-1358 the ε-SG isoform 2-specific peptide 
Chapter 2: Materials and methods 
 
[55] 
 
column (section 2.3.2) was used for affinity chromatography. All other antibodies were 
purified using immunogen affinity chromatography columns previously prepared by A. Waite 
(Table 2.2, section 2.3.6). Approximately 10ml of terminal bleed serum diluted to 20ml with 
PBS was repeatedly passed over a pre-clearing column (Table 2.2) equilibrated in PBS if 
required for 1h at room temperature. The diluted, pre-cleared serum was then passed over the 
appropriate PBS-equilibrated immunogen affinity chromatography column for 1h to bind 
antibodies. The column was then washed in PBS before antibodies were eluted using low-pH 
IgG elution buffer (Thermo Scientific). Eluted antibody was neutralised using 50µl 1M Tris 
pH 9 per 1ml IgG elution buffer. Columns were regenerated with a wash of IgG elution 
buffer and a wash of PBS. Columns were stored at 4°C with PBS containing 0.025% (w/v) 
sodium azide. Antibody elutions were quantified using the enhanced BCA assay kit (Piece) as 
per the manufacturer’s instructions, and stored at 4°C short term or -20°C for longer term. 
2.3.4.2. Purification of monoclonal antibodies from hybridoma culture media 
Mouse hybridoma culture supernatant containing monoclonal antibodies was supplied by A. 
Waite for the 9E10 antibody, or purchased from the Developmental Studies Hybridoma Bank 
(DSHB) for the MANDAG2 and MANDRA1 antibodies. MANDAG2 and MANDRA1 were 
both produced and deposited to the DSHB by G.E. Morris (Helliwell et al., 1994, Nguyen et 
al., 1992). Antibodies were purified from the culture supernatant by passing the supernatant 
over a PBS-equilibrated 1ml bed of packed PBS-equilibrated Protein G-sepharose (GE 
Healthcare Life Sciences) in an Econo-Pac® disposable chromatography column (Bio-Rad) 
for 2h. The column was then washed once with PBS before antibodies were eluted using IgG 
elution buffer (Thermo Scientific). Eluted antibody was neutralised using 50µl 1M Tris pH 9 
per 1ml antibody elution. Antibodies were stored at 4°C short-term or -20°C long-term. The 
Protein G-sepharose columns were regenerated by washing once with IgG elution buffer and 
once with PBS. They were stored in PBS containing 0.025% (w/v) sodium azide at 4°C. 
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2.3.5. Cross-linking of antibodies to Protein A-agarose or Protein G-sepharose beads 
Mouse monoclonal antibodies 9E10, MANDAG2 and MANDRA1 (section 2.3.6, Table 2.2) 
were coupled to Protein G-sepharose beads (GE Healthcare Life Sciences) for 
immunoprecipitation (IP) and immunoaffinity purification (IAP) experiments (sections 2.6.2 
and 2.6.4), while rabbit anti-ε-SG and anti-Tenascin-R polyclonal antibodies (section 2.3.6, 
Table 2.2) were coupled to Protein A-agarose beads (Life Technologies). 2mg of PBS-diluted 
antibody per 1ml packed PBS-equilibrated beads was incubated with the beads either 
overnight at 4°C or for 2 hrs at room temperature with rotation. 10µl samples of the diluted 
antibody before and after incubation with the beads, and a 5µl (packed) sample of the beads 
after incubation with the antibody were taken. Beads were then spun down at 2000rpm for 
5min, washed once with PBS, and washed once with 0.1M borate buffer (0.2M di-sodium 
tetraborate, 0.2M boric acid, pH 9.0). To cross-link the antibodies to the beads, the beads 
were incubated for 30min at room temperature with 5ml 20mM dimethyl pimelimidate 
dihydrochloride (DMP) in 0.1M borate buffer. Beads were spun down at 2000rpm for 5min, 
and washed once in 5ml 0.1M ethanolamine pH 8.0. Remaining DMP was quenched by 
incubating the beads in 5ml 0.1M ethanolamine for 1h at room temperature with rotation. 
Beads were then centrifuged at 2000rpm for 5min and washed once in PBS, once in 5ml IgG 
elution buffer (Thermo Scientific) to remove unbound antibody, and 2-4 times in PBS. A 
sample of cross-linked antibody beads was taken. The beads were stored as a 50% slurry in 
PBS containing 0.025% (w/v) sodium azide at 4°C.  
To assess whether cross-linking of the beads was successful, samples collected during the 
protocol (diluted antibody, depleted antibody after incubation with the beads, beads after 
incubation with the antibody, and cross-linked antibody beads) were analysed via SDS-PAGE 
and Coomassie blue staining (sections 2.5.2-2.5.3). If antibody was adsorbed to the beads, 
then antibody would be reduced in the post-incubation antibody sample compared to the 
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original diluted antibody sample. If cross-linking was successful, less protein would be 
detected in the cross-linked antibody beads compared to the first antibody beads sample. 
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2.3.6. Antibodies used in this study 
Antibody Immunogen Pre-clear 
column 
Specificity Western 
blot dil. 
IP? Source 
Rabbit polyclonal  
esg3788 Thx-ε-SG isoform 1 C-term  Thx ε-SG C-term, all isoforms 1:250 Yes (Waite, 2009) 
esg3790 Thx-ε-SG isoform 1 C-term 
denatured in 2M urea 
Thx ε-SG C-term, all isoforms 1:350 No (Waite, 2009) 
Biotinylated esg3790 Thx-ε-SG isoform 1 C-term 
denatured in 2M urea 
Thx ε-SG C-term, all isoforms 1:250 No Gift from A.Waite 
esg4990 GST-ε-SG isoform 2 C-term GST ε-SG C-term, all isoforms 1:350 Yes (Esapa et al., 2007) 
esg2-1358 ε-SG isoform 2 peptide None ε-SG isoform 2 C-term - Yes Described herein 
(Waite et al., 2016) 
esg2-1355 ε-SG isoform 2 peptide None ε-SG isoform 2 C-term - Yes Described herein 
(Waite et al., 2016) 
anti-α-tubulin (loading 
control) 
Human α-tubulin aa1-100 - α-tubulin 1:2000 No Abcam 
Mouse monoclonal  
9E10 Human c-Myc aa408-439 - c-Myc  1:350 Yes DSHB 
MANDAG2 (clone 7A10) Last 16 aa of β-dystroglycan - β-dystroglycan 1:250 Yes DSHB (Helliwell et 
al., 1994) 
MANDRA1 (clone 7D11) Human dystrophin exons 45-50 - Dystrophin C-term 1:200 Yes DSHB (Nguyen et 
al., 1992) 
M2 anti-FLAG FLAG epitope tag - FLAG epitope tag 1:2000 No Sigma Aldrich 
HA.11 HA epitope tag - HA epitope tag 1:1000 No BioLegend 
Tenascin-R clone 619 Purified tenascin-R - Tenascin-R 1:200 Yes R&D Systems 
Secondary antibodies  
Alexa Fluor 680-conjugated 
donkey anti-rabbit IgG 
rabbit IgG - rabbit IgG 1:10,000 No Life Technologies 
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IRDye800CW-conjugated 
donkey anti-mouse IgG 
mouse IgG - mouse IgG 1:10,000 No Rockland 
Immunocyto-
chemicals 
Alexa Fluor 680-conjugate 
streptavidin 
- - biotin 1:5000 No Life Technologies 
Table 2.2 Antibodies used in this study. This table provides details for each antibody used in this thesis, including both commercially purchased and in-house antibodies.  For each antibody, 
the immunogen against which it was raised and the antigen to which it binds are given. Also provided are the Western blot dilution at which the antibody was used, whether it was used for 
immunoprecipitation (IP) experiments, and the source of the antibody. For antibodies developed in-house, the affinity chromatography column used to pre-clear non-specific antibodies from the 
antiserum is also given. Abbreviations: dil., dilution; IP, immunoprecipitation; Thx, thioredoxin; GST, glutathione S-transferase; C-term, carboxyl terminus; aa, amino acids; IgG, 
immunoglobulin G; DSHB, Developmental Studies Hybridoma Bank.
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2.4. Tissue culture 
2.4.1. Mammalian cell line 
For the biochemistry experiments described herein, HEK293T cells were employed. These 
are a human embryonic kidney cell line, although the gene expression profile suggests 
potentially neuronal or adrenal origin (DuBridge et al., 1987, Lin et al., 2014). The cell line 
was originally obtained from the European Collection of Authenticated Cell Cultures 
(ECACC).  
2.4.2. Standard cell culture conditions 
HEK293T cells were cultured in high-glucose Dulbecco’s modified Eagle medium containing 
GlutaMAX supplement (DMEM, Life Technologies), with 10% foetal bovine serum (FBS, 
Life Technologies) and 1% w/v penicillin/streptomycin (Life Technologies) added. They 
were maintained as semi-adherent cultures in standard tissue culture flasks with appropriate 
volumes of media, in humidified incubators at 5% CO2. At 60-90% confluence cultures were 
passaged to maintain their viability. To passage cells, the media was removed and the cells 
washed twice in Ca2+- and Mg2+-free Hanks balanced salt solution (HBSS, Sigma). Cells 
were then detached from the flask by incubation in an appropriate volume of 1x trypsin-
EDTA (Sigma) solution at 37°C for 3min. Trypsinisation was terminated by adding the 
standard culture growth DMEM, and cells were collected through centrifugation at 1000rpm 
for 3 minutes at room temperature. The cell pellet was resuspended in an appropriate volume 
of DMEM, and reseeded in culture flasks at a 1:5 to 1:20 dilution depending on original 
confluence. For cryopreservation of cell aliquots, the cell pellet was resuspended in DMEM 
containing 10% (v/v) DMSO for a density of 1-3x106 cells/ml, aliquoted into cryovials, and 
frozen at -80°C using a Mr. Frosty (Life Technologies) to preserve cells. 
For experiments, cells were seeded into dishes or multi-well plates as follows: 
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 10cm dish: 2.5x106 cells in 10ml media per dish 
 6cm dishes: 8-8.5x105 cells in 4ml media per dish 
 6 well dish: 3.5x105 cells in 2ml media per well 
 12 well dish: 2x105 cells in 1ml media per well 
 24 well dish: 1x105 cells in 0.5ml media per well 
2.4.3. Transfection of mammalian cell cultures 
Transfection of HEK293T cells at 40-50% confluency was carried out using the FuGENE 6 
transfection reagent (Promega) as per the manufacturer’s protocol. For each 1µg of DNA to 
be transfected, 3µL of FuGENE was used. For each 6cm dish, no more than 6µg total DNA 
was transfected; for other dish/well sizes, this was scaled up or down as appropriate.  
2.4.4. Treatment of cells with bortezomib to inhibit proteasome activity 
A 1mM stock of the proteasome inhibitor bortezomib (Santa Cruz Biotech) in DMSO was 
diluted to 1µM with standard cell culture media. The culture media on 100% confluent cells 
was replaced with bortezomib-containing media. To control for the effects of the diluent 
DMSO on the cells, a second set of 100% confluent cells were treated with an equal volume 
of DMSO diluted in standard cell culture media. Cells were allowed to grow overnight (15-
18hrs) after addition of bortezomib or DMSO before collection and analysis by SDS-PAGE 
and Western blot (sections 2.5.1-2.5.4).  
2.5. Protein analysis 
2.5.1. General sample preparation for SDS-PAGE and Western blots 
2.5.1.1. Sample preparation from tissue 
Mouse tissue was homogenised in treatment buffer (75mM Tris pH 6.8, 3.8% (w/v) SDS, 4M 
urea, 20% (v/v) glycerol) using a Polytron PT 3100 bench-top homogeniser (Kinematica). 
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Cell debris was removed from the homogenate by centrifugation at 4000rpm for 10 minutes 
at 4°C. Protein concentration in the homogenate was determined using the BCA assay 
(section 2.4.3), and the homogenate was diluted to 10mg/ml using treatment buffer 
containing 0.001% (w/v) bromophenol blue and a final concentration of 5% (v/v) 2-
mercaptoethanol. Samples were stored at -20°C. For SDS-PAGE, 50-100µg was diluted to an 
appropriate volume in treatment buffer containing bromophenol blue but no 2-
mercaptoethanol. 2-mercaptoethanol was then added to a final concentration of 5% (v/v), the 
sample was boiled at 95°C for 5min and cooled on ice before being loaded onto the 
polyacrylamide gel (section 2.5.2). 
2.5.1.2. Sample preparation from cultured cells 
Cells at 100% confluency were lysed in an appropriate volume of 2x Laemmli sample buffer 
(0.125M Tris pH 6.8, 4% (w/v) SDS, 20% (v/v) glycerol, 0.001% (w/v) bromophenol blue), 
and scraped off the bottom of the plate or well. These lysates were transferred to 
microcentrifuge tubes, and sonicated using a Vibra-Cell Ultrasonic Processor (Sonics), with 
10s pulses at 50W for 2 cycles. Lysates were stored at -20°C. Prior to SDS-PAGE, 2-
mercaptoethanol was added to the lysate at a final concentration of 5% (v/v) and the sample 
was boiled at 95°C for 5min then cooled on ice before being loaded onto the polyacrylamide 
gel. 
2.5.2. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) under 
denaturing conditions 
Depending on molecular weight and the protein size differences to be resolved, proteins were 
visualised on 8-12% linear polyacrylamide gels by SDS-PAGE using the Mini Protean III gel 
system (Bio-Rad). For each gel, a resolving gel containing 380mM Tris-HCl pH 8.9, 8-12% 
(v/v) acrylamide (ProtoGel 30% (w/v) acrylamide:0.8% (w/v) bis-acrylamide 37.5:1 National 
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Diagnostics), 0.1% (w/v) sodium dodecyl sulphate (SDS), 0.1% (w/v) ammonium 
persulphate (APS) and 0.08% (v/v) N,N,N’,N’-Tetramethylethylenediamine (TEMED) was 
poured in either an 0.75mm or a 1.5mm spacer plate with short plate to complete the mould. 
During polymerisation, isopropanol was layered on the top of the resolving gel to ensure a 
level interface between that and the stacking gel. Once the gel was polymerised, the 
isopropanol was rinsed off the gel with distilled water and the gel was dried. Subsequently, a 
stacking gel containing 125mM Tris-HCl pH 6.8, 5% (v/v) acrylamide (30% (w/v) 
acrylamide:0.8% (w/v) bis-acrylamide 37.5:1), 0.1% (w/v) SDS, 0.1% (w/v) APS and 0.1% 
(v/v) TEMED was layered on top of the resolving gel. A lane-forming comb was inserted into 
this stacking gel, and it was allowed to fully polymerise at room temperature. Gels were then 
immobilised in the Mini-Protean clamp system (Bio-Rad) and submerged in 1x SDS-PAGE 
running buffer (25mM Tris-base, 192mM glycine, 1% (w/v) SDS). Samples were loaded into 
the gel lanes with volume loaded dictated by sample concentration and gel thickness: 1.5mm 
thickness gels accommodated up to about 45µl of sample per lane, whereas 0.75mm 
thickness gels accommodated up to 25µl of sample. An identical volume was loaded into 
each well on a gel to ensure even running of the gel. To determine approximate protein sizes, 
the pre-stained Protein Marker, Broad Range 6-175kDa (New England Biolabs) or its 
replacement the Blue Prestained Protein Standard, Broad Range 11-190kDa (New England 
Biolabs) was run alongside the samples. Proteins were separated by electrophoresis at 150V 
for 60-90min or until the protein markers or standards were appropriately resolved. 
2.5.3. Coomassie staining of SDS-PAGE gels 
To directly visualise proteins in an SDS-PAGE gel, the gel was stained using Coomassie blue 
stain (0.1% (w/v) Coomassie brilliant blue, 40% (v/v) methanol, 10% (v/v) acetic acid). The 
gel was incubated in the stain for 2h at room temperature with agitation. The stain was then 
drained off, and the gel was destained in 40% (v/v) methanol, 10% (v/v) acetic acid at room 
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temperature for 2-6h at room temperature or overnight at 4°C with agitation. After rinsing in 
distilled water, the stained gel was scanned using the Odyssey® Infrared Imaging System (LI-
COR Biosciences) in the 700nm channel. 
2.5.4. Western blotting 
After electrophoresis, proteins from unstained SDS-PAGE gels were transferred to 0.2µm 
pore size nitrocellulose (Amersham™ Protran®). This was accomplished using the Mini 
Trans-blot electrophoretic transfer cell (Bio-Rad). Transfers were carried out with the gel and 
nitrocellulose completely submerged in transfer buffer (25mM Tris-base, 192mM glycine, 
1% (w/v) SDS, 20% (v/v) methanol) for 1h at 75V if a single gel or 85V if proteins from two 
gels were being transferred. After protein transfer, non-specific binding sites on the 
nitrocellulose membrane were blocked by incubating the membrane in TBST (1.5M NaCl, 
500mM Tris pH 7.5, 1% (v/v) Tween) containing 5% (w/v) dried skimmed milk powder 
either for 1h at room temperature or overnight at 4°C with agitation. The blocking solution 
was removed, and replaced with the primary antibody or antibodies diluted appropriately 
(section 2.3.6, table 2.2) in 5% milk-TBST solution. The membrane was incubated in the 
primary antibody solution for 1 hr at room temperature with agitation, then washed three 
times in 1x TBST at room temperature for 5min per wash with agitation. The Alexa Fluor 
680 (Life Technologies) or IRDye 800 (Rockland Immunocytochemicals) conjugated 
secondary antibodies were diluted in TBST as appropriate (section 2.3.6, table 2.2) and added 
to the membrane; this was incubated in the dark for 30min at room temperature with 
agitation. The membrane was washed 3 further times in TBST as before. The membrane was 
then imaged using the two-channel Odyssey Infrared Imaging System (LI-COR Biosciences). 
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2.5.5. Quantitation of Western blots 
Western blot signal intensity was quantified using the Odyssey Infrared Imaging System (LI-
COR Biosciences) with Image Studio Lite Version 5.2 software (LI-COR Biosciences). To 
quantify signal intensity in a Western blot protein band, the Image Studio software was used 
to draw a rectangle around the entire band on the digital image of the blot. The intensity of 
immunofluorescence signal per channel was determined for the region inside the rectangle 
and the upper and lower boundaries of the rectangle. The background signal was calculated 
from the upper and lower boundaries of the rectangle, and subtracted from the signal within 
the rectangle to give the signal intensity of the protein band, corrected for background signal.
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2.6. Proteomics 
2.6.1. PNGase F treatment of recombinant protein 
PNGase F (New England Biolabs) is an amidase cleaving between the innermost N-
acetylglucosamine of an oligosaccharide and the asparagine to which it is linked. Transfected 
HEK293T cells in 6-well plates were collected 24-48h after transfection and washed once in 
PBS. Cells were then lysed in 100µl per well of 1x glycoprotein denaturing buffer (New 
England Biolabs). The lysate was scraped up from the well bottom, transferred to a 
microcentrifuge tube, and briefly sonicated. It was then boiled at 95°C for 10min and chilled 
on ice. For each sample, two reactions were set up as follows: 
Reagent PNGase F Undigested 
Lysate 35µl 35 µl 
GlycoBuffer 2 (New England Biolabs) 5 µl 5 µl 
PNGaseF (New England Biolabs) 1 µl - 
NP-40 (New England Biolabs) 5 µl 5 µl 
PBS 4 µl 5 µl 
 
The reaction mixtures were incubated at 37°C for 2h, and then 2x Laemmli sample buffer 
plus 2-mercaptoethanol to a final concentration of 5% (v/v) was added. Samples were 
analysed by SDS-PAGE and Western blot, as described in sections 2.5.1.2, 2.5.2 and 2.5.4 
respectively. 
2.6.2. Immunoprecipitation from cell lines 
Transfected or wild-type HEK293T cells were collected 24-48h after transfection, at 100% 
confluency. Cells were washed in ice-cold PBS, and then lysed in either ice-cold RIPA buffer 
(150mM NaCl, 50mM Tris pH 8.0, 1% (v/v) Triton X-100, 0.5% (w/v) sodium deoxycholate, 
and 1mM EGTA) or NP-40 buffer (50mM Tris pH 7.4, 150mM NaCl, 1% (v/v) NP-40) for 
30min on ice. Cells were scraped off the dish or well bottom, and triturated by repeated 
passage through a 20-23 gauge needle. Cell debris was removed by centrifugation at 
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13,000rpm for 10min at 4°C. An aliquot of the lysate was taken, and the remainder was pre-
cleared for 1h at room temperature under rotation with 10µl of packed Protein A-agarose or 
Protein G-sepharose equilibrated in the lysis buffer used. The pre-cleared lysate was then 
incubated overnight at 4°C under rotation with either cross-linked antibody beads or antibody 
pre-absorbed onto Protein A-agarose/Protein G-sepharose beads. The antibody beads with 
bound protein were then washed three times in the appropriate lysis buffer, and bound 
proteins were eluted in 20-60µl of 2x Laemmli sample buffer containing 5% 2-
mercaptoethanol by boiling at 95°C, 5min. Samples were analysed by SDS-PAGE and 
Western blot (sections 2.5.2 and 2.5.4 respectively). 
2.6.3. Cell surface biotinylation 
Biotinylation of cell surface proteins was performed using a modified version of the protocol 
in (Esapa et al., 2007). Transfected HEK293T cells at approximately 100% confluency and a 
minimum of 24 hrs post-transfection were washed once in ice-cold PBS. To biotinylated cell 
surface proteins, cells were then incubated with an appropriate volume of freshly-prepared 
0.5-1mg/ml membrane-impermeable EZ-Link sulfo-NHS-LC biotin (Pierce) in PBS at 4°C 
for 30min with gentle agitation. For a 6cm dish, 1ml of biotin solution was used; this volume 
was scaled up or down as appropriate for the surface area of the culture dish or well. To 
quench the biotinylation reaction, the biotin solution was removed and cells were incubated 
in 50mM Tris pH8.0 for 10 minutes at room temperature with gentle agitation. Cells were 
then rinsed twice in PBS; the PBS used was centrifuged to retrieve any cells that detached 
during the rinsing process. Cells were lysed in either ice-cold NP-40 lysis buffer (50mM Tris 
pH 7.4, 150mM NaCl, 1% (v/v) NP-40) or ice-cold RIPA buffer (150mM NaCl, 50mM Tris 
pH 8.0, 1% (v/v) Triton X-100, 0.5% (w/v) sodium deoxycholate, and 1mM EGTA) for 
30min on ice (500µl per 6cm dish). Lysed cells were scraped off the dish, triturated by 
passage through a 20-23G needle, and centrifuged at 13,000rpm for 10 minutes to remove 
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cell debris. Samples of the lysate were taken for subsequent analysis of protein content using 
Western blot. Proteins were then immunoprecipitated from the lysate as described in section 
2.6.2. To enrich for total biotinylated protein, High-Capacity NeutrAvidin Agarose Resin 
(Pierce) was used for affinity purification (AP). Immunoprecipitation, affinity purification 
and lysate samples were analysed by SDS-PAGE and Western blot (sections 2.5.2 and 2.5.4). 
2.6.4. Immunoaffinity purification (IAP) from mouse tissue 
Mouse tissue (brain or lung) was homogenised in 10ml of either ice-cold RIPA buffer 
(150mM NaCl, 50mM Tris pH8.0, 1% (v/v) Triton X-100, 0.5% (w/v) sodium deoxycholate, 
and 1mM EGTA) or ice-cold digitonin buffer (150mM NaCl, 50mM Tris pH8.0, 1% (w/v) 
digitonin (Merck Chemicals), and 1mM EGTA) containing EDTA-free protease inhibitors 
(Roche) and 1mM sodium orthovanadate. RIPA buffer extractions were performed in 10ml of 
buffer per 2 mouse brains, while digitonin buffer extractions were performed in 10ml of 
buffer per 1 mouse brain. Homogenisation was carried out using a Polytron PT 3100 bench-
top homogeniser (Kinematica). The homogenates were incubated on ice for 30min, volume 
adjusted to 12ml with either RIPA buffer or dilution buffer (150mM NaCl, 50mM Tris 
pH8.0, and 1mM EGTA) for RIPA-lysed and digitonin buffer-lysed samples respectively, 
and transferred to 13.2ml Thinwall polypropylene tubes (Beckman Coulter). To remove cell 
debris and clarify the samples, homogenates were centrifuged for 30min at 25000rpm 
(100000g) at 4°C in an ultracentrifuge using a SW41Ti rotor (Beckman Coulter). Samples of 
clarified homogenates were taken, and the remainder pre-cleared for 3 hrs at 4°C with 
rotation on Protein A-agarose or Protein G-Sepharose beads equilibrated in RIPA 
buffer/dilution buffer, depending on the antibody to be used for the IAP. Approximately 
200µl of packed beads per brain or lung were used for pre-clearing. The pre-cleared 
homogenate was then divided into individual samples and incubated with 60µl dilution 
buffer-equilibrated packed antibody beads per brain or lung overnight at 4°C under rotation. 
Chapter 2: Materials and methods 
 
[69] 
 
A sample of the unbound fraction was taken, and the beads were then washed three times in 
either RIPA buffer or dilution buffer depending on the original lysis buffer used. Beads were 
then transferred to 1.5ml screwcap microcentrifuge tubes, and washed once more.  
To elute bound proteins, two sequential elutions in 60µl each of 2x lithium dodecyl sulphate 
(LDS) sample buffer (Life Technologies) or 2x Laemmli sample buffer were performed: 
1. Beads incubated in sample buffer without reducing agent at 65°C for 30min, then 
boiled at 95°C for 5min before being cooled on ice. The supernatant containing eluted 
proteins was removed to a sterile microcentrifuge tube, and DTT was added to a final 
concentration of 50mM. The elution with added DTT was then boiled again at 95°C 
for 5min. This was elution 1. 
2. Beads boiled in sample buffer containing 50mM DTT at 95°C for 5min. This was 
elution 2. 
For one immunoaffinity purification (IAP) experiment, proteins were eluted sequentially 
in 60µl Rapigest SF elution buffer (Waters) as follows: 
1. Beads incubated with 60µl Rapigest at 65°C for 35min, then boiled at 95°C for 
5min. Supernatant removed to a sterile tube as elution 1. 
2. Beads boiled in 60µl Rapigest at 95°C for 5min. Supernatant removed to a sterile 
tube as elution 2. 
3. Beads boiled in 60µl 2x Laemmli sample buffer with 50mM DTT at 95°C for 
5min. This was elution 3. 
For each IAP elution, an aliquot was analysed by SDS-PAGE and Western blot as 
described in sections 2.5.2 and 2.5.4. 
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2.6.5. IAP sample preparation for mass spectrometry 
If an IAP sample was to be analysed by mass spectrometry (MS), a 40µl aliquot of elution 1 
(section 2.6.4) was resolved by electrophoresis on a 4-12% gradient NuPAGE® Novex Bis-
Tris gel (Life Technologies). Gels were run at 150V in 1x MOPS Running Buffer (Life 
Technologies), using the XCell Surelock™ Mini-Cell system (Life Technologies). If the entire 
IAP sample was to be analysed by MS, the gel was electrophoresed for 12-15min. If specific 
protein bands were to be excised and analysed by MS, the gel was run for 90min. After 
electrophoresis, gels were fixed by incubation at room temperature for 15min in 50% (v/v) 
methanol and 7% (v/v) acetic acid diluted with molecular biology-grade water. Gels were 
then washed twice for 5min per wash in molecular biology-grade water. To stain for proteins, 
gels were incubated at room temperature in colloidal Coomassie blue stain, either Gelcode 
Blue Stain (Pierce) for 2h or InstantBlue (Expedeon) for 1h. If Gelcode Blue Stain was used, 
the gel was then destained in molecular biology-grade water. The stained gels were imaged 
with the Odyssey® Infrared Imaging System (LI-COR Biosciences) in the 700nm channel. 
Bands were then excised with clean scalpel blades and placed in sterile 1.5ml screwcap 
microcentrifuge tubes to be sent for MS analysis. 
2.6.6. Protein identification by mass spectrometry 
Excised gel plugs were sent to The Functional Genomics and Proteomics Laboratories in the 
School of Biosciences at the University of Birmingham for processing. There, the samples 
were first digested using automated in-gel trypsin digest with a Qiagen 3000 robot. The 
resultant peptides were extracted into 1% formic acid, and size separated through a 2-
dimensional nano-liquid chromatography system (Dionex). Peptides were then ionised and 
sprayed into a Velos Orbitrap mass spectrometer (Thermo Fisher) using the Triversa 
Nanomate (Advion) chip-based electrospray system. The Velos Orbitrap is a hybrid mass 
spectrometer containing a linear ion trap and Orbitrap analyser (Eliuk and Makarov, 2015). 
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Output mass spectra were analysed using the SEQUEST algorithm as implemented in the 
Proteome Discoverer software suite (Thermo Fisher) to correlate mass spectra with protein 
identities (Eng et al., 1994, Yates et al., 1995). Excel pivot tables of assigned spectra that 
were exported from Proteome Discoverer were used in further cross-sample comparison and 
filtration as described in Chapter 3.  
2.7. General bioinformatics 
Gene and protein sequences were obtained from four databases: NCBI GenBank and RefSeq, 
Ensembl, UniProtKB/Swiss-Prot, and the Leiden Open Variation Database (LOVD) (Brown 
et al., 2015, Flicek et al., 2014, Fokkema et al., 2011, Harrow et al., 2012). General DNA and 
protein sequence similarity searches were carried out using the BLAST (Basic Local 
Alignment Search Tool) suite of programs (Altschul et al., 1990, Altschul et al., 1997, 
Camacho et al., 2009). To compare sequences between species, the BLAT (BLAST-Like 
Alignment Tool) program was used (Kent, 2002). Sequences were aligned using Clustal 
Omega (Sievers et al., 2011). The RepeatMasker program web server with the cross_match 
search engine was used to identify sequences derived from transposable elements  (Smit et 
al., 2013-2015). The Swiss Institute of Bioinformatics ExPASy (Expert Protein Analysis 
System) proteomics portal was used for DNA to protein translation (Artimo et al., 2012). To 
identify translation initiation codons, ATGpr and NetStart servers were used (Nishikawa et 
al., 2000, Pedersen and Nielsen, 1997, Salamov et al., 1998). The NetNGlyc 1.0 server 
(http://www.cbs.dtu.dk/services/NetNGlyc/) was used to predict N-linked glycosylation sites, 
while signal sequences were predicted using SignalP 4.1 (Petersen et al., 2011). Venn 
diagrams were produced using the Venn diagram tool from the Bioinformatics and Systems 
Biology server at Ghent University was used 
(http://bioinformatics.psb.ugent.be/webtools/Venn/). 
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Chapter 3: ε-SG protein interactions in the brain 
3.1. Introduction 
While the role of SGCE mutations in the genetic aetiology of MD is well-established, little is 
known about the function of ε-SG in the brain. As discussed in Chapter 1 (section 1.4.2), 
complexes containing ε-SG have been described in cardiac and smooth muscle, adipose tissue 
and peripheral nerve Schwann cells (Cai et al., 2007, Durbeej and Campbell, 1999, Groh et 
al., 2009, Imamura et al., 2000, Lancioni et al., 2011, Liu and Engvall, 1999, Straub et al., 
1999). In these tissues, ε-SG is part of prototypical εβδγ or εβδζ heterotetramers that 
associate with other DGC components (Cai et al., 2007, Durbeej and Campbell, 1999, Groh 
et al., 2009, Imamura et al., 2000, Lancioni et al., 2011, Liu and Engvall, 1999, Straub et al., 
1999). Despite ε-SG’s broad expression and integration into muscle sarcoglycan complexes, 
SGCE mutation-positive MD patients have no evident muscle pathology (Asmus et al., 2002, 
Durbeej and Campbell, 1999, Hjermind et al., 2008, Straub et al., 1999). By contrast, no MD-
like features have been described in LGMD patients with sarcoglycan mutations (Hjermind et 
al., 2008). Several explanations have been proposed for this apparent paradox. For example, 
the early onset and severe muscle phenotype of LGMD could mask any movement disorder 
features in patients with sarcoglycan mutations. Alternatively, ε-SG in the brain may have a 
function independent of the DGC. Alternative splicing of SGCE pre-mRNA results in brain-
specific ε-SG isoforms, and a putative unique function of the brain-specific ε-SG isoform 2 
has been suggested to underlie the purely neurological phenotype of MD (Nishiyama et al., 
2004, Ritz et al., 2011, Yokoi et al., 2005). To gain further insight into the role of ε-SG in the 
brain and thus in the pathogenesis of MD, I used immunoaffinity purification (IAP) followed 
by mass spectrometry (MS) to identify proteins interacting with ubiquitous isoform 1 and 
brain-specific isoform 2 of ε-SG in the brain. 
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3.2. Results 
IAP was used to identify proteins interacting with ε-SG in the brain because it enabled 
unbiased identification of protein interactions from native protein complexes in 
physiologically relevant tissues. Other approaches to defining protein-protein interactions 
rely on prior knowledge of probable interactions (co-immunoprecipitation, fluorescence 
resonance energy transfer), use non-native environments to identify interactions (yeast 2-
hybrid), or require protein overexpression that can lead to false positives through excessive 
protein abundance (tandem affinity purification) (Carneiro et al., 2016). By contrast, IAP 
using validated anti-ε-SG antibodies allowed isolation of native ε-SG-containing complexes 
directly from brain tissue. MS analysis of the purified ε-SG-containing complexes was then 
used to identify the proteins in those complexes. In order to determine whether the brain-
specific ε-SG isoform 2 was part of the same protein complexes as the ubiquitous isoform 1, 
an antibody that binds only the brain-specific ε-SG isoform 2 was used for IAP along with 
antibodies against all ε-SG isoforms. 
3.2.1. Generation and validation of the esg2-1358 antibody specific to ε-SG isoform 2 
To specifically detect ε-SG isoform 2, polyclonal antibodies against the unique C-terminal 
peptide of human ε-SG isoform 2 were raised in rabbits (Chapter 2 section 2.3.1 and 2.3.4). 
Briefly, two rabbits were immunised with a peptide antigen (Figure 3.1), and polyclonal 
antibodies were isolated from terminal bleed serum by peptide affinity chromatography. 
Initial evaluation of these antibodies indicated that neither was useful for Western blotting, 
while the esg2-1358 antibody performed better for immunoprecipitation (IP) and was 
therefore used in preference to the esg2-1355 antibody in subsequent experiments (data not 
shown).  
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To determine the specificity of esg2-1358 in immunoprecipitation, this antibody was used to 
perform an IAP of ε-SG from RIPA-solubilised mouse whole brain tissue in parallel with the 
previously characterised esg4990 antibody (Chapter 2 section 2.6.4, Table 2.2) (Waite et al., 
2011). Esg4990 was raised against the entire C-terminus of ε-SG isoform 2 and detects all ε-
SG isoforms (Figure 3.1). As predicted, the esg4990 antibody enriched ε-SG isoform 1, ε-SG 
isoform 2 exon 8+ and ε-SG isoform 2 exon 8- (Figure 3.2). By contrast, esg2-1358 enriched 
only ε-SG isoform 2 exon 8+ and ε-SG isoform 2 exon 8- (Figure 3.2). This confirmed 
specificity of esg2-1358 to ε-SG isoform 2 and validated its use for IAP.  
Figure 3.1 Major features of ε-SG isoforms 1 and 2, and antibody antigens. The polypeptides for ε-SG isoforms 1 and 2 
are shown, with the signal sequence marked in red, transmembrane domain (TM) marked in yellow, region encoded by exon 
8 marked in blue (8), N-linked glycosylation sites marked with N and the unique C-terminus sequences of isoforms 1 and 2 
marked in pink and purple respectively. The amino acid sequences of the exon 8-encoded region and the C-termini for the 
isoforms are provided below. Brackets enclose residues encoded at splice sites. Mouse protein immunogens used to raise 
antibodies used in this study are indicated. Abbreviations: TM, transmembrane domain; 8, peptide encoded by exon 8. 
Figure 3.2 IAP of endogenous ε-SG from mouse whole brain using two distinct anti-ε-SG antibodies. The pan-ε-SG 
antibody esg4990 binding all major isoforms of ε-SG and the ε-SG isoform 2-specific esg2-1358 antibody were used to 
enrich ε-SG from RIPA-lysed mouse whole brain through IAP. Three sequential elutions were performed after IAP to 
ensure elution of all ε-SG from the protein A-agarose-conjugated antibodies. Immunoblot of IAP elutions using the 
biotinylated pan-ε-SG antibody esg3790 (see Figure 3.1) demonstrated that three distinct ε-SG proteins were present in the 
esg4990 IAP; these were ε-SG isoform 1, ε-SG isoform 2 exon 8-, and ε-SG isoform 2 exon 8+ from smallest to largest. By 
contrast just two ε-SG bands were detected in the esg2-1358 IAP, corresponding to ε-SG isoform 2 exon 8- and ε-SG 
isoform 2 exon 8+ only. No ε-SG isoform 1 could be detected in any esg2-1358 IAP elution, indicating that the esg2-1358 
antibody specifically isolated ε-SG isoform 2. Abbreviations: kDa, kilodaltons; E1, IAP elution 1; E2, IAP elution 2; E3, 
IAP elution 3; ε-SG 2, ε-SG isoform 2; ε-SG 1, ε-SG isoform 1. 
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3.2.2. Identification of a brain sarcoglycan complex containing ε-SG isoform 2 
3.2.2.1. ε-SG isoform 2 co-purifies with β-SG, δ-SG and ζ-SG in mouse brain 
The esg2-1358 and esg2-1355 antibodies were conjugated to Protein A-agarose beads and 
used for IAP of ε-SG isoform 2-containing complexes from RIPA-solubilised wild-type 
mouse whole brain as previously described (Chapter 2 section 2.6.4) (Waite et al., 2016). A 
control IAP using non-specific immunoglobulin derived from an immunogen-naïve rabbit 
(pre-immune immunoglobulin) conjugated to protein A-agarose beads was also performed in 
parallel to identify non-specific interactions with immunoglobulin and the Protein A-agarose 
beads. Western blot confirmed enrichment of ε-SG isoform 2 only in IAPs from mouse brain 
tissue using the esg2-1355 and esg2-1358 antibodies but not in the pre-immune 
immunoglobulin IAP (Figure 3.3a). ε-SG isoform 1 running at approximately 48kDa (Figure 
3.2) was not detected in any of these IAPs. Importantly, these data also indicated that ε-SG 
isoforms 1 and 2 do not co-purify in mouse brain and therefore form separate protein 
complexes. Subsequent IAPs using the esg2-1358 antibody (sections 3.2.4, 3.2.5) confirmed 
this result.  
Having shown enrichment of ε-SG isoform 2 in the esg2-1358 IAPs, samples were analysed 
by MS to identify proteins co-purifying with ε-SG isoform 2. To prepare samples for MS 
analysis, the IAPs were resolved by polyacrylamide gel electrophoresis, fixed and stained 
with colloidal Coomassie blue (Chapter 2 section 2.6.5). Eight protein bands covering a range 
of sizes including the 25-55kDa region predicted to contain all sarcoglycans were excised 
from the esg2-1358 IAP as indicated (Figure 3.3b). These were analysed by MS at the 
University of Birmingham Functional Genomics and Proteomics Laboratories (Chapter 2 
section 2.6.6). After filtering out common contaminants such as keratins and 
immunoglobulins, the list of protein identities in each band were ranked by Proteome 
Discoverer protein identity score as shown in Table 3.1 (Trinkle-Mulcahy et al., 2008).  
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Figure 3.3 IAP of complexes containing ε-SG isoform 2 from whole mouse brain lysed in RIPA buffer. Protein 
complexes were enriched from mouse whole brain lysed in RIPA buffer using pre-immune IgG as a control, or the ε-SG 
isoform 2-specific antibodies esg2-1355 and esg2-1358 to enrich for complexes containing ε-SG isoform 2. A) Immunoblot 
analysis of the IAP elutions using a biotinylated pan-ε-SG antibody confirmed enrichment of ε-SG isoform 2 in the esg2-
1355 and esg2-1358 IAPs but not in the pre-immune IgG control IAP. B) IAP elutions were resolved via PAGE, fixed, and 
stained for proteins using colloidal Coomassie blue. Bands A1 through A8 (blue rectangles) were excised and analysed by 
MS. Abbreviations: kDa, kilodaltons; Pre-immune, IAP using pre-immune IgG; esg2-1355, IAP using esg2-1355; esg2-
1358, IAP using esg2-1358; E1, IAP elution 1; E2, IAP elution 2. 
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Band Gene Description Protein 
identity score 
Number of 
unique peptides 
Spectral 
count 
A1 
Prss1 protease, serine 1 124.34 2 21 
Jup Junction plakoglobin 74.73 2 5 
A2 
Map3k5 mitogen activated protein kinase kinase kinase 5 2924.17 48 232 
Rab11fip5 rab11 family-interacting protein 5 isoform 1 845.64 25 50 
Uhrf1bp1l UHRF1-binding protein 1-like 690.12 22 44 
Map3k15 mitogen-activated protein kinase kinase kinase 15 369.35 11 48 
Tnr Tenascin R 339.79 12 16 
Clasp2 CLIP-associating protein 2 300.99 10 14 
Tjp1 Tight junction protein ZO-1 187.13 10 14 
Nefh Neurofilament heavy polypeptide 184.4 7 9 
Kiaa1109 Uncharacterized protein KIAA1109 174.73 6 11 
Kcna3 Potassium voltage-gated channel subfamily A member 3 167.48 3 15 
Dgkh Diacylglycerol kinase eta 160.09 5 10 
Nsf Vesicle-fusing ATPase 151.5 6 13 
Map3k6 Mitogen-activated protein kinase kinase kinase 6 139.38 9 21 
Atp1a3 Sodium/potassium-transporting ATPase subunit alpha-3 122.8 1 4 
Ampd2 AMP deaminase 2 113.16 5 12 
Kcna6 Potassium voltage-gated channel subfamily A member 6 105.93 2 9 
Atp1a1 Sodium/potassium-transporting ATPase subunit alpha-1 103.09 1 3 
Kcna2 Potassium voltage-gated channel subfamily A member 2 99.98 1 9 
Cadps Calcium-dependent secretion activator 1 97.49 4 5 
Ccdc136 coiled-coil domain-containing protein 136 isoform 2  83.49 2 2 
Prss1 protease, serine 1 80.49 1 10 
Fmnl1 Formin-like protein 1 80.04 1 7 
Tjp2 Tight junction protein ZO-2 74.33 2 9 
Slc1a2 Excitatory amino acid transporter 2 72.01 3 7 
Wdr7 WD repeat-containing protein 7 71.74 3 4 
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A3 
Tpd52l2 tumor protein D52-like 2 746.33 3 95 
C1orf43 Uncharacterized protein C1orf43 homolog 292.74 8 28 
Rab34 Ras-related protein Rab-34 249.92 7 17 
Fam26e Protein FAM26E 141.07 3 15 
Atp6v1d V-type proton ATPase subunit D 140.89 3 4 
Tppp Tubulin polymerization-promoting protein 129.51 3 4 
Vapa Vesicle-associated membrane protein-associated protein A 118.11 3 8 
Hsd17b8 Estradiol 17-beta-dehydrogenase 8 114.97 3 3 
Impa1 Inositol monophosphatase 1 113.23 4 5 
Ppp3ca Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform 111.93 4 8 
Prss1 protease, serine 1 109.92 1 24 
Tpd52 Tumor protein D52 108.4 2 3 
Hsd17b12 Very-long-chain 3-oxoacyl-CoA reductase 106.57 2 3 
Rbm15 Putative RNA-binding protein 15 104.98 4 8 
Atp6v1e1 V-type proton ATPase subunit E 1 97.59 4 6 
Fhl3 Four and a half LIM domains protein 3 87.97 1 2 
Vapb Vesicle-associated membrane protein-associated protein B 85.89 2 6 
Ampd2 AMP deaminase 2 76.87 3 7 
A5 
Flot1 Flotillin-1 1170.32 22 47 
Mb21d2 Protein MB21D2 920.69 16 54 
Scrn1 Secernin-1 524.14 13 29 
Trim21 E3 ubiquitin-protein ligase TRIM21 387.62 11 22 
Eno1 Alpha-enolase 328.32 6 16 
Kcna6 Potassium voltage-gated channel subfamily A member 6 297.08 8 19 
Kcna3 Potassium voltage-gated channel subfamily A member 3 280.61 7 18 
Ap2m1 AP-2 complex subunit mu 258.02 11 17 
Camk2a Calcium/calmodulin-dependent protein kinase type II subunit alpha 254.79 7 12 
Sept7 Septin-7 240.56 6 12 
Ccdc136 Coiled-coil domain-containing protein 136 238.14 8 12 
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Blmh Bleomycin hydrolase 195.47 5 8 
Eno2 Gamma-enolase 175.73 2 8 
Sept6 Septin-6 156.53 4 9 
Sept11 Septin-11 145.54 2 8 
Btbd17 BTB/POZ domain-containing protein 17 121.32 2 3 
Clcc1 Chloride channel CLIC-like protein 1 117.78 2 3 
Ppp2r2a Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B 
alpha isoform 
114.83 2 3 
Endod1 Endonuclease domain-containing 1 protein 113.64 5 6 
Slc1a3 Excitatory amino acid transporter 1 104.79 3 6 
Ckb Creatine kinase B-type 98.4 2 2 
Gda Guanine deaminase 90.75 2 3 
Ina Alpha-internexin 88.49 3 7 
Ampd2 AMP deaminase 2 88.12 6 8 
Dctn2 Dynactin subunit 2 87.36 2 3 
Atp1b1 Sodium/potassium-transporting ATPase subunit beta-1 87.3 4 6 
Rufy3 Protein RUFY3 78.11 2 4 
Map3k5 mitogen activated protein kinase kinase kinase 5 73.13 3 4 
Samm50 Sorting and assembly machinery component 50 homolog 69.28 3 6 
Rbm15 Putative RNA-binding protein 15 63.06 2 4 
Slc1a2 Excitatory amino acid transporter 2 54.73 2 3 
Atp6v1h V-type proton ATPase subunit H 54.71 3 4 
Nsf Vesicle-fusing ATPase 54.12 2 2 
Ctbp1 C-terminal binding protein 1 51.3 3 4 
Psmc3 26S protease regulatory subunit 6A 49.32 2 2 
Fam26e Protein FAM26E 46.01 2 3 
Sh3glb2 Endophilin-B2 45.92 3 5 
Fscn1 Fascin 45.58 2 2 
Mapt Microtubule-associated protein tau 45.47 3 4 
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Serbp1 Plasminogen activator inhibitor 1 RNA-binding protein 44.17 2 3 
Sgce Epsilon sarcoglycan, isoform 2 302.64 8 24 
Sgce Epsilon sarcoglycan 276.02 10 25 
Prss1 protease, serine 1 141.38 1 16 
Atp6v1b2 V-type proton ATPase subunit B, brain isoform 70.58 1 1 
Pdia6 Protein disulfide-isomerase A6 70.03 1 1 
A6 
Glul Glutamine synthetase 401.75 14 33 
Ckb Creatine kinase B-type 318.23 9 21 
Kcnab1 Voltage-gated potassium channel subunit beta-1 307.56 8 23 
Mbip MAP3K12-binding inhibitory protein 1 301.03 10 22 
Map2k1 Dual specificity mitogen-activated protein kinase kinase 1 282.89 7 23 
Jup Junction plakoglobin 260.28 8 14 
Kcnab3 Voltage-gated potassium channel subunit beta-3 252.87 4 8 
Sept5 Septin-5 221.05 7 17 
Erlin2 Erlin-2 189.13 6 8 
Aldoa Fructose-bisphosphate aldolase A 178.69 8 17 
Actr1b Beta-centractin 158.81 2 8 
Actr1a Alpha-centractin 157.55 3 12 
Aldoc Fructose-bisphosphate aldolase C 150.56 2 6 
Pdcd6 Programmed cell death protein 6 137.33 4 8 
Serpinb5 Serpin B5 132.15 4 6 
Sept2 Septin-2 119.81 4 5 
Eppk1 Epiplakin 116.33 2 14 
Prss1 protease, serine 1 102.95 1 19 
Pcmtd1 protein-L-isoaspartate O-methyltransferase domain-containing protein 1 101.11 2 5 
Actr2 Actin-related protein 2 99.82 3 7 
Sh3gl2 Endophilin-A1 98.08 2 4 
Vcp Transitional endoplasmic reticulum ATPase 97.54 4 5 
Eno1 Alpha-enolase 93.79 4 6 
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Evpl Envoplakin 92.09 3 9 
Got1 Aspartate aminotransferase, cytoplasmic 89.08 3 4 
Kcnab2 Voltage-gated potassium channel subunit beta-2 83.51 2 7 
Pkp1 Plakophilin-1 82.82 1 2 
Sept3 Neuronal-specific septin-3 80.23 2 6 
Ampd2 adenosine monophosphate deaminase 2 77.11 3 8 
Clcc1 chloride channel CLIC-like protein 1 76.21 2 3 
Sgcb Beta sarcoglycan 76.08 4 6 
Atp1b1 Sodium/potassium-transporting ATPase subunit beta-1 74.66 2 2 
Nccrp1 F-box only protein 50 74.64 1 1 
Pdia6 Protein disulfide-isomerase A6 73.74 1 1 
Pkm Pyruvate kinase PKM 71.06 2 3 
A7 
Kcnab2 Voltage-gated potassium channel subunit beta-2 707.42 15 92 
Gnao1 Guanine nucleotide-binding protein G(o) subunit alpha 370.96 9 23 
Kcnab1 Voltage-gated potassium channel subunit beta-1 271.04 4 48 
Aldoa Fructose-bisphosphate aldolase A 202.2 3 7 
Clcc1 chloride channel CLIC-like protein 1 172.36 8 13 
Gnai2 Guanine nucleotide-binding protein G(i) subunit alpha-2 170.71 3 11 
Aldoc Aldolase C, fructose-bisphosphate 156.58 5 9 
Capza2 F-actin-capping protein subunit alpha-2 152.41 7 15 
Acot7 Cytosolic acyl coenzyme A thioester hydrolase 146.95 4 6 
Mapk1 mitogen-activated protein kinase 1 134.84 9 15 
Bub3 Mitotic checkpoint protein BUB3 130.83 6 11 
Tpd52l2 tumor protein D52-like 2 130.42 4 7 
Rbm15 Putative RNA-binding protein 15 125.42 4 13 
Strap Serine-threonine kinase receptor-associated protein 123.28 5 9 
Sirt2 NAD-dependent protein deacetylase sirtuin-2 123.23 6 7 
Phyhip Phytanoyl-CoA hydroxylase-interacting protein 119.09 5 7 
Psat1 Phosphoserine aminotransferase 112.24 4 6 
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Glul Glutamine synthetase 111.24 4 8 
Ppp1ca Serine/threonine-protein phosphatase PP1-alpha catalytic subunit 111.01 1 6 
Rpsa 40S ribosomal protein SA 110.73 3 6 
Gnai1 guanine nucleotide binding protein (G protein), alpha inhibiting 1 105.72 2 9 
Ppp1cc Serine/threonine-protein phosphatase PP1-gamma catalytic subunit 105.14 2 7 
Taldo1 transaldolase 104.9 4 9 
Ppp1cb Serine/threonine-protein phosphatase PP1-beta catalytic subunit 103.02 1 5 
Atp6v0d1 V-type proton ATPase subunit d 1 101.72 6 11 
Syp Synaptophysin 101.26 3 8 
Mdh1 Malate dehydrogenase, cytoplasmic 100.6 4 4 
Sgcd Delta sarcoglycan 96.54 4 5 
Dcaf7 DDB1- and CUL4-associated factor 7 92.72 4 4 
Dnajb2 DnaJ homolog subfamily B member 2 91.46 4 4 
Fbxo2 F-box only protein 2 91.14 1 1 
Prss1 protease, serine 1 90.88 1 14 
Sgcz Zeta sarcoglycan 88.3 1 1 
Blvra Biliverdin reductase A 87.15 3 6 
Lancl1 LanC-like protein 1 85.95 4 10 
Clu Clusterin 83.97 4 5 
Kcna3 Potassium voltage-gated channel subfamily A member 3 82.6 3 6 
Gpd1 Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic 82.26 4 6 
Gnb5 Guanine nucleotide-binding protein subunit beta-5 81.22 3 4 
Gnb1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 78.41 4 6 
Gpd1l Glycerol-3-phosphate dehydrogenase 1-like protein 77.59 2 8 
PPP2CB Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform 75.73 2 3 
Pcmtd2 Protein-L-isoaspartate O-methyltransferase domain-containing protein 2 75.59 4 5 
Ampd2 Adenosine monophosphate deaminase 2 74.92 5 10 
Zadh2 Zinc-binding alcohol dehydrogenase domain-containing protein 2 73.2 2 3 
Fam26e Protein FAM26E 72.3 2 6 
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Napg Gamma-soluble NSF attachment protein 70.74 2 6 
A8 
Tpd52l2 tumor protein D52-like 2 395.85 3 26 
Phb Prohibitin 192.65 7 13 
Fam26e Protein FAM26E 179.44 6 24 
Vdac2 Voltage-dependent anion-selective channel protein 2 132.15 7 14 
Tppp Tubulin polymerization-promoting protein 115.34 3 5 
Map1b Microtubule-associated protein 1B 110.15 3 6 
Napa Alpha-soluble NSF attachment protein 102.36 3 8 
Cops7a COP9 signalosome complex subunit 7a 96.18 2 2 
Vdac3 Voltage-dependent anion-selective channel protein 3 91.67 5 14 
Clta Clathrin light chain A 91.17 4 6 
Rack1 Receptor of activated protein C kinase 1 91.03 6 7 
Atp6v1e1 V-type proton ATPase subunit E 1 82.03 4 5 
Vdac1 Voltage-dependent anion-selective channel protein 1 77.65 3 6 
Vapb Vesicle-associated membrane protein-associated protein B 76.28 1 4 
Fhl2 Four and a half LIM domains protein 2 75.42 4 11 
Rogdi Protein rogdi homolog 73.49 2 5 
Table 3.1 Proteins identified by MS in the esg2-1358 IAP from RIPA-lysed mouse whole brain. The esg2-1358 antibody was used for IAP of ε-SG isoform 2 from RIPA-lysed mouse 
whole brain tissue. This table summarises the proteins identified in the IAP via mass spectrometry, ordered by the gel band in which the protein was identified and the protein identity score. 
Protein identity score is calculated by the SEQUEST algorithm implemented in Proteome Discover, and indicates the likelihood that a given protein was present in the sample. Also provided are 
the gene symbol, number of unique peptides corresponding to that particular protein and accession number detected in the sample, and the spectral count associated with that protein. Spectral 
count represents the number of mass spectra detected in the sample that corresponded to that particular protein, and can reflect abundance. Band A4 contained only immunoglobulins and 
contaminants. The sarcoglycans are highlighted in green, TnR is highlighted in blue, and the Shaker-related voltage-gated potassium channel subunits are highlighted in orange.
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Gene Uniprot 
acc. 
Gel 
band 
Unique peptide sequences Identity 
score 
Total 
peptides 
Spectral 
count 
Protein 
coverage 
SGCE O70258 A5 
NVYPSAGVLFVHVLER 
302.64 23 49 35.13% 
QVSTYQEVVR 
GEGILPDGGEYKPPSDSLK 
NMNVEEMLASEVLGDFLGAVK 
THFHIDWCK 
FEVNGIPEER 
VPLPINDMK 
TPYSDGVLYGSPTAENVGKPTIIEITAYNRR 
EVENPQNQLR 
KLTEAMSL 
NVWQPER 
DMQTPDIQLVHHSSIQK 
SGCB P82349 A6 
AAAAAAAAATEQQGSNGPVKK 
76.08 4 6 25% 
RNENLVITGNNQPIVFQQGTTK 
THNILFSTDYETHEFHLPSGVK 
TSITSDIGMQFFDPR 
SGCD P82347 A7 
LLFSADDSEVVVGAER 
96.54 5 5 20.42% 
LEGDSEFLQPLYAK 
VLTQLVTGPK 
VLGAEGTVFPK 
SIETPNVR 
SGCZ Q8BX51 A7 VLFSADEDEITIGAEK 88.3 1 1 6.87% 
Table 3.2 Sarcoglycan peptides identified in the esg2-1358 IAP of ε-SG from whole CD-1 mouse brain lysed in RIPA buffer. For each sarcoglycan identified in the esg2-1358 IAP from 
RIPA-lysed mouse whole brain, all unique peptide sequences detected in the sample and the band in which they were present are given. The protein identity score provides the confidence in that 
protein’s presence in the sample analysed by MS. The protein’s Uniprot accession code, the number of total peptides detected, spectral count, and coverage by identified peptides (Protein 
coverage) are all also provided. Peptides in bold are specific to ε-SG isoform 2.
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Only immunoglobulins and keratins were detected in protein band A4, but all other bands 
contained multiple protein matches. Peptides corresponding to ε-SG, β-SG, δ-SG and ζ-SG 
were all identified with high confidence in the IAP, including peptides derived from the 
unique ε-SG isoform 2 C-terminus (Table 3.2). No γ-SG peptides were identified, which was 
consistent with the reported low expression of γ-SG in the brain (Durbeej and Campbell, 
1999, Noguchi et al., 1995, Noguchi et al., 2001, Waite et al., 2016). Co-purification of β-SG, 
δ-SG and ζ-SG with ε-SG isoform 2 suggested that ε-SG isoform 2 may be incorporated into 
a prototypical heterotetramer comprising εβδζ in the brain.  
In addition to the sarcoglycans, Shaker-related voltage-gated K+ channel subunits were 
identified in bands A2, A5, A6 and A7 (Table 3.1). These were later examined for a potential 
cross-reaction with the esg2-1358 antibody (section 3.2.4). Additionally, the extracellular 
matrix protein proteoglycan tenascin-R was identified in band A2 (Table 3.1). Subsequent 
IAP-MS experiments suggested this protein did indeed co-purify with ε-SG (section 3.2.5).  
3.2.2.2. Alternative splicing of ε-SG does not affect formation and localisation of 
an εβδζ tetramer in heterologous cells 
The IAP-MS experiment described above supported the existence of prototypical εβδζ 
sarcoglycan heterotetramers in the brain. Moreover, ε-SG isoforms 1 and 2 must be part of 
separate tetramers since isoform 1 did not co-purify with isoform 2 in the esg2-1358 IAP. 
Though both isoforms were part of prototypical heterotetramers, alternatively spliced ε-SG 
isoforms as described in Chapter 1 (section 1.3.2.2) could affect complex assembly and 
trafficking. Therefore, assembly and trafficking of the brain sarcoglycan complex with 
different ε-SG isoforms was examined in HEK293T cells co-transfected with different 
combinations of plasmids encoding epitope-tagged sarcoglycans. For these experiments, 
plasmids encoding human sarcoglycans were used since they had already been generated as 
Chapter 3: ε-SG protein interactions in the brain 
 
[86] 
 
part of the study described in Chapter 4 and have high similarity to their mouse orthologues. 
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Transfected cells were treated with a membrane-impermeable biotin reagent to label cell 
surface sarcoglycan complexes only, and proteins were either immunoprecipitated using 
esg4990-Protein A agarose beads to enrich for ε-SG-containing complexes or affinity purified 
using NeutrAvidin resin to enrich for biotinylated proteins (Chapter 2 section 2.6.3). 
Immunoprecipitated proteins were analysed by Western blot. All experiments were repeated 
three times as previously described (Waite et al., 2016).  
Western blotting with streptavidin-Alexa Fluor 680 to detect biotinylated proteins showed 
that all ε-SG isoforms trafficked to the cell surface both independently and with other 
sarcoglycans, though co-expression with other sarcoglycans increased cell surface ε-SG 
(Figures 3.4 and 3.5, lanes 2, 5, 8, 11; Figure 3.6). By contrast, β-SG and δ-SG were robustly 
detected at the cell surface only when co-expressed with ε-SG and ζ-SG (Figure 3.4a, b lanes 
2, 5, 8 and 11). The low levels of endogenous expressed ε-SG in HEK293T cells were 
insufficient for membrane trafficking of β-, δ- and ζ-SG without exogenous ε-SG (Figure 
3.4a lanes 13 and 14). These data recapitulate previous studies describing assembly of ε-SG 
into a membrane-associated sarcoglycan complex in heterologous cells, and highlight the 
importance of the βδ-SG interaction for trafficking of the sarcoglycan heterotetramer to the 
plasma membrane, despite ε-SG’s ability to traffic independently (Chen et al., 2006, Draviam 
et al., 2006a, Esapa et al., 2007, Hack et al., 2000, Shi et al., 2004, Shiga et al., 2006). All 
four ε-SG isoforms tested co-immunuoprecipitated with the other sarcoglycans, indicating 
Figure 3.4 Membrane trafficking of the brain sarcoglycan complex in vitro with different ε-SG isoforms. HEK293T 
cells were transfected with different combinations of plasmids encoding epitope-tagged sarcoglycans as indicated, and cell 
surface proteins were biotinylated. ε-SG and associated proteins were immunoprecipitated using esg4990 antibody beads. 
For comparative purposes, data are presented in groups of three (lanes 1-12) corresponding to the four major brain ε-SG 
isoforms. Each group follows the same scheme; ε-SG isoform alone, ε-SG isoform in an εβδζ tetramer with wild-type β-SG, 
and ε-SG isoform in a tetramer with mutant β-SG. A) Biotinylated surface proteins immunoprecipitated by esg4990 were 
identified using streptavidin-Alexa Fluor 680. Although ε-SG isoforms trafficked to the cell surface in the absence of the 
other sarcoglycans (panel A, lanes 1, 4, 7 and 10), the highest levels of sarcoglycans at the membrane were observed in cells 
co-expressing a tetramer with wild-type β-SG (lanes 2, 5, 8 and 11). By contrast, levels of δ-SG and to a lesser extent ε- and 
ζ-SG were drastically reduced at the cell surface in cells expressing the LGMD2E-associated β-SG T182A mutant (lanes 3, 
6, 9 and 12). B) Complex formation was demonstrated by co-immunoprecipitation for all four ε-SG isoforms. Robust co-
immunoprecipitation of each sarcoglycan was observed for all heterotetramers that contain wild-type β-SG (lanes 2, 5, 8 and 
11). By contrast, βδ-SG core formation was severely disrupted in cells expressing mutant β-SG compared to wild-type; 
however, the association of ε- and ζ-SG was apparently unaffected by the mutant (lanes 3, 6, 9 and 12). Lanes 13 and 14 
shows that trimers formed in the absence of transfected ε-SG do not traffic to the cell surface. C) Whole cell RIPA lysates 
are shown for comparative purposes while α-tubulin was used as a loading control. Abbreviations: kDa, kilodaltons. 
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that they were all capable of assembling into prototypical sarcoglycan heterotetramers 
(Figure 3.4b).  
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Previous studies in cell models showed that sarcoglycan mutants impair assembly and cell 
surface trafficking of the sarcoglycan complex, recapitulating the cell surface sarcoglycan 
complex deficiencies observed in sarcoglycanopathies (Chen et al., 2006, Draviam et al., 
2006a, Duggan et al., 1997a, Duggan and Hoffman, 1996, Fanin et al., 1997, Holt and 
Campbell, 1998). The SGCB c.544A>G mutation, encoding T182A mutant β-SG protein, 
causes a severe muscular dystrophy phenotype and cardiomyopathy with complete loss of the 
SGC from the sarcolemma in skeletal muscle, and has been shown to disrupt the βδ-SG core 
in heterologous cells (Chen et al., 2006, Draviam et al., 2006a, Duggan et al., 1997a, Duggan 
and Hoffman, 1996, Fanin et al., 1997, Holt and Campbell, 1998). Different ε-SG isoforms 
might react differently to the presence of mutant β-SG in the sarcoglycan heterotetramer. 
Therefore, each ε-SG isoform was tested in a complex containing the T182A mutant β-SG, 
wild-type δ-SG and wild-type ζ-SG as above. As expected, only residual amounts of T182A 
mutant β-SG were detected at the cell surface using streptavidin-Alexa Fluor 680 (Figure 
3.4a) or in NeutrAvidin affinity purifications (Figure 3.5a). Similarly, cell surface levels of δ-
SG were substantially reduced. However, ε-SG and ζ-SG still co-purified, and some was 
biotinylated indicating membrane trafficking (Figures 3.4 and 3.5, lanes 3, 6, 9 and 12). 
These findings were consistent for all ε-SG isoforms. Therefore the T182A mutant β-SG did 
not disrupt the physical interaction between and membrane trafficking of ε-SG and ζ-SG. 
These data correspond with a recent observation of reduced but still present (residual) cell 
surface ε-SG and ζ-SG in the brain of δ-SG-deficient BIO14.6 hamster (Waite et al., 2016). 
Figure 3.5 Assessing membrane trafficking of the brain SGC using NeutrAvidin capture. The figure is arranged 
following the scheme detailed for figure 3. HEK293T cells were transfected with different combinations of plasmids 
encoding epitope-tagged sarcoglycans as indicated. After surface biotinylation, NeutrAvidin agarose beads were used to 
affinity purify biotinylated membrane proteins. A) NeutrAvidin capture of cell surface localised sarcoglycans in 
heterologous cells. Although ε- and ζ-SG were always detected at the membrane, co-expression of all four sarcoglycans 
promoted robust trafficking of the wild-type sarcoglycan tetramer (lanes 2, 5, 8 and 11). By contrast, in cells expressing the 
LGMD2E-associated β-sarcoglycan T182A mutant, the levels of βδ-SG core were severely reduced at the cell surface (lanes 
3, 6, 9 and 12). Importantly, membrane trafficking of ε- and ζ-sarcoglycan was apparently unaffected by the T182A mutant. 
B) Whole cell lysates are shown for comparative purposes while α-tubulin was used as a loading control. Abbreviations: 
kDa, kilodaltons. 
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Figure 3.6 Levels of ε-SG at the cell surface do not differ significantly between single transfections and transfections in the presence of mutant β-SG. The relative amount of biotinylated 
(cell surface) ε-SG in IP of ε-SG from cells transfected with ε-SG alone, in combination with wild-type sarcoglycans, or in a tetrameric context with mutant β-SG was estimated by quantifying 
immunofluorescence on the immunoblot, and averaging over three experimental replicates. The level of biotinylated ε-SG in cells transfected with the wild-type εβδζ tetramer were set as 100%, 
and levels in the single or β-SG mutant transfections were expressed as a percentage of that wild-type tetramer level within each ε-SG isoform set. No significant difference between surface ε-
SG in single transfections and with mutant β-SG was found using Student’s T-test assuming unequal variances. Error bars represent standard error of the mean.
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3.2.3. Dp71 and β-dystroglycan co-purify with ε-SG under mild lysis conditions 
MS analysis of the esg2-1358 antibody IAP using RIPA-solubilised brain tissue described 
above included protein sizes expected to include a range of DGC proteins. However, only 
peptides corresponding to the sarcoglycans and no other DGC proteins were identified. 
Buffer stringency could have disrupted interactions between these other DGC proteins, 
despite apparent stability of the sarcoglycan complex in RIPA. Therefore, a buffer containing 
the milder, non-ionic detergent digitonin (1% (w/v)) was used to solubilise proteins from 
mouse brain and lung tissue, and IAP was performed using the esg4990 antibody against all 
ε-SG isoforms. In lung, ε-SG isoform 1 is known to be part of a prototypical sarcoglycan 
Figure 3.7 β-dystroglycan and Dp71 co-purify with ε-SG from digitonin-solubilised but not RIPA-solubilised brain 
and lung. Mouse brain and lung tissue was solubilised in either digitonin (Dig) or RIPA buffer, and an antibody (esg3790) 
against all ε-SG isoforms was used to enrich for ε-SG. Western blot with a biotinylated anti-ε-SG antibody demonstrated 
that ε-SG isoforms 1 and 2 can be purified from brain, but only ε-SG isoform 1 can be purified from lung. β-dystroglycan 
and dystrophin isoform Dp71 co-purified with ε-SG from both brain and lung, but only in digitonin buffer. However, ε-SG 
solubilisation was greater in RIPA compared to digitonin buffer. Abbreviations: kDa, kilodaltons; Dig, digitonin buffer-
lysed tissue; RIPA, RIPA buffer-lysed tissue; ε-SG 2, ε-SG isoform 2; ε-SG 1, ε-SG isoform 1. 
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complex that is integrated into the DGC (Durbeej and Campbell, 1999, Liu and Engvall, 
1999). Western blotting of immunoaffinity purified proteins from brain or lung demonstrated 
co-purification of β-dystroglycan and Dp71 with ε-SG from digitonin-solubilised but not 
RIPA-solubilised tissue (Figure 3.7). This demonstrated that in brain as well as in lung, ε-SG 
is associated with other DGC proteins.  
The IAPs were repeated using esg2-1358 (detects ε-SG isoform 2 only) and esg3788 (detects 
all ε-SG isoforms) to determine whether both the widely-expressed ε-SG isoform 1 and the 
brain-specific isoform 2 co-purified with β-dystroglycan and Dp71 (Figure 3.8). As expected, 
β-dystroglycan and Dp71 co-purified with ε-SG using the esg3788 antibody from digitonin-
solubilised but not RIPA-solubilised tissue. However, only β-dystroglycan and not Dp71 
Figure 3.8 β-dystroglycan and Dp71 predominantly co-purified with ε-SG isoform 1 from whole brain tissue. 
Complexes containing ε-SG were isolated from mouse brain tissue solubilised in either digitonin or RIPA buffer using 
either the pan-ε-SG antibody esg3788 or the ε-SG isoform 2-specific antibody esg2-1358. Western blot of immunoaffinity 
purified proteins using biotinylated anti-ε-SG antibody showed enrichment of ε-SG isoforms 1 and 2 with esg3788, but 
only ε-SG isoform 2 with esg2-1358. β-dystroglycan and Dp71 co-purified with ε-SG in the esg3788 IAP, while β-
dystroglycan co-purified in the esg2-1358 IAP as well; in both cases, this occurred in digitonin buffer but not RIPA buffer. 
Thus, both major isoforms of ε-SG in the brain interacted with β-dystroglycan, and ε-SG isoform 1 interacted with Dp71. 
Abbreviations: kDa, kilodaltons; Dig, digitonin-lysed tissue; RIPA, RIPA-lysed tissue; ε-SG 2, ε-SG isoform 2; ε-SG 1, ε-
SG isoform 1. 
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could be detected in esg2-1358 immunoaffinity-purified proteins (Figure 3.8). Additionally, 
ε-SG and β-dystroglycan signal intensity on Western blot was weaker in the esg2-1358 IAP 
compared to the esg3788 IAP. These results were most likely due to the smaller total amount 
of ε-SG purified using the esg2-1358 antibody compared to the esg3788 antibody (Figure 
3.8). Subsequent IAPs carried out on wild-type C57BL/6J and Sgcem+/pGT mice as described 
later in this chapter (sections 3.2.5.3-4) replicated these results.  
To confirm that β-dystroglycan and dystrophin were genuinely co-purifying with ε-SG, 
reciprocal IAPs from digitonin-solubilised tissue using antibodies against β-dystroglycan and 
Figure 3.9 ε-SG co-purified with β-dystroglycan and Dp71 from both brain and lung. IAPs using the MANDAG2 and 
MANDRA1 antibodies to enrich for β-dystroglycan and dystrophin respectively were carried out with digitonin-solubilised 
brain and lung tissue. Parallel IAPs using esg3788 to enrich for all ε-SG isoforms and Protein G-sepharose only to isolate 
non-specific interactions were also included. In both tissues, Dp71 and β-dystroglycan weakly co-purified. ε-SG was also 
detected in the MANDAG2, MANDRA1 and esg3788 IAPs but not the Protein G-sepharose only IAP. Dp140 was also 
identified in the MANDRA1 IAP from brain tissue only. Abbreviations: kDa, kilodaltons; ε-SG 2, ε-SG isoform 2; ε-SG 1, 
ε-SG isoform 1. 
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dystrophin were performed. The antibodies used were MANDAG2 against β-dystroglycan 
and MANDRA1 against the dystrophin C-terminus, both of which were developed and 
validated by Professor Glenn Morris, and obtained through the Developmental Studies 
Hybridoma Bank (Helliwell et al., 1994, Nguyen et al., 1992). Western blot analysis of 
immunoaffinity purified protein demonstrated that ε-SG was present in both the MANDAG2 
and the MANDRA1 IAPs, from brain and lung tissue (Figure 3.9). However, only isoform 1 
was clearly present; ε-SG isoform 2 might have been present in the IAPs from brain tissue, 
but could not be clearly detected on the Western blot. Dp71 and β-dystroglycan also weakly 
co-purified with each other from both tissues (Figure 3.9). These data supported genuine co-
purification of β-dystroglycan, Dp71 and ε-SG from brain tissue. 
3.2.4. The Shaker-related voltage-gated potassium channels cross-react with the 
esg2-1358 antibody 
Alongside the sarcoglycans, several Shaker-related voltage-gated potassium channel subunits 
were identified with high confidence by MS in the esg2-1358 IAP from RIPA-solubilised 
mouse brain tissue (Table 3.1). While these proteins may genuinely interact with ε-SG 
isoform 2, alternatively their presence in the IAP could be caused by cross-reaction with the 
esg2-1358 antibody. Kcna3 was identified at high confidence in multiple bands from the 
esg2-1358 IAP, and was therefore tested for cross-reaction with the esg2-1358 antibody. A c-
Myc-tagged Kcna3 construct was overexpressed in HEK293T cells, and protein was 
immunoprecipitated from cell lysates using Protein A-agarose-conjugated esg2-1358, 
esg4990 or pre-immune immunoglobulin to check for non-specific interactions (Figure 3.10). 
Western blot of immunoprecipitated proteins showed that c-Myc-Kcna3 co-purified with the 
esg2-1358 antibody but not with the esg4990 antibody or pre-immune immunoglobulin 
(Figure 3.10). Therefore, Kcna3 cross-reacted with the esg2-1358 antibody. Since the Shaker-
related voltage-gated potassium channels are tightly associated, purification of one subunit 
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typically results in co-purification of other subunits (Vacher et al., 2008). Consequently, 
enrichment of all Shaker-related voltage-gated potassium channels in the esg2-1358 IAP was 
most likely due to the cross-reaction between Kcna3 and the esg2-1358 antibody. 
3.2.5. Identifying other components of ε-SG-containing complexes in the brain 
The interactions between ε-SG and DGC proteins described above were all identified by 
looking for specific proteins in the ε-SG IAPs, either through MS analysis or Western blot. 
To identify other proteins that co-purify and therefore might interact with ε-SG in brain 
tissue, a series of hypothesis-free IAP-MS experiments using anti-ε-SG antibodies were 
carried out. IAPs were performed using two different anti-ε-SG antibodies: esg2-1358 which 
detects ε-SG isoform 2 only, and esg3788 which detects all ε-SG isoforms. These antibodies 
were raised against non-overlapping immunogens, and therefore a protein that co-purified 
Figure 3.10 Kcna3 cross-reacts with the anti-ε-SG isoform 2 antibody esg2-1358. HEK293T cells were transfected 
with a plasmid encoding c-Myc-Kcna3. After transfection, proteins were immunoprecipitated from NP-40 buffer cell 
lysates using the esg4990 antibody, the esg2-1358 antibody, or pre-immune immunoglobulin. Immunoblot of the IPs for 
c-Myc-Kcna3 showed that Kcna3 purified with esg2-1358 but not esg4990 or pre-immune IgG. Therefore, Kcna3 cross-
reacted with the esg2-1358 antibody. Abbreviations: kDa, kilodaltons; lys, cell lysate; IP, immunoprecipitation; 4990, 
esg4990 antibody; 1358, esg2-1358 antibody; PI, pre-immune immunoglobulin 
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with ε-SG using both antibodies would have a greater likelihood of genuinely interacting with 
ε-SG rather than cross-reacting with an anti-ε-SG antibody (Figure 3.1). Digitonin-solubilised 
mouse brain tissue was used for these IAPs, since this buffer appeared to preserve protein 
interactions better than RIPA buffer as demonstrated by co-purification of Dp71 and β-
dystroglycan with ε-SG (section 3.2.3). Additionally, rather than selecting specific protein 
bands from the IAP for MS analysis, each IAP was divided into two samples that were both 
analysed by MS (Figure 3.11). This approach allowed identification of all protein sizes, but 
also increased MS sample complexity and therefore reduced protein coverage compared to 
the individual protein bands approach used in the initial esg2-1358 IAP (section 3.2.2.1).  
The proteins identified in each IAP-MS experiment were ranked using several parameters 
generated by the Proteome Discoverer SEQUEST algorithm implementation used to assign 
peptide identities to spectra (Chapter 2 section 2.6.6). The SEQUEST protein identity score 
gave the likelihood that a given protein was genuinely present in the sample; a higher score 
indicated greater confidence. The number of unique peptides provided the number of distinct 
peptide sequences assigned to that particular protein/accession number detected in the 
sample. Finally, spectral count is the number of spectra corresponding to that 
Figure 3.11 Polyacrylamide gel showing immunoaffinity purified protein complexes prepared for MS analysis. Two-
thirds of each IAP described in figure 3.8 – esg3788 and esg2-1358 IAPs from digitonin (Dig)-solubilised or RIPA-
solubilised brain tissue, pre-immune immunoglobulin (PI) IAP from digitonin-solubilised brain tissue – were briefly 
resolved by PAGE. Proteins were visualised by staining the gel with a colloidal Coomassie stain. Each IAP/lane shown here 
was divided into two samples across the horizontal axis as shown, and both samples were processed for MS. Abbreviations: 
PI, IAP using pre-immune IgG; esg3788, IAP using the esg3788 antibody; esg2-1358, IAP using the esg2-1358 antibody; 
dig, IAP from tissue lysed in digitonin buffer; RIPA, IAP from tissue lysed in RIPA buffer. 
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protein/accession number detected in the sample, and was used as a semi-quantitative 
representation of protein abundance in the IAP (Bantscheff et al., 2007). 
3.2.5.1. IAP MS data were filtered to remove non-specifically interacting and 
cross-reacting proteins 
In addition to proteins co-purifying with ε-SG itself, IAPs using anti-ε-SG antibodies were 
expected to enrich proteins interacting non-specifically with immunoglobulin or Protein A-
agarose, or cross-reacting with the anti-ε-SG antibody. To identify and filter out non-
specifically interacting proteins, an IAP using pre-immune immunoglobulin conjugated to 
protein A-agarose was performed in parallel with other IAPs and analysed by MS (Appendix 
II).  Only proteins interacting non-specifically with immunoglobulin or Protein A-agarose – 
the bead proteome - would be present in this IAP. Therefore, all proteins detected in the pre-
immune IAP were filtered out of IAPs using anti-ε-SG antibodies as shown in Figure 3.12.  
Proteins cross-reacting with the anti-ε-SG antibodies were identified through two different 
approaches. As described above, use of two distinct antibodies could help identify cross-
Figure 3.12 Comparison of proteins identified in the esg3788, esg2-1358, and pre-immune IAPs from digitonin-
solubilised mouse brain. Venn diagram of overlap between proteins identified by MS in the pre-immune immunoglobulin 
(PI), esg3788 IAP, and esg2-1358 IAPs performed in parallel on digitonin-solubilised mouse brain tissue. Overlap was based 
on gene symbols. Proteins present in the PI IAP were likely to be enriched through non-specific interactions with 
immunoglobulin or Protein A-agarose, and were eliminated from the esg3788 and esg2-1358 IAP datasets. This removed 
143 proteins from the esg2-1358 IAP and 129 proteins from the esg3788 IAP. The remaining 103 proteins in the esg2-1358 
IAP dataset and 86 proteins in the esg3788 IAP were expected to be enriched through interaction with ε-SG or cross-reaction 
with the antibody. 
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reacting proteins. However, esg3788 and esg2-1358 have only partially overlapping 
reactivity: esg3788 binds all ε-SG isoforms, whereas esg2-1358 binds only ε-SG isoform 2. 
Therefore a protein genuinely interacting with ε-SG isoform 1 but not isoform 2 would be 
enriched in an IAP using esg3788, but not in an IAP using esg2-1358. To further identify 
cross-reacting proteins, the proteins enriched by IAP from digitonin-solubilised tissue were 
compared to those enriched by IAP from RIPA-solubilised tissue. Proteins that cross-react 
with an antibody should always be enriched through IAP unless antibody-antigen interactions 
are disrupted. By contrast, proteins enriched through interaction with ε-SG will only be 
enriched in the IAP if lysis conditions are mild enough to maintain the interaction. Therefore, 
cross-reacting proteins were expected to be more abundant in IAPs from RIPA-solubilised 
tissue, whereas proteins co-purified through interaction with ε-SG were expected to be more 
abundant in IAPs from digitonin-solubilised tissue; ε-SG itself should be enriched equally 
under both conditions. 
The parallel esg3788 and esg2-1358 IAPs from digitonin-solubilised and RIPA-solubilised 
tissue described in section 3.2.3 (Figure 3.8) were therefore analysed by MS and the resultant 
datasets were compared. As predicted, spectral counts (a semi-quantitative measure of 
abundance) for β-SG, δ-SG and ζ-SG which are known to genuinely interact with ε-SG were 
generally increased in IAPs from digitonin-solubilised tissue compared to IAPs from RIPA-
solubilised tissue (Table 3.3). Conversely, the Shaker-related voltage-gated potassium 
channels specifically cross-react with the esg2-1358 antibody and had increased spectral 
counts in IAPs from RIPA-solubilised tissue compared to IAPs from digitonin-solubilised 
tissue (Table 3.3). ε-SG spectral counts were comparable between the two tissue 
solubilisation conditions. Dp71 and β-dystroglycan could not be detected in any IAP by MS, 
despite their detection in digitonin-solubilised IAPs using Western blot. Based on these 
results, additional proteins directly binding the antibodies were identified by their greater or  
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Gene 
Digitonin lysis, esg3788 
antibody 
RIPA lysis, esg3788 
antibody 
Digitonin lysis, esg2-1358 
antibody 
RIPA lysis, esg2-1358 
antibody 
Change in 
abundance, RIPA 
to digitonin 
Spectral 
count 
Unique 
peptides 
Spectral 
count 
Unique 
peptides 
Spectral 
count 
Unique 
peptides 
Spectral 
count 
Unique 
peptides 
Sgce 28 4 15 3 14 3 14 4 + 
Sgcz 8 6 1 1 6 5 0 0 + 
Sgcd 6 5 2 2 1 1 0 0 + 
Sgcb 2 2 1 1 2 2 0 0 + 
Kcna3 0 0 0 0 11 8 50 9 - 
Kcna2 0 0 0 0 8 1 30 7 - 
Kcnab2 0 0 0 0 11 6 18 9 - 
Table 3.3 Semi-quantitative MS data for sarcoglycans and Shaker-related voltage-gated potassium channel subunits in ε-SG IAPs from RIPA- and digitonin-solubilised mouse brain 
tissue. For IAPs using the same antibody but tissue solubilised under different conditions, the spectral counts and number of unique peptides for sarcoglycans and Shaker-related voltage-gated 
potassium channel subunits were compared. Spectral count refers to the number of spectra corresponding to the protein detected in the sample, while the number of unique peptides is how many 
distinct peptides in the sample could be assigned to the protein identity. Shaker-related voltage-gated potassium channel subunits cross-react with the esg2-1358 antibody; their spectral counts 
and numbers of unique peptides were increased in IAPs from RIPA-solubilised tissue compared to digitonin-solubilised tissue. By contrast, β-, δ- and ζ-SG are known to interact with ε-SG from 
other tissues. Their spectral counts and numbers of unique peptides were increased in IAPs from digitonin-solubilised tissue compared to RIPA-solubilised tissue.
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equal spectral counts in IAPs from RIPA-solubilised tissue compared to digitonin-solubilised 
tissue (Figure 3.13). The remaining proteins in the IAPs from digitonin-solubilised tissue 
were ranked by protein identity score (Figure 3.13). The lowest sarcoglycan protein identity 
score was used as the minimum threshold to define proteins with a high probability of 
genuinely interacting with ε-SG. This process generated a list of 26 high-confidence proteins 
from the esg3788 IAP and 23 proteins from the esg2-1358 IAP; 17 proteins including the 
sarcoglycans were shared between the two lists (Tables 3.4 and 3.5).  
Filter by protein identity score using lowest-confidence sarcoglycan 
as minimum
esg3788: 26 proteins esg2-1358: 23 proteins
Manual removal of remaining probable contaminants (keratins, IgG, 
mitochondrial and nuclear proteins)
esg3788: 46 proteins remaining esg2-1358: 52 proteins remaining 
RIPA vs digitonin buffer filter 
(remove likely antibody cross-reacting proteins)
esg3788: 69 proteins remaining esg2-1358: 69 proteins remaining
Filter out pre-immune proteins (experimentally shown to bind non-
specifically to IgG or Protein A-agarose)
esg3788: 86 proteins remaining esg2-1358: 103 proteins remaining
Proteins identified via MS in IAPs from digitonin buffer-lysed whole 
mouse brain tissue
esg3788: 253 proteins esg2-1358: 279 proteins
Figure 3.13 Overview of the IAP MS analysis filtering process to remove non-specific interacting proteins, cross-
reacting proteins, and contaminants. Starting with MS data from IAPs performed with digitonin buffer-lysed whole 
mouse brains, several filtering steps were applied to remove potential contaminants and likely cross-reacting proteins. Each 
step is summarised here, with the number of proteins remaining after the filtering step below. Probable contaminants 
removed in the penultimate step were identified primarily by subcellular localisation; predominantly cell surface-localised 
ε-SG is unlikely to interact with proteins localised to the mitochondrial matrix or nucleus. 
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Gene 
symbol 
Protein 
Protein 
identity 
score 
Unique 
peptides 
(digitonin) 
Spectral 
count 
(digitonin) 
Spectral 
count 
(RIPA) 
Map2 Microtubule-associated protein 2 948.82 85 284 105 
Dync1h1 Cytoplasmic dynein 1 heavy chain 1 205.15 47 61 0 
Sptan1 Spectrin alpha chain, non-erythrocytic 1 171.39 45 53 3 
Plec Plectin 154.97 46 50 0 
Sptbn1 Spectrin beta chain, non-erythrocytic 1 91.06 20 28 0 
Rnf213 E3 ubiquitin-protein ligase RNF213 81.76 23 26 1 
Sgce Epsilon sarcoglycan 81.3 4 28 15 
Map1a Microtubule-associated protein 1A 64.98 20 25 0 
Dmxl2 DmX-like protein 2 63.27 13 19 0 
Sgcz Zeta sarcoglycan 27.22 6 8 1 
Myh10 Myosin-10 22.14 6 6 0 
Itpr1 
Inositol 1,4,5-trisphosphate receptor 
type 1 
21.56 8 8 0 
Usp9x Ubiquitin carboxyl-terminal hydrolase 19.16 4 6 0 
Sgcd Delta sarcoglycan 18.51 5 6 2 
Sptbn2 Spectrin beta chain, non-erythrocytic 2 18.25 4 6 0 
Sbf1 Myotubularin-related protein 5 17.51 6 6 0 
Slc12a5 Solute carrier family 12 member 5 16.92 3 8 0 
Tnr Tenascin-R 15.65 6 6 0 
Tln2 Talin-2 15.4 2 4 0 
Fasn Fatty acid synthase 14.24 3 4 0 
Myh9 Myosin-9 13.69 2 5 0 
Flg2 Filaggrin-2 9.16 3 3 0 
Nf1 Neurofibromin 9.08 2 3 0 
Ryr2 Ryanodine receptor 2 8.94 2 3 0 
Arfgef2 
Brefeldin A-inhibited guanine 
nucleotide-exchange protein 2 
7.56 2 2 0 
Sgcb Beta sarcoglycan 6 2 2 1 
Table 3.4 High-confidence proteins identified in the esg3788 IAP after filtering against RIPA IAP results to remove 
cross-reacting proteins. After filtering against the RIPA IAP MS results, proteins identified in the esg3788 IAP were 
ranked by protein identity score and number of high-quality unique peptides found to produce a list of top priority proteins. 
Protein identity score gives the probability that a protein was genuinely present in the sample analysed. Unique peptides 
refers to the number of distinct peptides from a given protein identified in the sample; each unique peptide may be detected 
multiple times in the sample. Spectral count refers to the number of spectra corresponding to that protein detected in the 
sample. Sarcoglycans are highlighted in green; other proteins shared with the esg2-1358 IAP are highlighted in orange. 
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Gene Protein 
Protein 
identity 
score 
Unique 
peptides 
(digitonin) 
Spectral 
count 
(digitonin) 
Spectral 
count 
(RIPA) 
Sptan1 
Spectrin alpha chain, non-
erythrocytic 1 
220.86 51 70 37 
Dync1h1 Cytoplasmic dynein 1 heavy chain 1 138.77 32 41 6 
Itpr1 
Inositol 1,4,5-trisphosphate receptor 
type 1 
119.8 32 42 1 
Ryr2 Ryanodine receptor 2 92.75 21 29 20 
Dmxl2 DmX-like protein 2 91.4 23 29 1 
Sptbn1 
Spectrin beta chain, non-
erythrocytic 1 
79.24 24 26 18 
Map1a Microtubule-associated protein 1A 77.47 21 25 7 
Clcc1 Chloride channel CLIC-like protein 1 61.73 10 17 13 
Sgce Epsilon sarcoglycan 55.19 3 14 14 
Sptbn2 
Spectrin beta chain, non-
erythrocytic 2 
45.42 11 13 3 
Ehd2 EH domain-containing protein 2 20.17 5 6 0 
Plec Plectin 19.84 8 9 0 
Tenm4 Teneurin-4 19.33 6 6 5 
Sgcz Zeta sarcoglycan 18.82 5 6 0 
Tnr Tenascin-R 10.66 4 4 3 
Cul9 Cullin-9 9.35 3 3 1 
Myh10 Myosin-10 8.58 2 2 0 
4933434 
E20Rik 
Uncharacterized protein C1orf43 
homolog 
8.23 3 3 2 
Sgce Epsilon sarcoglycan isoform 2 7.96 1 2 0 
Sgcb Beta sarcoglycan 7.69 2 2 0 
Nf1 Neurofibromin 6.15 2 2 0 
Sbf1 Myotubularin-related protein 5 5 2 2 0 
Sgcd Delta sarcoglycan 2.86 1 1 0 
Table 3.5 High-confidence proteins identified in the esg2-1358 IAP after filtering against RIPA IAP results to remove 
cross-reacting proteins. After filtering against the RIPA IAP MS results, proteins identified in the esg2-1358 IAP were 
ranked by protein identity score and number of high-quality unique peptides found to produce a list of top priority proteins 
likely to genuinely interact with ε-SG in the brain. Protein identity score gives the probability that a protein was genuinely 
present in the sample analysed. Unique peptides refers to the number of distinct peptides from a given protein identified in 
the sample; each unique peptide may be detected multiple times in the sample. Spectral count refers to the number of mass 
spectra from the protein detected in the sample. Sarcoglycans are highlighted in green; other proteins shared with the 
esg3788 IAP are highlighted in orange. 
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3.2.5.2. Identification of high-confidence ε-SG interactions in multiple mouse 
strains 
Up to this point, IAP-MS experiments had been carried out exclusively on brain tissue from 
CD-1 mice, which were obtained from an inbred colony at Cardiff University based on the 
outbred CD-1 stock (Chia et al., 2005). CD-1 mice were assumed to have generally similar 
brain biochemistry to other Mus musculus strains. However, multiple transcriptomic studies 
have demonstrated that gene expression varies between mouse strains to produce detectable 
differences in protein levels, including those for several synaptic proteins (Loos et al., 2016, 
Nadler et al., 2006, Sandberg et al., 2000, Turk et al., 2004). Differences in protein 
abundance between mouse strains could result in a different pattern of contaminants (non-
specifically interacting proteins and cross-reacting proteins) in IAPs using the same antibody 
from these different mouse strains. By contrast, proteins that genuinely interact with ε-SG 
should be consistently enriched in ε-SG IAPs regardless of mouse strain. Therefore, a protein 
consistently enriched in ε-SG IAPs from brain tissue of different mouse strains would be 
more likely to genuinely interact with ε-SG.  
Consequently, the ε-SG IAPs were repeated on frozen brain tissue from C57BL/6J mice, a 
gift from Mark LeDoux and Jianfeng Xiao. These mice were wild-type littermates of the 
Sgcem+/pGt mice described below (section 3.2.5.3); IAPs on wild-type C57BL/6J and 
Sgcem+/pGt tissue were performed in parallel.  Alongside the esg3788 and esg2-1358 IAPs, a 
pre-immune immunoglobulin control IAP was performed from digitonin-solubilised 
C57BL/6J brain tissue to provide strain-specific contaminant data. MS data for the two anti-
ε-SG antibody IAPs were filtered against the C57BL/6J pre-immune IAP, and then compared 
to equivalently filtered data from IAPs using CD-1 mouse brains. In addition to use of 
different strains, these two sets of experiments differed in person performing the dissection, 
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tissue processing (the CD-1 brains were used fresh while C57BL/6J brains were snap-frozen 
and stored at -80°C before use), and time elapsed between dissection and experiment.  
The protein overlap between IAP-MS datasets from the two mouse strains was smaller than 
expected (Figure 3.14). Sarcoglycan complexes were identified by MS in IAPs from both 
mouse strains using both anti-ε-SG antibodies, and β-dystroglycan was detected by Western 
blot (Figures 3.8 and 3.15). β- and α-dystroglycan were also identified by MS analysis in the 
esg3788 IAP from C57BL/6J mouse brains (Table 3.6). This was the first identification of 
dystroglycan by MS in IAPs, though it had been consistently identified by Western blot 
Figure 3.14 Overlap of proteins identified in ε-SG IAPs from CD-1 and C57BL/6J whole mouse brains. After filtering 
against pre-immune IAPs, the esg3788 and esg2-1358 IAPs from digitonin-solubilised CD-1 and C57BL/6J mouse brains 
were compared to identify shared proteins that would have the highest probability of being genuine ε-SG interactors. A) 
Overlap of IAPs using the esg3788 antibody between CD-1 and C57BL/6J whole mouse brains. B) Overlap of IAPs using 
the esg2-1358 antibody between CD-1 and C57BL/6J. C) Overlap between proteins identified in both mouse strain esg3788 
IAPs and proteins identified in both esg2-1358 IAPs. The five proteins shared between all four IAPs were the four 
sarcoglycans plus Glul, a common contaminant typically filtered out. 
Chapter 3: ε-SG protein interactions in the brain 
 
[105] 
 
analysis in all previous IAPs using digitonin-solubilised tissue. Aside from the sarcoglycans, 
only glutamine synthase (Glul) was identified in IAPs from both mouse strains with both 
antibodies; this protein is a known contaminant (Trinkle-Mulcahy et al., 2008). Several 
proteins were identified in IAPs from both strains but not with both antibodies. While most of 
these were predicted to be cross-reacting with antibodies based on IAPs from RIPA-
solubilised tissue, two were identified as probably co-purifying with ε-SG itself: inositol 
1,4,5-triphosphate receptor 1 (Itpr1) and tenascin-R (Tnr). 
 
Figure 3.15 The Sgce intron 11 gene trap mouse has greatly reduced levels of ε-SG. A) Schematic of the Sgce gene-trap 
allele. The Gt(148G1)Cmhd gene-trap cassette including the lacZ and neor coding sequences is inserted into intron 9. Note: 
mouse Sgce does not have an exon 10. B) Complexes containing ε-SG were isolated from digitonin-solubilised brains of 
Sgcem+/pGt and wild-type (Sgce+/+) littermates, using both the esg3788 antibody that detects all ε-SG isoforms and the esg2-
1358 antibody that detects only ε-SG isoform 2. A negative control IAP using pre-immune IgG was also conducted on wild-
type tissue. Immunoblot of the IAPs using a separate biotinylated anti-ε-SG antibody identified both ε-SG isoforms 1 and 2 
in wild-type mice but no clear signal in Sgcem+/pGt mice. A smeared band observed around 50kDa in both the pre-immune 
IAP and the Sgcem+/pGt ε-SG IAPs may represent an IgG-related species. Overall, substantially less ε-SG was detected in 
IAPs from the Sgcem+/pGt mice compared to wild-type littermates. Additionally, β-dystroglycan which interacts with ε-SG 
could be detected in both ε-SG IAPs from wild-type mice but at a reduced level in the esg3788 IAP only from Sgcem+/pGt 
mice. Abbreviations: kDa, kilodaltons; PI, pre-immune IgG IAP; 3788, esg3788 IAP; 1358, esg2-1358 IAP; ε-SG 1, ε-SG 
isoform 1; ε-SG 2, ε-SG isoform 2. 
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3.2.5.3. Evaluation of an Sgce gene trap mouse line to identify esg2-1358 cross-
reacting proteins 
In parallel with the above IAPs on brain tissue from wild-type C57BL/6J mice, a novel Sgce 
mutant mouse line on the C57BL/6J background was investigated as an alternative method to 
identify proteins cross-reacting with the esg2-1358 antibody. The SgceGt(148G1)Cmhd gene trap, 
henceforth abbreviated as SgceGt, was generated by the Centre for Modelling Human 
Diseases and consists of a Gep-SD5 LacZ-neo construct inserted into intron 9 of the mouse 
Sgce locus (Figure 3.15a) (Xiao et al., 2017). Homozygous (SgceGt/Gt) and paternal 
heterozygous (Sgcem+/pGt) mutant mice exhibited a transient movement disorder from 
postnatal days 14-16 and a mild anxiety-like behavioural phenotype, but were otherwise 
normal (Xiao et al., 2017). Quantitative RT-PCR indicated overall reduction of Sgce 
transcript levels by 60-70% compared to wild-type littermates in the brains of Sgcem+/pGt 
mice, with no detectable exon 11b+ transcripts (Xiao et al., 2017). The absence of Sgce exon 
11b-containing transcripts suggested this model might represent a specific knockout of ε-SG 
isoform 2. In that case, any proteins enriched from Sgcem+/pGt mouse brains using the esg2-
1358 antibody would be non-specific interactors or cross-reacting proteins.  
IAPs using the esg3788 and esg2-1358 antibodies were performed on digitonin-solubilised 
Sgcem+/pGt mouse brain tissue to identify which ε-SG isoform(s) were present and identify 
proteins purified by the esg2-1358 antibody from these mice. This was done in parallel with 
the IAPs on wild-type C57BL/6J littermates as described above (section 3.2.5.2). Snap-frozen 
Sgcem+/pGt mouse brain and lung tissue was a gift from Mark LeDoux and Jianfeng Xiao. 
Immunoaffinity-purified proteins from the Sgcem+/pGt mice were compared to proteins 
purified from wild-type littermates in parallel (section 3.2.5.2) by Western blot analysis. IAP 
using the esg3788 antibody showed reduced ε-SG from the Sgcem+/pGt mice compared to  
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C57BL/6J esg3788 IAP C57BL/6J esg21358 IAP 
Gene 
Uniprot 
acc. 
Wild-type Gene trap Wild-type Gene trap 
Unique peptides 
Spectral 
count 
Unique peptides 
Spectral 
count 
Unique peptides 
Spectral 
count 
Unique 
peptides 
Spectral 
count 
Sgce O70258 
TPYSDGVLYGSPTAENVGKPTIIEITAYNRR 
9 
  
1 
  
2 0 0 
QVSTYQEVVR QVSTYQEVVR QVSTYQEVVR 
EVENPQNQLR   EVENPQNQLR 
FEVNGIPEER     
KLTEAMSL     
Sgcb P82349 
RNENLVITGNNQPIVFQQGTTK 
17 
RNENLVITGNNQPIVFQQGTTK 
2 
RNENLVITGNNQPIVFQQGTTK 
8 0 0 
LPSSSSGDQSGSGDWVR   LPSSSSGDQSGSGDWVR 
THNILFSTDYETHEFHLPSGVK     
TSITSDIGMQFFDPR TSITSDIGMQFFDPR TSITSDIGmQFFDPR 
LCMCADGTLFK   LCMCADGTLFK 
GNEGVFIMGK   GNEGVFIMGK 
Sgcd P82347 
GVEINAEAGNMEAICR 
13 
  
5 
GVEINAEAGNMEAICR 
8 0 0 
LEGDSEFLQPLYAK LEGDSEFLQPLYAK LEGDSEFLQPLYAK 
LLFSADDSEVVVGAER LLFSADDSEVVVGAER LLFSADDSEVVVGAER 
VLGAEGTVFPK VLGAEGTVFPK VLGAEGTVFPK 
VFEVCVCANGR   VFEVCVCANGR 
VLTQLVTGPK VLTQLVTGPK VLTQLVTGPK 
SRPGNALYFK     
SLVMEAPK     
Sgcz Q8BX51 
ELHLQSTEGEIFLNADSIR 
8 
  
2 
ELHLQSTEGEIFLNADSIR 
10 0 0 
VLFSADEDEITIGAEK   VLFSADEDEITIGAEK 
LEGISEFLLPLYVK LEGISEFLLPLYVK LEGISEFLLPLYVK 
LGNLPIGSFSSSTSSSNSR   LGNLPIGSFSSSTSSSNSR 
QTVYELCVCPNGK   QTVYELCVCPNGK 
GVQVSAAAGDFK GVQVSAAAGDFK GVQVSAAAGDFK 
    STDLDIQELK 
    VTGTEGAVFGHSVETPHIR 
Dag1 Q62165 
IPSDTFYDNEDTTTDKLK 
2 0 0 0 0 0 0 
ALSIAVTGSGScR 
Table 3.6 High-confidence sarcoglycan and dystroglycan peptides detected in ε-SG IAPs from wild-type C57BL/6J and Sgce intron 11 gene-trap homozygote mice. IAPs were carried 
out on wild-type C57BL/6J and Sgce intron 11 gene-trap homozygote mice using the esg3788 and esg2-1358 antibodies. The proteins present in each IAP were identified through MS analysis 
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of the sample. The sarcoglycan peptides present in each IAP are listed here, along with the spectral count for that protein in that IAP; the table is arranged so that identical peptides 
corresponding to a protein are shown in the same row. Peptides derived from the ε-SG isoform 2 unique C-terminal tail are in bold. No sarcoglycans at all were detected in the esg2-1358 IAP 
from gene-trap mouse brain, suggesting that ε-SG isoform 2 may be severely reduced or absent from these mice. 
 
  
CD-1 wild-type C57BL/6J wild-type Sgce gene trap 
Gene Protein esg3788 
spectral count 
esg2-1358 
spectral count 
esg3788 
spectral count 
esg2-1358 
spectral count 
esg3788 
spectral count 
esg2-1358 
spectral count 
Tnr Tenascin-R 6 4 3 0 0 0 
Sgcz Zeta sarcoglycan 8 6 8 10 2 0 
Sgce Epsilon sarcoglycan (both isoforms) 28 16 9 2 1 0 
Sgcd Delta sarcoglycan 6 1 2 8 5 0 
Sgcb Beta sarcoglycan 2 2 7 8 2 0 
Itpr1 Inositol 1,4,5-trisphosphate receptor 
type 1 
8 42 1 0 0 1 
Table 3.7 Comparison of spectral counts for proteins most likely to be genuine ε-SG interactors between CD-1 wild-type mice, C57BL/6J wild-type mice, and Sgcem+/pGt mice.  High 
probability proteins present in IAPs from both CD-1 and C57BL/6J mouse strains were identified, and the spectral counts in each IAP were compared: esg3788 and esg2-1358 IAPs from CD-1 
wild-type mice, C57BL/6 wild-type mice, and Sgcem+/pGt mice. Abbreviations: gene trap, Sgcem+/pGt mice.
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wild-type littermates, and correspondingly lower levels of co-purified β-dystroglycan (Figure 
3.15b). ε-SG isoform 2 was clearly detected at approximately 50kDa in the wild-type tissue, 
but not in the Sgcem+/pGt mice; faint signal just above ε-SG isoform 2 of approximately 50kDa 
was detected in Sgcem+/pGt mice, but this was also present in the pre-immune IAP and 
therefore was most likely immunoglobulin-related (Figure 3.15, Table 3.6). MS analysis of 
the esg3788 immunoaffinity-purified protein confirmed reduced sarcoglycan abundance in 
the Sgcem+/pGt mice based on lower spectral counts (Table 3.6). No sarcoglycans were 
detected in the esg2-1358 IAP from Sgcem+/pGt mice, and combined with the previously 
described RT-PCR data this suggested absence of ε-SG isoform 2 from the Sgcem+/pGt mice 
(Table 3.6). Therefore, the Sgcem+/pGt mice could be used to identify proteins cross-reacting 
with the ε-SG isoform 2-specific esg2-1358 antibody. Of the two high-likelihood proteins 
identified in ε-SG IAPs above (section 3.2.5.3), inositol 1,4,5-triphosphate receptor 1 (Itpr1) 
was detected by MS analysis in the Sgcem+/pGt mice (Table 3.7). Therefore this protein may 
cross-react with the esg2-1358 antibody rather than genuinely co-purifying with ε-SG.  
3.2.6. ε-SG isoform 2 co-purifies with Tenascin-R from mouse brain. 
Tenascin-R was consistently identified in ε-SG IAPs from whole mouse brain tissue using 
both esg3788 and esg2-1358 antibodies (Table 3.8). To determine whether tenascin-R was 
genuinely co-purifiying with ε-SG rather than cross-reacting with anti-ε-SG antibodies or 
interacting non-specifically, the mouse monoclonal anti-TnR antibody clone 619 (Chapter 2 
section 2.3.12, Table 2.2) was used for IAP to enrich tenascin-R-containing complexes from 
mouse brain. The 619 antibody binds the fibrinogen-like domain of tenascin-R and has been 
well-validated in several previous studies (Morawski et al., 2014, Morganti et al., 1990, 
Weber et al., 1999, Xiao et al., 1996). For comparison, parallel IAPs using esg3788 or Protein 
G-sepharose without antibody were also performed. As expected, the anti-tenascin-R 
antibody IAP successfully enriched tenascin-R as demonstrated by Western blot (Figure  
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Antibody 
Lysis 
buffer 
Mouse 
strain 
Year 
Protein 
identity score 
Distinct tenascin-R peptides 
Total TnR 
peptides 
TnR spectral 
count 
TnR protein 
coverage 
esg2-1358 RIPA CD-1 2013 339.79 
DGQEAVFAYYDK 
12 15 15.40% 
DKEEDMLEVLLDATKR 
ITFTPSSGISSEVTVPR 
LDSSVVPNTVTEFAITR 
LILNYSPR 
LYPATEYEISLNSVR 
SPPTSASVSTVIDGPTQILVR 
SSLTSTVFTTGGR 
VATHLSTPQGLQFK 
VVYSTLAGEQYHEVLVPK 
YEVSISAVR 
YGLVGGEGGK 
esg3788 Digitonin CD-1 2015 15.65 
DKEEDMLEVLLDATKR 
6 6 15.65% 
LEGLSENTDYTVLLQAAQEATR 
SSLTSTVFTTGGR 
VATHLSTPQGLQFK 
VGFGNLEDEFWLGLDNIHR 
YEVSISAVR 
esg2-1358 Digitonin CD-1 2015 10.66 
SSLTSTVFTTGGR 
4 4 4.05% 
VATHLSTPQGLQFK 
VGFGNLEDEFWLGLDNIHR 
YEVSISAVR 
esg2-1358 RIPA CD-1 2015 8.3 
VGFGNLEDEFWLGLDNIHR 
3 3 3.09% VATHLSTPQGLQFK 
YEVSISAVR 
esg3788 Digitonin C57BL/6J 2015 7.37 
AAIENYVLTYK 
3 3 2.72% LDSSVVPNTVTEFAITR  
YEVSISAVR 
Table 3.8 Tenascin-R peptides identified in IAPs from whole mouse brain using anti-ε-SG antibodies. Details of each ε-SG IAP in which tenascin-R (TnR) was identified are listed. The 
TnR peptides detected in the IAPs are also given, alongside the protein identity score (likelihood that TnR was actually present in the sample analysed by MS), total number of TnR peptides 
detected, TnR spectral count, and the percentage of the TnR protein covered by the peptides detected. Abbreviations: TnR, tenascin-R.
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3.16). In addition, ε-SG isoform 2 but not isoform 1 could be detected in the tenascin-R IAP 
(Figure 3.16). Therefore, ε-SG isoform 2 and tenascin co-purify using antibodies against both 
proteins as assessed by immunoblot and MS analysis of IAPs. However, tenascin-R could not 
be detected in the esg3788 IAP, despite its consistent detection in ε-SG IAPs by MS analysis 
(Table 3.8, Figure 3.16). Spectral counts for tenascin-R in ε-SG IAPs were comparatively 
low, so the inability of the anti-tenascin-R antibody to detect tenascin-R in the esg3788 IAP 
could reflect low antibody sensitivity on Western blot.  
Figure 3.16 ε-SG isoform 2 but not isoform 1 co-purifies with TnR from digitonin-solubilised mouse brain. An anti-
TnR mouse monoclonal antibody was used to isolate TnR-containing complexes from mouse whole brain solubilised with 
digitonin lysis buffer. The esg3788 antibody was used to enrich for ε-SG, and a Protein G-sepharose only capture with no 
antibody was included to evaluate for non-specific protein binding. Immunoblot using the anti-TnR antibody indicated 
detectable enrichment in the anti-TnR IAP but not in the ε-SG IAP. This may be due to inability of the anti-TnR antibody to 
detect low abundance TnR such as that observed in ε-SG IAPs, as TnR has consistently been detected in ε-SG IAPs via MS. 
Immunoblot using a biontinylated pan-ε-SG antibody demonstrated that both isoforms of ε-SG were present in the esg3788 
IAP, while only ε-SG isoform 2 co-purified with TnR. Thus, TnR appeared to specifically co-purify with ε-SG isoform 2. 
No ε-SG or TnR was present in the Protein G-sepharose control. Abbreviations: kDa, kilodaltons; 3788, IAP using the 
esg3788 antibody; TnR, IAP using the anti-TnR antibody; ProtG, IAP using Protein G-sepharose with no antibody. 
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3.3. Discussion 
The proteins with which ε-SG interacts in the brain could provide insight into its function and 
the molecular pathogenesis of MD. Therefore, in this study I aimed to identify proteins 
interacting with the widely-expressed ε-SG isoform 1 and the brain-specific ε-SG isoform 2 
in the mouse brain. MS and Western blot analysis of immunoaffinity-purified proteins from 
brain demonstrated that both ε-SG isoforms consistently co-purified with β-, δ- and ζ-SGs, 
demonstrating the existence of prototypical εβδγ sarcoglycan heterotetramers in the brain. 
Furthermore, under mild solubilisation conditions ε-SG co-purified with the other DGC 
proteins Dp71 and β-dystroglycan. This co-purification indicated that ε-SG may be part of 
DGC-like complexes in the brain. ε-SG isoform 2 was also found to co-purify with the 
extracellular matrix protein tenascin-R in the brain. 
Sgce is predominantly expressed in neuronal tissue, with some expression in vascular tissue 
and glial cells including astrocytes (Boulay et al., 2015, Chan et al., 2005, Nishiyama et al., 
2004). However, a recent study identified transcripts from all six sarcoglycans in blood 
vessels isolated from mouse brain tissue (Boulay et al., 2015). Intriguingly, ε-SG isoform 1 
only has been detected in astrocytes and brain vascular tissue, suggesting that ε-SG isoform 2 
may be restricted to neurons (Nishiyama et al., 2004). IAPs using either the esg3788 antibody 
against all ε-SG isoforms or the esg2-1358 antibody specific to ε-SG isoform 2 consistently 
co-purified β-SG, δ-SG and ζ-SG, indicating that both main ε-SG isoforms present in the 
brain were incorporated into prototypical εβδζ sarcoglycan heterotetramers (Tables 3.2, 3.4, 
and 3.5). γ-SG and α-SG were not detected in any ε-SG IAP, which was consistent with 
reported low expression of their respective genes in the brain (Durbeej and Campbell, 1999, 
Noguchi et al., 1995, Noguchi et al., 2001, Waite et al., 2016). However, a previous IAP 
performed in our research group using the esg4990 antibody to purify all ε-SG isoforms from 
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RIPA-solubilised rat brain did isolate γ-SG (Waite et al., 2016). This esg4990 IAP from rat 
brain was performed and analysed using an identical protocol to that used for the initial esg2-
1358 IAP enriching ε-SG isoform 2 from RIPA-solubilised mouse brain (section 3.2.2.1) 
(Waite et al., 2016). The co-purification of γ-SG with all ε-SG isoforms but not the possibly 
neuron-restricted ε-SG isoform 2 (Nishiyama et al., 2004) could indicate that γ-SG interacts 
only with ε-SG isoform 1 as part of sarcoglycan heterotetramers in non-neuronal tissue. 
These data were consistent with the presence of multiple DGC-like complexes in different 
brain cell types (Blake et al., 1999). Absence of γ-SG from subsequent IAPs performed using 
antibodies against all ε-SG isoforms may reflect a combination of low γ-SG abundance and 
use of a different protocol for MS analysis of immunoaffinity-purified proteins (section 
3.2.5).  
The incorporation of both the widely-expressed ε-SG isoform 1 and the brain-specific ε-SG 
isoform 2 into prototypical sarcoglycan heterotetramers in the brain raises important 
questions regarding the relevance of these complexes to MD. MD and LGMD are both 
caused by loss of function mutations leading to deficiency of the mutated sarcoglycan or 
entire sarcoglycan complex from the cell surface in the affected tissue (Esapa et al., 2007, 
Sandona and Betto, 2009, Waite et al., 2011). However, no MD-like symptoms have been 
identified in LGMD patients and vice versa. As previously discussed, the early onset and 
severity of muscle disease in LGMD could mask any MD-like features. Alternatively, 
differential assembly and trafficking of complexes, or the presence of residual cell surface 
complexes in the brain could prevent MD-like symptoms in LGMD patients.  
When modelled in heterologous cells, alternatively spliced ε-SG isoforms did not affect 
assembly or trafficking of wild-type brain sarcoglycan heterotetramers (Figures 3.4 and 3.5). 
Previous studies have highlighted the importance of β-SG for sarcoglycan complex assembly 
and trafficking, so the LGMD-associated T182A mutant β-SG was expected to result in 
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intracellular retention of the sarcoglycan complex in heterologous cells (Chen et al., 2006, 
Draviam et al., 2006a, Shi et al., 2004). Indeed, T182A β-SG abolished trafficking of the βδ-
SG core to the cell surface, but reduced levels of an εζ-SG complex could still be detected at 
the cell surface (Figures 3.4, 3.5 and 3.6). Cell surface ε-SG and ζ-SG has also been 
identified in the brain of the δ-SG-deficient BIO14.6 hamster (Waite et al., 2016). Therefore, 
in the brain a pool of ε- and ζ-SG may traffic to the cell surface despite intracellular retention 
of mutant βδ-SG complexes (Bianchini et al., 2014, Esapa et al., 2007, Gastaldello et al., 
2008, Soheili et al., 2012). Low abundance sarcolemmal sarcoglycan complexes have been 
shown to contribute to membrane stability in DMD-deficient mice, so it is possible that a low 
abundance cell surface sarcoglycan complex in the brain could be sufficient for normal brain 
function in LGMD patients (Li et al., 2009). 
Cai and colleagues showed that the Schwann cell sarcoglycan complex, in common with the 
brain complex described herein, was composed of an εβδζ sarcoglycan heterotetramer (Cai et 
al., 2007). In both brain and peripheral nerve, α- and γ-SG are known to be expressed at very 
low levels, if at all (Cai et al., 2007, Waite et al., 2016). However, Cai and colleagues found a 
severe reduction of Schwann cell surface ε-SG and ζ-SG in the δ-SG-deficient BIO14.6 
hamster (Cai et al., 2007). This contrasted markedly with the residual cell surface ε-SG and ζ-
SG detected in the brain of the BIO14.6 hamster and in heterologous cell models of εβδζ 
sarcoglycan heterotetramers containing an LGMD-associated mutant β-SG (section 3.2.2.2, 
Figures 3.4 and 3.5) (Waite et al., 2016). Although this may seem paradoxical, cytoplasmic 
components of the DGC are also preserved in the brains of the Dmdmdx and Dmdmdx3Cv mouse 
models of Duchenne Muscular Dystrophy when they are severely reduced in muscle (Blake 
et al., 1999). Thus, similar sarcoglycan complexes in nerve, muscle and brain appear to be 
differentially sensitive to the absence of specific sarcoglycans or other components of the 
DGC.  
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β-dystroglycan and Dp71 also co-purified with both the widespread ε-SG isoform 1 and 
brain-specific isoform 2 under mild tissue solubilisation conditions (Figures 3.7 and 3.8). For 
most IAPs, β-dystroglycan could only be detected by Western blot analysis of 
immunoaffinity-purified protein; however, two dystroglycan peptides were identified by MS 
in the esg3788 IAP from C57BL/6J mouse brain tissue (Table 3.6). One of these peptides was 
derived from α-dystroglycan rather than β-dystroglycan, demonstrating that digitonin did not 
disrupt the interaction between these two proteins (Table 3.6). Identification of dystroglycan 
by MS as well as Western blot further confirmed its presence in ε-SG IAPs from brain tissue. 
Additionally, IAPs using antibodies against β-dystroglycan or C-terminal dystrophin resulted 
in the co-purification of ε-SG (Figure 3.9). Co-purification of dystroglycan and dystrophin 
isoforms was lower than would be expected based on the known interaction between these 
proteins, however (Figure 3.9). The lower than expected co-purification of dystroglycan and 
dystrophin may have been caused by several factors, including incomplete solubilisation of 
full-length Dp427, use of monoclonal mouse antibodies on mouse tissue, absence of calcium 
from the lysis buffer, and partial disruption of the interaction between dystroglycan and 
dystrophin by the MANDAG2 antibody (Pereboev et al., 2001, Yoon et al., 2012). Overall 
the above experiments supported incorporation of ε-SG into brain DGC-like complexes, 
which would implicate DGC-like complexes in MD pathogenesis. DGC-like complexes have 
crucial roles during brain development and function, including in neuronal migration, 
synapse organisation and calcium homeostasis (Chapter 1 section 1.4.3) (Anderson et al., 
2002, Waite et al., 2012). In particular, perturbations of calcium homeostasis have been 
directly implicated in both muscular dystrophies and dystonias: paralogues ANO3 and ANO5 
encode calcium-activated proteins (potentially anion channels) that are mutated in autosomal 
dominant craniocervical dystonia (DYT23) and LGMD type 2L respectively (Bolduc et al., 
2010, Charlesworth et al., 2012, Hicks et al., 2011). Loss of cell surface ε-SG in MD may 
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result in disruption of DGC-like complexes in the brain, leading to neuronal dysfunction 
through one or more pathways.  
A hypothesis-free analysis of immunoaffinity purified ε-SG-containing complexes from 
mouse brain also identified a non-DGC protein that co-purified with ε-SG isoform 2: 
tenascin-R (section 3.2.6). Novel proteins interacting with ε-SG in the brain would provide 
additional insight into its function(s), but identifying these proteins would require careful 
analysis of IAP-MS datasets to eliminate proteins enriched through contamination, cross-
reaction with the antibody used, and/or non-specific interaction with immunoglobulin or the 
Protein A-agarose support matrix. Ideally, this would be achieved by carrying out a parallel 
IAP-MS experiment on ε-SG-deficient tissue; only contaminants, cross-reacting and non-
specifically interacting proteins would be enriched in an IAP performed on ε-SG deficient 
tissue using an anti-ε-SG antibody. As tissue from ε-SG-deficient mice could not be obtained 
for this study, cross-reacting proteins were identified through use of multiple antibodies and 
comparison of IAPs performed on digitonin versus RIPA-solubilised tissue, while non-
specifically interacting proteins were identified in a pre-immune immunoglobulin control. 
This approach resulted in the identification of tenascin-R as co-purifying with ε-SG using 
both esg3788 and esg2-1358 antibodies (sections 3.2.5 and 3.2.6).  
IAP of tenascin-R-containing complexes from digitonin-solubilised mouse brain resulted in 
co-purification of ε-SG isoform 2, confirming that tenascin-R did not cross-react with the 
anti-ε-SG antibodies (Figure 3.16). Although further experiments are required to confirm an 
interaction between tenascin-R and ε-SG isoform 2 in the brain, this could provide further 
clues to the function of ε-SG in the brain. Tenascin-R is an extracellular matrix proteoglycan 
principally involved in organisation of the perineuronal net (PNN) around a subset of CNS 
neurons (Anlar and Gunel-Ozcan, 2012, Chiovaro et al., 2015, Probstmeier et al., 2001). As 
part of PNNs, tenascin-R contributes to organisation of synapses including channel and 
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receptor clustering, synapse stability, extracellular ion concentrations, and presynaptic vesicle 
content (Anlar and Gunel-Ozcan, 2012, Aspberg et al., 1997, Bruckner et al., 2000, Geissler 
et al., 2013, Hagihara et al., 1999, Haunso et al., 2000, Morawski et al., 2014, Nikonenko et 
al., 2003, Oohashi et al., 2015, Weber et al., 1999). Therefore, if confirmed an interaction 
between ε-SG isoform 2 and tenascin-R might further implicate ε-SG in organisation of the 
synapses. Perturbation of synapses through disruption of both tenascin-R-containing 
complexes and DGC-like complexes by ε-SG deficiency might contribute to the pathogenesis 
of dystonia in SGCE mutation-positive MD. 
In conclusion, I have shown that prototypical sarcoglycan heterotetramers containing 
different ε-SG isoforms exist in brain. My data from heterologous cells and previously 
published data in the δ-SG-deficient BIO14.6 hamster suggest a pool of residual ε-SG and ζ-
SG may traffic and function independently in the presence of LGMD-associated sarcoglycan 
mutations (Waite et al., 2016). This could contribute to the absence of neurological signs in 
LGMD patients. In addition, ε-SG co-purified with β-dystroglycan and Dp71 from digitonin-
solubilised mouse brain; co-purification of these proteins suggests that ε-SG may be a 
component of DGC-like complexes in the brain. Dysfunction of DGC-like complexes could 
contribute to the molecular pathogenesis of MD. Finally, ε-SG isoform 2 co-purified with 
tenascin-R from mouse brain, which could provide a first clue to non-DGC interactions of ε-
SG in the brain. Further experiments to verify this result and determine whether tenascin-R 
and ε-SG interact could include immunohistochemistry to determine co-localisation, or in 
vitro knock-down and co-immunoprecipitation to determine whether these proteins interact 
and if so what effects disrupting this interaction might have. In addition, it is highly likely 
that additional ε-SG-interacting proteins exist in the brain. Refinements of the IAP protocol 
described here – use of different buffers to capture proteins differentially soluble in RIPA 
versus digitonin buffers, reduction of sample complexity for MS analysis, repetition of the 
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IAPs to obtain better coverage, and use of fresh tissue for all experiments – might help 
identify additional interacting proteins. Alternatively, distinct methods such as proximity-
dependent labelling could be employed to identify proteins in close physical proximity to ε-
SG that might interact with it (Carneiro et al., 2016). Regardless, the present study presents 
the first identification of proteins that may interact with ε-SG in the brain and provides a 
framework for future studies.
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Chapter 4: Alternative splicing of sarcoglycan pre-mRNA 
4.1. Introduction 
In the previous chapter  I showed that ε-SG interacts with β-, δ- and ζ-SG to form 
prototypical sarcoglycan complexes in the brain (Chapter 3 sections 3.2.2 and 3.2.4), yet only 
SGCE mutations cause neurological dysfunction (Ozawa et al., 2005). Several possible 
explanations for this have been proposed, including an as-yet unknown unique function for 
the brain-specific ε-SG isoform 2 produced through pre-mRNA alternative splicing (Ritz et 
al., 2011). Alternative splicing of SGCA, SGCB, SGCD, SGCG and SGCZ pre-mRNA could 
also contribute to differences in sarcoglycan protein levels and functions between tissues, but 
has not been studied systematically. Up to 95-100% of mammalian multi-exonic genes are 
thought to produce alternatively spliced transcripts, so all sarcoglycans were predicted to 
undergo alternative splicing (Berget et al., 1977, Chow et al., 1977, Early et al., 1980, 
Kornblihtt et al., 2013, Pan et al., 2008, Wang et al., 2008).  
Alternative splicing can have a number of different effects on a transcript’s product. If an 
alternative splicing event affects the transcript coding region without inhibiting translation, 
the encoded protein isoform might differ from the full-length isoform in properties such as 
localisation, protein interactions, stability, and protein motifs or domains (Kelemen et al., 
2013). This could affect the assembly and function of sarcoglycan complexes. By contrast, 
alternative splicing events that change the sequence of untranslated regions (UTRs) might 
affect translation by changing mRNA localisation, stability, translation kinetics, or nuclear 
export (Kelemen et al., 2013, Zheng and Black, 2013). Finally, alternative splicing events 
that introduce premature termination codons (PTCs) into the transcript coding region more 
than 50-55 nucleotides (nt) upstream of the final exon:exon junction can trigger nonsense-
mediated decay or translational repression (NMD/R) of the transcript that leaves the 
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transcript unproductive (untranslatable) (Isken and Maquat, 2007, Lewis et al., 2003, Mendell 
et al., 2004, Skandalis et al., 2010). While some unproductive transcripts may represent 
splicing errors, unproductive transcripts and those with UTR sequence changes can modulate 
protein production from a transcriptionally active gene (Lewis et al., 2003). For example, the 
splicing factor SRSF4 directly binds and induces inclusion of a so-called “poison” exon into 
its own transcript, which introduces a PTC and results in reduced protein synthesis (Änkö et 
al., 2012). Therefore, alternative splicing of sarcoglycan pre-mRNA could affect both 
sarcoglycan protein levels and functions to modulate the composition and/or function of 
sarcoglycan complexes.  
In order to identify alternatively spliced human SGCA, SGCB, SGCD, SGCG and SGCZ 
transcripts, I used an RT-PCR-based approach to screen human adult cerebellum and skeletal 
muscle tissue for transcripts derived from these genes. Human tissue was used so that 
alternatively spliced transcripts could be related directly to LGMD and MD. In addition, 
studies on other genes have suggested that overall levels of alternative splicing may be 
greater in humans than in mice (Barbosa-Morais et al., 2012, Kim et al., 2007). Cerebellum 
was selected for its implication in the aetiology of MD by both physiological studies and high 
ε-SG isoform 2 levels, while skeletal muscle contains a prototypical sarcoglycan 
heterotetramer and is the tissue predominantly affected by LGMD (Marelli et al., 2008, 
Ozawa et al., 2005, Popa et al., 2014, Ritz et al., 2011, van der Meer et al., 2012, van der 
Salm et al., 2013, Yokoi et al., 2012a, Yoshida et al., 1994). 
4.2. Results 
To identify alternatively spliced SGCA, SGCB, SGCD, SGCG and SGCZ transcripts, poly-
d(T)-primed first strand cDNA synthesis followed by gene-specific PCR was used to generate 
cDNA mini-libraries from human adult cerebellum and skeletal muscle total RNA (Chapter 2 
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sections 2.1.1-2.1.3, 2.1.7, 2.2.8-2.2.11). Use of both brain and muscle tissue facilitated 
screening of the muscle-specific SGCA and SGCG transcripts in addition to predominantly 
non-muscle SGCZ (Barresi et al., 2000b, Liu et al., 1997, Wheeler et al., 2002). The resultant 
cDNA mini-libraries were screened by overlapping PCR and then sequencing of cDNA 
inserts to identify alternatively spliced cDNAs (Chapter 2 sections 2.1.1-2.1.3, 2.1.7, 2.2.8-
2.2.11) (Figure 4.1). Promoters and transcription termination sites for each gene were 
obtained from reference sequences in NCBI RefSeq, ENSEMBL, and Leiden Open Variation 
Figure 4.1 Overview of protocol for identification of alternatively spliced sarcoglycan transcripts. Gene-specific RT-
PCR of sarcoglycan cDNA was performed to produce mini-libraries of cDNAs corresponding to transcripts from the 
sarcoglycan genes in skeletal muscle and cerebellum. Mini-library clones were then screened for alternatively spliced 
transcripts. A) Schematic of a cDNA inserted into the plasmid vector pCI-neo; half arrows mark sites of primers for 
overlapping PCR amplicons covering the entire cDNA insert. “Amplicon A” represents the region amplified using primers 
AF and AR. B) Insert sizes were determined via agarose gel electrophoresis of PCR products. For Amplicon A, two sizes of 
PCR product were observed: the expected size for clones 1 and 2, and a smaller product for clones 3 and 4. C) Clones were 
sequenced to identify the transcript insert. Clones 1 and 2 represented the full-length major transcript, while clones 3 and 4 
represented a transcript lacking exon 2 (gene transcript Δ exon 2). 
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Database (LOVD) (Brown et al., 2015, Flicek et al., 2014, Fokkema et al., 2011, Harrow et 
al., 2012). Figure 4.2 shows the genomic architecture for each sarcoglycan gene. SGCA, 
SGCB, SGCG and SGCZ each had one annotated promoter and one transcription termination 
site, and therefore required a single cDNA mini-library per tissue. By contrast, SGCD had 
two annotated promoters and two transcription termination sites (Figure 4.2). While the 
termination sites were both well-supported in expressed sequence tag databases, ENCODE 
annotation for the upstream promoter was weaker than for the downstream (proximal to exon 
2) promoter (Figure 4.3) (Rosenbloom et al., 2015, Rosenbloom et al., 2013). However, 
cDNA from both promoters was detected in the human tissue samples so transcripts from 
both were screened. 
Figure 4.2 Overview of genomic architecture for the human SGCA, SGCE, SGCB, SGCD, SGCG and SGCZ genes. 
SGCE data from (Ritz et al., 2011). All known exons – both previously annotated and identified in the present study – are 
depicted. Black or grey fill indicates potentially coding sequence; grey indicates exons typically excluded from the mature 
transcript. Figure is not to scale, although relative sizes and positions of exons are approximately correct. * denotes novel 
exons identified in the present study. 
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Each transcript was described relative to the full-length, major transcript from that gene as 
annotated in LOVD and RefSeq (Brown et al., 2015, Fokkema et al., 2011). A transcript 
containing the novel exon 1b in addition to the canonical exons would be described as SGCx 
exon 1b+ transcript, whereas a transcript lacking exon 2 would be described as the SGCx Δ 
exon 2 transcript. RT-PCR allowed splicing events to be identified in the context of the entire 
transcript, rather than in isolation; therefore, complex alternative splicing events involving 
multiple sequences could be identified. This method also provided an estimate of relative 
transcript abundance, as transcripts abundant in tissue should be more abundant in a cDNA 
mini-library derived from that tissue. However, PCR can preferentially amplify shorter 
targets, which would bias the cDNA mini-library in favour of shorter transcripts. This 
precluded accurate calculation of transcript abundance. 
Figure 4.3 Transcription activity markers around the SGCD promoters from ENCODE. Screenshot of the UCSC 
Genome Browser (http://genome.ucsc.edu/) display of annotated histone modifications and transcription levels assessed in 
cell lines by the ENCODE project (Consortium, 2012, Kent et al., 2002, Rosenbloom et al., 2013). A) Downstream/exon 2 
proximal promoter for SGCD. B) Upstream/distal promoter. 
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4.2.1. Few alternatively spliced SGCB transcripts were identified in cerebellum and 
skeletal muscle 
Figure 4.4 SGCB transcripts and novel exons identified in human cerebellum and skeletal muscle. A) For each SGCB 
transcript identified in this study, the splicing pattern is displayed against the genomic architecture of the gene. Thin lines 
connect exons included in the mature transcript. Features such as premature termination codons (PTC) and frameshift sites 
(FS) are annotated. For translated transcripts, the encoded polypeptide with major features annotated is depicted below the 
splicing pattern. Yellow indicates a transmembrane domain, N represents N-linked glycosylation sites, and green lines 
connect cysteine residues involved in disulphide bonds. B) Sequence and splice sites for the novel exon 2b. Abbreviations: 
5’SS, 5’ splice site; 3’SS, 3’ splice site. 
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In total, five distinct alternatively spliced SGCB transcripts were identified in 100 cerebellum 
cDNA mini-library clones and 103 skeletal muscle cDNA mini-library clones (Figure 4.4).  
The major transcript, RefSeq sequence NM_000232.4, was observed at similar abundance in 
each mini-library: 81% of cerebellum cDNA mini-library clones, and 83% in skeletal muscle  
(Figure 4.5). Also present in both mini-libraries was a SGCB Δ exon 2 transcript (exon 2 
skip) predicted to encode an alternative β-SG isoform 2 without the transmembrane domain 
found in full-length isoform 1 (Table 4.1, Figure 4.4). A novel exon 2b with sequence 
similarity to the HAL1 transposable element was detected in 4-8% of clones per mini-library, 
Figure 4.5 SGCB transcripts identified in human cerebellum and skeletal muscle. Stacked bar chart representing the 
abundance of each transcript (described in figure 4.4) identified for the SGCB gene in mini-libraries. All transcripts are 
described relative to the full-length, major transcript. 
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but introduced a PTC predicted to stimulate NMD/R of the transcript (Table 4.1, Figures 4.4 
and 4.6a) (Kent, 2002, Smit et al., 2013-2015).  
SGCB 
transcript 
Effect on 
mRNA 
Type of 
alternative 
splicing 
event 
Observed frequency 
Predicted effect on encoded protein Isoform 
NCBI RefSeq 
accession 
Cerebellum 
(100 
clones) 
Skeletal 
muscle (103 
clones) 
Major 
transcript 
- - 0.81 0.83 
Full-length protein isoform 1: 
transmembrane domain at I66-I86; N-linked 
oligosaccharides at N158, N211 and N258; 
disulphide bonds between C288:C314 and 
C290:C307; 318aa 
1 NM_000232.4 
Δ exon 2 
Omission of 
exon 2 
Exon skipping 0.15 0.10 
Isoform 2 with in-frame loss of Q12-I81 
(69aa), removing transmembrane domain 
but leaving glycosylation sites and 
disulphide bonds unaffected; 248aa 
2 XM_011534403.1 
Δ exon 2, 
exon 2b+ 
Omission of 
exon 2 and 
inclusion of 
novel exon 
2b (110nt) 
Exon skipping 
and alt. exon 
inclusion 
  0.04 
Introduction of frameshift and PTC – 
NMD/R target, non-productive. 
- - 
Δ exon 2, 
exon 3 
truncation 
Omission of 
exon 2; 
omission of 
97nt from 3' 
end exon 3 
Exon skipping 
and use of 
alternate 5' 
splice site 
  0.01 
Introduction of frameshift and PTC – 
NMD/R target, non-productive. 
- - 
Exon 2b+ 
Inclusion of 
novel exon 
2b (110nt) 
Alt. exon 
inclusion 
0.04 0.03 
Introduction of frameshift and PTC – 
NMD/R target, non-productive. 
- - 
Table 4.1 Summary of SGCB transcripts identified in human cerebellum and skeletal muscle. Over two mini-libraries of human SGCB transcripts derived from cerebellum and skeletal 
muscle total RNA respectively, five distinct transcripts were identified. This table summarises the major characteristics of each transcript: the effect on the mRNA, the type of alternative 
splicing event involved, the frequency of the transcript in each SGCB transcript mini-library, the predicted effect on the protein relative to the major isoform 1, and the predicted protein size. 
Abbreviations: Alt. exon inclusion, alternative or novel exon inclusion in RNA; PTC, premature termination codon; NMD/R, nonsense-mediated decay/repression; aa, amino acid.
 Figure 4.6 Alignment of novel exons to transposable elements using RepeatMasker. Each novel exon was screened 
using RepeatMasker to identify any similarity to transposable elements (transposons) (Smit et al., 2013-2015). Five exons 
showed similarity to transposons, and the alignments are shown here: A) SGCB exon 2b to the HAL1 LINE. B) SGCD exon 
2a to AluSq2. C) SGCD exon 2b to AluY. D) SGCZ exon 1b to L1M2 retrotransposon ORF2. E) SGCG exon 6b to AluYc. 
Abbreviations: i, transition at that position between transposable element and exon; v, transversion at that position between 
transposable element and exon. 
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4.2.2. Numerous alternatively spliced SGCD transcripts were identified in cerebellum 
and skeletal muscle 
Since SGCD has two promoters and two transcription termination sites as discussed above, 
four combinations of promoter and transcription termination site were possible for transcripts 
(Figure 4.2). However, in this study cDNA from only three could be detected: upstream 
promoter with exon 9 termination site, downstream promoter with exon 9 termination site, 
and downstream promoter with exon 8b termination site (Figure 4.7). Therefore, three SGCD 
cDNA mini-libraries per 
tissue were generated and 
screened for alternative 
splicing. No transcripts 
originating in the upstream 
promoter and terminating in 
exon 8b could be detected, 
but may still exist at low 
levels. Promoter usage only 
affected the 5’ UTR 
sequence, but SGCD 
transcription termination site 
altered the C-terminus of the 
encoded δ-SG protein. 
Transcripts terminating in 
exon 8b encoded a δ-SG isoform 2 with a truncated C-terminus compared to δ-SG isoform 1 
encoded by transcripts terminating in exon 9 (Figure 4.8).  
Figure 4.7 RT-PCR of SGCD cDNA from human cerebellum and skeletal 
muscle. SGCD cDNA was isolated using promoter- and terminal exon-specific 
primers from first strand cDNA. Each PCR reaction was resolved on an agarose 
gel stained using ethidium bromide. Products could be detected using three 
combinations of primers: downstream promoter and exon 9 termination, 
downstream promoter and exon 8b termination, upstream promoter and exon 9 
termination. The final pair, upstream promoter and exon 8b termination, was not 
successfully amplified from the sample. Abbreviations: DP, downstream 
promoter; UP, upstream promoter; +, cDNA in PCR; -, water control PCR. 
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Figure 4.8 SGCD transcripts identified in human cerebellum and skeletal muscle cDNA mini-libraries. For each SGCD 
transcript identified in this study, the splicing pattern is displayed against the genomic architecture of the gene. Exons 
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included in the transcript are connected, while features such as premature termination codons and frameshift sites are 
annotated. For translated transcripts, the encoded polypeptide with major domains is depicted below the transcript. Yellow 
indicates a transmembrane domain, N represents N-linked glycosylation sites, blue and turquoise indicate isoform-specific 
sequences, and green lines connect cysteine residues involved in disulphide bonds. Abbreviations: PTC, premature 
termination codon; FS, frameshift; Met, methionine translation initiation codon. 
All three SGCD transcript mini-libraries in both skeletal muscle and cerebellum contained 
alternatively spliced transcripts (Figure 4.9 and Table 4.2). In both tissues, cDNA mini-
libraries of transcripts from the upstream promoter had a greater overall abundance of 
alternatively spliced transcripts, particularly SGCD Δ exon 2 transcripts (Figure 4.9). The 
SGCD Δ exon 2 transcript was in fact the most abundant alternatively spliced transcript 
overall, and has previously been described (Figure 4.9, Table 4.2) (Jung et al., 1996, Nigro et 
al., 1996). However, it was not predicted to substantially affect the encoded protein (Figure 
4.8). Two additional alternatively spliced transcripts were also detected at greater than 5% 
frequency in one or more cDNA mini-libraries, suggesting they may be physiologically 
relevant (Figure 4.9, Table 4.2). The SGCD exon 3 truncation transcript lacked the 3’ 129nt 
from exon 3 due to alternative 5’ splice site usage, and was predicted to encode a δ-SG 
isoform missing residues 22-64 including the transmembrane domain (Figure 4.8, Table 4.2). 
This transcript was identified in 8-12% of clones from upstream promoter cDNA mini-
libraries (Figure 4.9, Table 4.2). The SGCD Δ exon 7 transcript was less abundant at 8-9% of 
cerebellum cDNA mini-library clones and only 1% of skeletal muscle cDNA mini-library 
clones, but was predicted to introduce a frameshift and PTC to the coding region (Figure 4.9, 
Table 4.2). If the SGCD Δ exon 7 transcript terminated in exon 9, the PTC would be more 
than 50nt upstream of the final exon:exon junction and therefore should induce NMD/R 
(Figure 4.8). By contrast, if the SGCD Δ exon 7 transcript terminated in exon 8b the PTC 
would be within the final exon and therefore the transcript was predicted to encode a δ-SG 
isoform 3 with a truncated extracellular region (Figure 4.8).  
All other alternatively spliced transcripts identified in SGCD cDNA mini-libraries were low 
abundance, at less than 5% of cDNA mini-library clones each (Table 4.2). In addition, most 
Figure 4.9 Relative abundance of discrete transcripts in SGCD cDNA mini-libraries from cerebellum and skeletal muscle. Stacked bar chart representing the abundance 
of each transcript (described in figure 4.7) identified for the SGCD gene in mini-libraries. All transcripts are described relative to the full-length, major transcript. 
 
Figure 4.9 Relative abundance of discrete transcripts in SGCD cDNA mini-libraries from cerebellum and skeletal muscle. Stacked bar chart representing the abundance 
of each transcript (described in figure 4.7) identified for the SGCD gene in mini-libraries. All transcripts are described relative to the full-length, major transcript. 
were not predicted to be translated (Figure 4.8). An exception was the SGCD Δ exon 6 
transcript, which although rare in the cDNA mini-libraries was predicted to encode a δ-SG 
isoform lacking residues 128-167 from the extracellular region (Figure 4.8, Table 4.2). In 
addition, six low-abundance (1-2% of cDNA mini-library clones) alternatively spliced 
transcripts were identified in skeletal muscle but not cerebellum cDNA mini-libraries (Table 
4.2). There were also two novel SGCD exons among the low abundance alternatively spliced 
transcripts: exons 2a and 2b (Figure 4.10). Both of these exons showed high similarity to Alu 
transposable elements, albeit of different families (Figure 4.6b,c) (Kent, 2002). Exon 2b 
appears to be derived from an Alu element as annotated in the TranspoGene database (Levy 
et al., 2008). Exon 2a affected only the 5’ UTR while exon 2b slightly changed the coding 
region as summarised in table 4.2. However, these exons were rare in the cDNA mini-
libraries.  
Figure 4.10 Novel exons identified in SGCD transcripts from human cerebellum and skeletal muscle. DNA sequences 
for novel and truncated exons. The 5’ splice sites (SS) and 3’ splice sites (SS) both cryptic and canonical are indicated in the 
sequence. 
SGCD 
transcript  
Effect 
on the 
mRNA 
Alternative 
splicing 
event 
UP DP Ex8b ter. Predicted effect on protein and RefSeq accession 
CB SM CB SM CB SM 
Isoform 1 protein (Exon 9 
termination) 
Isoform 2 protein (Exon 8b 
termination) 
Major 
transcript 
- - 0.41 0.51 0.78 0.89 0.81 0.92 
Full-length isoform 1: 290aa; 
transmembrane domain F37-L57; N-
linked glycans at N61, N109 and 
N285; disulphide bonds at C264:C289 
and C266:C282. DP: NM_000337.5; 
UP: XM_017009724.1 
Full-length isoform 2: 256aa; 
transmembrane domain F37-L57; 
alternate sequence after E233 compared 
to isoform 1; N-linked glycans at N61 and 
N109; no disulphide bonds. NM_172244.2 
Exon 2a+ 
Insertion 
of 
~134bp 
sequence 
into 5' 
UTR 
Alt. exon 
inclusion 
0.06 0.01   0.01   0.01 Full-length isoform 1 Full-length isoform 2 
Exon 2b+ 
Insertion 
of 66bp 
sequence 
after 
exon 2 
Alt. exon 
inclusion 
          0.01   
Introduces PTC immediately following 
exon 2 initiation site, but translation can 
initiate from exon 3 for a full-length 255aa 
isoform 2 protein lacking the first 
methionine. 
Δ exon 2 
Omission 
of exon 2 
Exon skipping 0.42 0.29 0.13 0.03 0.04   
Use of exon 3 translation initiation 
site; protein lacks 1st methionine but 
is otherwise identical to full-length 
isoform 1; 289aa. NM_001128209.1 
Use of exon 3 translation initiation site; 
protein lacks 1st methionine but is 
otherwise identical to full-length isoform 
2; 255aa 
Δ exon 2-3 
Omission 
of exons 
2 and 3 
Exon skipping   0.02         
No translation initiation site – non-
productive transcript 
  
Δ exon 2-4 
Omission 
of exons 
2-4 
Exon skipping 0.01           
No translation initiation site – non-
productive transcript 
  
Exon 3 
truncation 
Lacks 3' 
129bp 
from 
exon 3 
Use of 
alternate 5' 
splice site 
0.08 0.12   0.04 0.03 0.02 
Omission of V22-I64 inclusive 
including 1st N-glycan; lose 
transmembrane domain; 247aa. 
Isoform 1 exon 3 tr. 
Omission of V22-I64 inclusive including 1st 
N-glycan; lose transmembrane domain; 
213aa. Isoform 2 exon 3 tr. 
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Δ exon 6 
Omission 
of exon 6 
Exon skipping 0.03 0.01   0.02 0.03   
Omission of G128-L167 inclusive; 
transmembrane domain, N-linked 
glycans and disulphide bonds un-
affected; 249aa. Isoform 1 Δ exon 6 
Omission of G128-L167 inclusive; 
transmembrane domain and N-linked 
glycans unaffected; 215aa. Isoform 2 Δ 
exon 6 
Exon 6 
truncation, 
Δ exon 7 
Lacks 3' 
82nt 
from 
exon 6; 
omission 
of exon 7 
Use of 
alternate 5' 
splice site 
and exon 
skipping 
          0.02   
Introduces frameshift in exon 6; unique 
extracellular domain sequence after V141 
with termination after G184; 
transmembrane domain and first two 
glycosylation sites maintained; 184aa; 
isoform 4 
Δ exon 7 
Omission 
of exon 7 
Exon skipping     0.09   0.08 0.01 
Introduces frameshift and a PTC >55nt 
downstream of the final exon:exon 
junction – NMD/R target 
Introduces frameshift; unique 
extracellular domain sequence after G168 
with termination after L175; final N-linked 
glycosylation site and both disulphide 
bonds lost; 175aa: isoform 3 
Exon 2a+,  
Δ exon 7 
Insertion 
of 
~134bp 
sequence 
into 5' 
UTR; 
omission 
of exon 7 
Alt. exon 
inclusion; 
exon skipping 
  0.02         
Frameshift and alternate sequence 
after G168 with termination after 
L175; retain N-linked glycans at N61 
and N109 but lose final site and both 
disulphide bonds. Isoform 1 Δ exon 7 
  
Exon 2a+,  
Δ exon 2-4 
Insertion 
of 
~134bp 
sequence 
into 5' 
UTR; 
omission 
of exons 
2-4 
Alt. exon 
inclusion; 
exon skipping 
  0.01         
Introduction of frameshift and PTC – 
NMD/R target, non-productive. 
  
Δ exon 2, 6 
Omission 
of exons 
2 and 6 
Exon skipping   0.01       0.01 
Omission of 1st methionine and 
G128-L167 inclusive; transmembrane 
domain, N-linked glycans and 
Omission of 1st methionine and G128-
L167 inclusive; transmembrane domain 
and N-linked glycans unaffected; 215aa. 
Isoform 2 Δ exon 2, 6. 
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disulphide bonds remain unaffected; 
249aa. Isoform 1 Δ exon 2, 6. 
Table 4.2 Summary of SGCD transcripts identified in human cerebellum and skeletal muscle. Based on the gene architecture of SGCD, three mini-libraries of transcripts were required per 
tissue. Transcript abundance is provided in each of the six total mini-libraries, alongside the change in the mRNA sequence, the type of alternative splicing event involved, and the predicted 
effect on the isoform 1 protein and/or the isoform 2 protein depending on which transcript mini-libraries the transcript was identified. Abbreviations: cerebellum, CB; skeletal muscle, SM; 
transcripts originating from the upstream promoter and terminating in exon 9, UP; transcripts originating from the downstream promoter and terminating in exon 9, DP; transcripts originating 
from the downstream promoter and terminating in exon 8b, Ex8b ter; Alt. exon inclusion, alternative or novel exon inclusion in RNA; PTC, premature termination codon; NMD/R, nonsense-
mediate decay/repression; aa, amino acid.
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4.2.3. Alternatively spliced SGCZ transcripts in the cerebellum were varied 
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A total of nine different transcripts were identified in 215 clones from the human cerebellum 
SGCZ cDNA mini-library (Figure 4.11). Only 58% of clones screened comprised the 
canonical, full-length transcript; the remainder were alternatively spliced transcripts (Figure 
4.12, Table 4.3). In particular, two alternatively spliced transcripts predicted to encode novel 
ζ-SG isoforms accounted for nearly a quarter of the cDNA mini-library clones screened: the 
SGCZ Δ exon 3 transcript (15% of clones) and the SGCZ Δ exon 5 transcript (9%) of clones 
(Figure 4.12, Table 4.3). Both transcripts were predicted to encode isoforms lacking in-frame 
sections from the extracellular region, without affecting post-translational modifications 
(Figure 4.11). Three other alternatively spliced transcripts were also predicted to encode ζ-SG 
isoforms, but were each present at or less than 1% of clones and therefore are unlikely to be 
abundant in tissue (Table 4.3). 
The last three alternatively spliced SGCZ transcripts were all predicted to be unproductive 
due to insertion of a PTC more than 50nt upstream of the final exon:exon junction, which 
would induce NMD/R (Figure 4.11). However, the SGCZ exon 2 truncation transcript 
produced by use of an alternate 5’ splice site within exon 2 accounted for 11% of SGCZ 
cDNA mini-library clones (Figure 4.12, Table 4.3). This high abundance may indicate escape 
from NMD/R, possibly through proximity of the PTC to the translation initiation site or use 
of an alternate translation initiation site (Figure 4.12 and Table 4.3) (Isken and Maquat, 
2007). Another predicted unproductive transcript contained two novel SGCZ exons: exons 1a 
and 1b, the latter of which contained an in-frame termination codon (Figure 4.11). Exon 1b 
Figure 4.11 Transcripts and novel exons identified from SGCZ in human cerebellum. A) For each SGCZ transcript 
identified in this study, the splicing pattern is displayed against the genomic architecture of the gene. Exons included in the 
transcript are connected, while features such as premature termination codons and frameshift sites are annotated. For 
translated transcripts, the encoded polypeptide with major domains is depicted below the transcript. Yellow indicates a 
transmembrane domain, N represents N-linked glycosylation sites, and green lines connect cysteine residues involved in 
disulphide bonds. B) DNA sequences for novel and truncated exons. The 5’ splice sites (SS) and 3’ splice sites (SS) both 
cryptic and canonical are indicated in the sequence. Abbreviations: PTC, premature termination codon; FS, frameshift; SS, 
splice site. 
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showed high similarity to the L1M2 transposable element (Figure 4.6d) (Smit et al., 2013-
2015).  
Figure 4.12 Relative abundance of discrete transcripts in SGCZ cDNA mini-library from human cerebellum. 
Stacked bar chart representing the abundance of each transcript (described in figure 4.10) identified for the SGCZ gene in 
mini-libraries. All transcripts are described relative to the full-length, major transcript. 
 
Figure 4.12 Relative abundance of discrete transcripts in SGCZ cDNA mini-library from human cerebellum. 
Stacked bar chart representing the abundance of each transcript (described in figure 4.10) identified for the SGCZ gene in 
mini-libraries. All transcripts are described relative to the full-length, major transcript. 
Chapter 4: Alternative splicing of sarcoglycan pre-mRNA 
 
[142] 
 
SGCZ 
transcript 
Effect on 
mRNA 
Alternative 
splicing 
event 
Observed 
frequency 
(215 clones) 
Predicted effect on protein 
Predicted 
polypeptide 
size 
Protein 
isoform 
Major 
transcript 
- - 0.58 
Full-length protein isoform 1: transmembrane domain F51-L71; N-
linked glycans at N75 and N123; disulphide bond at C286:C302. 
312aa 1 
Exon 1a+, 
1b+ 
Inclusion of 2 
novel exons 
(86nt total) 
from intron 1 
Alt. exon 
inclusion 
0.03 Introduction of frameshift and PTC – NMD/R target, non-productive. - - 
Exon 2 
truncation 
Loss of 3' 94bp 
from exon 2 
Use of 
alternate 5' 
splice site 
0.11 Introduction of frameshift and PTC – NMD/R target, non-productive. - - 
Δ exon 3 
Omission of 
exon 3 
Exon skipping 0.15 
Omission of G80-D113 from the extracellular juxtamembrane domain; 
N-linked glycosylation sites and disulphide bonds unaffected. 
278aa  2 
Δ exon 5 
Omission of 
exon 5 
Exon skipping 0.09 
Omission of A143-G182 from the extracellular domain; N-linked 
glycosylation sites and disulphide bonds unaffected. 
271aa 3 
Exon 7 
truncation 
Loss of 3' 72bp 
from ex7 
Use of 
alternate 5' 
splice site 
0.005 
Omission of V225-E248 from the extracellular domain; N-linked 
glycosylation sites and disulphide bonds unaffected. 
288aa 5 
Exon 7b 
Insertion of 
81bp from 
intron 7 
Alt. exon 
inclusion 
0.005 
Frameshift and new termination codon introduced into exon 8; unique 
sequence after E248 and termination after F277; disulphide bond lost. 
277aa 6 
Exon 2 
truncation, 
Δ exon 3 
Loss of 3' 94bp 
from exon 2; 
loss of exon 3 
Use of 
alternate 5' 
splice site; 
exon skipping 
0.01 Introduction of frameshift and PTC – NMD/R target, non-productive. - - 
Δ exon 3, 5 
Omission of 
exons 3 and 5 
Exon skipping 0.01 
Omission of G80-D113 and A143-G182; N-linked glycosylation sites and 
disulphide bonds theoretically unaffected. 
237aa 4 
Table 4.3 Summary of SGCZ transcripts identified in human cerebellum.  A total of nine transcripts including the major transcript were identified in clones of human cerebellum SGCZ 
mRNA. The change to the RNA sequence, type of alternative splicing event responsible for the transcript, the observed frequency in the SGCZ transcript mini-library, predicted effect on the 
encoded protein, predicted polypeptide size and isoform designation are provided. Where an alternative translation start size was proposed, the probability that site would actually be used as a 
translation initiation site based on the NetStart and ATGpr algorithms is provided. Abbreviations: Alt. exon inclusion, alternative or novel exon inclusion; PTC, premature termination codon; 
NMD/R, nonsense-mediated decay/repression; aa, amino acid. 
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4.2.4. SGCA pre-mRNA undergoes extensive alternative splicing in skeletal muscle 
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Figure 4.13 SGCA transcripts and exons identified in human skeletal muscle. A) For each SGCA transcript identified in 
this study, the splicing pattern is displayed against the genomic architecture of the gene. Exons included in the transcript are 
connected, while features such as premature termination codons and frameshift sites are annotated. For translated transcripts, 
the encoded polypeptide with major domains is depicted below the transcript. Yellow indicates a transmembrane domain, N 
represents N-linked glycosylation sites, and turquoise indicates isoform-specific sequences. B) DNA sequences for truncated 
exons. The 5’ splice sites (SS) and 3’ splice sites (SS) both cryptic and canonical are indicated in the sequence. 
Abbreviations: PTC, premature termination codon; FS, frameshift; SS, splice site. 
A total of 12 distinct alternatively spliced SGCA transcripts were identified in 97 clones from 
a skeletal muscle cDNA mini-library, plus the full-length, canonical transcript (Figure 4.13). 
Less than 50% of the clones screened were the full-length transcript containing all 10 exons; 
the remainder consisted of alternatively spliced transcripts (Figure 4.14, Table 4.4). There 
were no novel exons, and all alternative splicing events involved either exon omission of 
alternate splice site usage (Figure 4.13, Table 4.4). Two of the alternatively spliced 
transcripts had previously been described: the SGCA Δ exon 6-7 transcript was first reported 
by McNally et al (McNally et al., 1994), while the SGCA Δ exon 9b transcript is annotated in 
the LOVD database despite not appearing in published literature (Fokkema et al., 2011). The 
first of these transcripts, SGCA Δ exon 6-7, accounted for 26% of the clones screened in the 
present study, making it by far the most abundant alternatively spliced SGCA transcript 
(Figure 4.14, Table 4.4). It was predicted to encode a potentially secreted α-SG isoform 2 
lacking the transmembrane domain and extracellular juxtamembrane region but retaining the 
signal peptide (Figure 4.13). The SGCA Δ exon 9b transcript was also predicted to be 
translated, but would encode an α-SG isoform 4 with an extended intracellular region 
compared to the main α-SG isoform 1; this transcript was rare in the cDNA mini-library at 
1% of clones (Figure 4.14, Table 4.4). 
Several other alternatively spliced SGCA transcripts were newly identified in this study. The 
majority were predicted to be NMD/R targets due to introduction of a PTC, with one 
exception (Figure 4.13). This exception was the SGCA exon 6 truncation transcript, present in 
2% of clones and generated by use of an alternate 5’ splice site (Figure 4.14, Table 4.4). It 
was predicted to encode an α-SG isoform 3 lacking the extracellular juxtamembrane region 
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(Figure 4.13). In summary, two previously reported and ten novel alternatively spliced SGCA 
transcripts were identified.  
 
Figure 4.14 Relative abundance of discrete transcripts in a SGCA cDNA mini-library from human skeletal muscle. 
Stacked bar chart representing the abundance of each transcript (described in Figure 4.13) identified for the SGCA gene in 
mini-libraries. All transcripts are described relative to the full-length, major transcript. 
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Transcript 
variant 
Effect 
on 
mRNA 
Type of 
splicing 
event 
Observed 
frequency 
(97 clones) 
Predicted effect on encoded protein 
Predicted 
polypeptide 
size 
Protein 
isoform 
NCBI 
accession 
Major 
transcript 
- - 0.46 
Full length protein: type I transmembrane; signal 
peptide M1-A23 (cleaved off); transmembrane 
domain L291-V311; N-linked oligosaccharides in the 
extracellular domain at N174 and N246. 
387aa 1 NM_000023.2 
Δ exon 3 
Omission 
of exon 3 
Exon 
skipping 
0.04 
Introduction of frameshift and PTC – NMD/R target, 
non-productive. 
-  - 
XM_011525124.1 
(with exon 9b-) 
Exon 6 
truncation 
Loss of 3' 
150nt 
from 
exon 6 
Alternate 
5' splice 
site 
usage 
0.02 
Omission of G201-V250 from the extracellular 
juxtamembrane domain including the second N-linked 
oligosaccharide; remaining features unaffected. 
337aa 3 
XM_011525121.1 
(with exon 9b-) 
Δ exon 7 
Omission 
of exon 7 
Exon 
skipping 
0.02 
Introduction of frameshift and PTC in exon 9 >50nt 
from final exon junction: NMD target – non-
productive transcript 
-  - 
XM_011525122.1 
(with exon 9b-) 
Exon 7 
truncation 
Loss of 5' 
92nt from 
exon 7 
Alternate 
3' splice 
site 
usage 
0.03 
Introduction of frameshift and PTC – NMD/R target, 
non-productive. 
253aa   - 
Δ exon 6-7 
Omission 
of exons 
6 and 7 
Exon 
skipping 
0.27 
Omission of V195-R319 with loss of transmembrane 
domain, extracellular juxtamembrane domain and 
second N-linked glycosylation site. Likely secreted. 
263aa 2 NM_001135697.1 
Δ exon 9b 
Loss of 3' 
74nt from 
exon 9 
(loss of 
exon 9b) 
Alternate 
5' splice 
site 
usage 
0.01 
Frameshift after T367 for a unique, extended carboxyl 
terminus/intracellular domain; signal peptide, 
transmembrane domain and both N-linked 
glycosylation sites unaffected. 
413aa 4 XM_011525120.1 
Δ exon 3, 6-
7 
Omission 
of exons 
3, 6 and 7 
Exon 
skipping 
0.01 
Introduction of frameshift and PTC – NMD/R target, 
non-productive. 
-  - - 
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Δ exon 6-7, 
9b 
Omission 
of exons 
6 and 7; 
loss of 
exon 9b 
Exon 
skipping, 
alternate 
5' splice 
site 
usage 
0.02 
Omission of V195-R319 with loss of transmembrane 
domain, extracellular juxtamembrane domain and 
second N-linked glycosylation site. Carboxyl terminus 
extended as in isoform 4. Likely secreted. 
289aa 5 - 
Δ exon 6, 
9b 
Omission 
of exon 6; 
loss of 
exon 9b 
Exon 
skipping, 
alternate 
5' splice 
site 
usage 
0.01 
Introduction of frameshift and PTC – NMD/R target, 
non-productive. 
-  - - 
Δ exon 2-3, 
6-7 
Omission 
of exons 
2, 3, 6 
and 7 
Exon 
skipping 
0.02 
Introduction of frameshift and PTC – NMD/R target, 
non-productive. 
-  - - 
Δ exon 2-3, 
6-7, 9b 
Omission 
of exons 
2, 3, 6 
and 7; 
loss exon 
9b 
Exon 
skipping, 
alternate 
5' splice 
site 
usage 
0.02 
Introduction of frameshift and PTC – NMD/R target, 
non-productive. 
-  - - 
Δ exon 2-7 
Omissions 
of exons 
2 through 
7 
Exon 
skipping 
0.06 
Loss of most of the coding region – non-productive 
transcript 
-  - - 
Table 4.4 Summary of SGCA transcripts identified in human skeletal muscle. For each transcript type, the change to the mRNA relative to the major transcript, type of alternative splicing 
event involved, observed frequency in the SGCA skeletal muscle transcript mini-library, predicted effect on the encoded protein, predicted size of the encoded polypeptide, isoform designation, 
and the corresponding NCBI mRNA sequence if applicable are provided. Abbreviations: PTC, premature termination codon; NMD/R, nonsense-mediated decay/repression; aa, amino acids.
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4.2.5. Few alternatively spliced SGCG transcripts were identified 
In the skeletal muscle 
SGCG cDNA mini-
library, the full-length 
major transcript accounted 
for 73% of the 105 clones 
screened (Figure 4.15). 
However, an alternatively 
spliced transcript 
incorporating a novel 
exon 1b accounted for 
another 21% of clones 
(Figure 4.15). Exon 1b 
was within the 5’ UTR, so 
this transcript would 
encode full-length γ-SG 
isoform 1 (Figure 4.16, 
Table 4.5). The two 
remaining alternatively 
spliced transcripts 
accounted for only 6% of 
cDNA mini-library clones 
together, but both were 
predicted to encode γ-SG 
isoforms differing in the 
Figure 4.15 Relative abundance of discrete transcripts in SGCG cDNA mini-
library from human skeletal muscle. Stacked bar chart representing the abundance 
of each transcript (described in figure 4.16) identified for the SGCG gene in mini-
libraries. All transcripts are described relative to the full-length, major transcript. 
 
Figure 4.15 Relative abundance of discrete transcripts in SGCG cDNA mini-
library from human skeletal muscle. Stacked bar chart representing the abundance 
of each transcript (described in figure 4.16) identified for the SGCG gene in mini-
libraries. All transcripts are described relative to the full-length, major transcript. 
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extracellular region. The SGCG Δ exon 5 transcript was predicted to encode a γ-SG isoform 2 
lacking residues 130-169 from the extracellular region, while inclusion of exon 6b (SGCG 
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exon 6b+ transcript) was predicted to cause a frameshift and encode an isoform 3 with a 
unique sequence from residue 193 (Figure 4.16, Table 4.5). SGCG exon 6b showed strong 
sequence similarity to the AluYc transposable element (Smit et al., 2013-2015). In summary, 
although few alternatively spliced SGCG transcripts were identified in skeletal muscle all 
were protein-coding.  
Figure 4.16 Transcripts and novel exons identified for SGCG in a cDNA mini-library from human skeletal muscle. A) 
For each SGCG transcript identified in this study, the splicing pattern is displayed against the genomic architecture of the 
gene. Exons included in the transcript are connected, while features such as premature termination codons and frameshift 
sites are annotated. For translated transcripts, the encoded polypeptide with major domains is depicted below the transcript. 
Yellow indicates a transmembrane domain, N represents N-linked glycosylation sites, turquoise marks isoform-specific 
sequence, and green lines connect cysteine residues involved in disulphide bonds. B) DNA sequences for novel and 
truncated exons. The 5’ splice sites (SS) and 3’ splice sites (SS) both cryptic and canonical are indicated in the sequence. 
Abbreviations: SS, splice site. 
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Transcript 
variant 
Effect on 
mRNA 
Type of 
splicing 
event 
Observed 
frequency 
(105 clones) Predicted effect on protein 
Predicted 
polypeptide 
size 
Protein 
isoform NCBI mRNA 
Major 
transcript - - 0.73 
Full-length protein: transmembrane domain L38-L58; N-
linked glycan at N110; disulphide bonds at C265:C290 and 
C267:C283. 291aa 1 NM_000231.2 
Exon 1b+ 
Inclusion of 
151nt exon 
1b after exon 
1 
Alt. exon 
inclusion 0.21 
Affects only the 5' UTR sequence; full-length isoform 1. 
291aa 1 XM_005266505.2 
Δ exon 5 
Omission of 
exon 5 
Exon 
skipping 0.01 
Omission of P130-G169 from the extracellular domain; N-
linked glycosylation sites and disulphide bonds maintained. 251aa 2 - 
Exon 6b+ 
Inclusion of 
142nt exon 
6b after exon 
6 
Alt. exon 
inclusion 0.05 
Introduces a frameshift and PTC into the conventional CDS, 
but PTC is within 50nt of the final exon:exon junction so 
probably escapes NMD; encoded protein has a unique 71aa 
sequence after R193 and lacks both disulphide bonds. 265aa 3 - 
Table 4.5 Overview of SGCG transcripts identified in human skeletal muscle. For each transcript type, the change in mRNA sequence relative to the major transcript, type of alternative 
splicing event responsible, observed frequency in the transcript mini-library, predicted effect on the encoded protein size, protein isoform and relevant NCBI mRNA are provided. 
Abbreviations: Alt. exon inclusion, alternative or novel exon inclusion into the mRNA; UTR, untranslated region; aa, amino acid. 
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Gene 
Number of 
alternatively 
spliced 
transcripts 
Alternatively spliced 
transcripts affecting 
UTR only 
Alternatively spliced 
transcripts predicted to be 
NMD/R targets 
Alternatively spliced 
transcripts encoding 
protein isoforms 
Transcripts 
only found in 
skeletal 
muscle 
Transcripts 
only found in 
cerebellum No. 
Freq 
(CB) 
Freq 
(SM) No. 
Freq 
(CB) 
Freq 
(SM) 
No. Freq 
(CB) 
Freq 
(SM) 
SGCB 4 0 0 0 3 4% 8% 1 15% 10% 2 0 
SGCD 
UP 
12 3 
48% 
13% 
4% 
30% 
4% 
2% 
4* 
1% 
9% 
0% 
3% 
0% 
0% 
6* 
11% 
0% 
14% 
16% 
6% 
6% 
5 1 DP 
8b 
SGCZ 8 0 0% NT 3 15% NT 5 26% NT NT NT 
SGCG 3 1 NT 21% 0 NT 0% 2 NT 6% NT NT 
SGCA 12 0 NT 0% 8 NT 21% 4 NT 32% NT NT 
Table 4.6 Summary of alternatively spliced transcripts for SGCB, SGCD, SGCZ, SGCG and SGCA. This table summarises the types of alternatively spliced transcript identified in cDNA 
mini-libraries of sarcoglycan transcripts from human adult skeletal muscle and cerebellum. For each sarcoglycan gene screened, the number of alternative spliced transcripts identified, the 
number and frequency in cDNA mini-libraries of alternatively spliced transcripts that only affect an UTR sequence, the number and frequency in cDNA mini-libraries of alternatively spliced 
transcripts encoding protein isoforms, and the number and frequency in cDNA mini-libraries of alternatively spliced transcripts predicted to be non-productive due to NMD/R are provided. 
SGCB and SGCD were screened in both skeletal muscle and cerebellum; the numbers of transcripts identified in only one or other cDNA mini-library are provided. For SGCD, data are 
separated by promoter/transcription termination site: UP, upstream promoter and exon 9 termination; DP, downstream promoter and exon 9 termination; 8b, downstream promoter and exon 8b 
termination. Abbreviations: UTR, untranslated region; No., number; Freq (CB), frequency of transcripts in cerebellum cDNA mini-library; Freq (SM), frequency of transcripts in skeletal muscle 
cDNA mini-library; NMD/R, nonsense-mediated decay or translational repression; NT, not tested.*: one alternatively spliced SGCD transcript either encoded a novel protein isoform or was 
predicted to be a NMD/R target depending on the transcription termination site; therefore, it was included in both counts.
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4.3. Discussion 
While tissue-specific alternative splicing of SGCE pre-mRNA was first described in 2004-
2005 and has subsequently been studied in depth, there have been only sporadic reports of 
alternatively spliced transcripts from the other sarcoglycans (McNally et al., 1994, Nishiyama 
et al., 2004, Ritz et al., 2011, Yokoi et al., 2005). Alternative splicing of SGCA, SGCB, 
SGCD, SGCG and SGCZ could contribute to variation in the assembly and function of 
sarcoglycan complexes, so in this study I systematically identified alternatively spliced 
transcripts from these genes using RT-PCR. In order to screen all five of these genes, two 
disease-relevant tissues were examined: cerebellum, which has been implicated in MD, and 
skeletal muscle, which is affected in sarcoglycan-related LGMD. Use of RT-PCR facilitated 
identification of complete transcripts rather than isolated alternative splicing events, but could 
not accurately determine transcript abundance due to PCR amplification bias: shorter 
transcripts would be preferentially amplified over longer transcripts, resulting in an 
overestimate of shorter transcripts’ abundance. All five of the sarcoglycan genes generated 
alternatively spliced transcripts, but patterns of splicing differed between sarcoglycan genes 
as summarised in table 4.6.  
Alternatively spliced transcripts encoding novel protein isoforms were uncommon for SGCB, 
SGCD and SGCG. Between 81% and 94% of the cDNA mini-library clones screened for each 
of these genes either encoded the full-length, canonical isoform or encoded an isoform 
predicted to be indistinguishable from the full-length isoform (i.e. SGCD Δ exon 2 transcript) 
(Tables 4.1, 4.2 and 4.5). Alternatively spliced transcripts predicted to encode novel protein 
isoforms accounted for 6-15% of cDNA mini-library clones screened, while the remainder 
consisted of predicted unproductive transcripts (Table 4.6). The large number of 
unproductive transcripts and those differing in only the 5’ UTR sequence from the major 
transcript suggested that proteome expansion may not be a key result of SGCB, SGCD and 
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SGCG pre-mRNA alternative splicing. Instead, alternative splicing of transcripts from these 
genes could help regulate protein levels. Alternative splicing to produce unproductive 
transcripts or transcripts with altered translation kinetics can modulate protein levels without 
altering overall gene transcription, as has been described for transcription factors in particular 
(Änkö et al., 2012, Isken and Maquat, 2007, Lewis et al., 2003, Mendell et al., 2004). Both 
knockout and overexpression of Sgcg in mice cause muscular dystrophy, and skeletal muscle 
is thought to contain equal amounts of each sarcoglycan protein (Hack et al., 1998, Jung et 
al., 1996, Mizuno et al., 1994, Sandona and Betto, 2009, Zhu et al., 2001). This implies that 
sarcoglycans must be maintained at the correct level for normal muscle function. Alternative 
splicing may be one mechanism used to fine-tune sarcoglycan protein levels. 
Alternative splicing of SGCZ differed strongly from that of its paralogue SGCG, however. 
While 94% of SGCG skeletal muscle cDNA mini-library clones encoded the full-length γ-SG 
isoform 1, only 58% of SGCZ cerebellum cDNA mini-library clones encoded ζ-SG isoform 1 
(Tables 4.3 and 4.5). Alternatively spliced SGCZ transcripts predicted to encode novel ζ-SG 
isoforms accounted for 26% of SGCZ cDNA mini-library clones in total, and just two 
transcripts encoding protein isoforms comprised 24% of clones (Tables 4.3 and 4.6). 
Furthermore, no predicted unproductive SGCG transcripts were identified in skeletal muscle 
whereas three unproductive SGCZ transcripts accounting for 15% of cerebellum cDNA mini-
library clones were identified (Tables 4.3 and 4.5). One alternative splicing event, skipping of 
exon 5, was conserved between SGCG and SGCZ but substantially more common in SGCZ 
transcripts compared to SGCG (Tables 4.3 and 4.5). These differences in alternative splicing 
pattern between SGCG and SGCZ were unexpected, and might reflect differences in function. 
At present very little is known about ζ-SG, and there is a possibility it may have roles other 
than those proposed for γ-SG and other sarcoglycans. The ζ-SG isoforms encoded by the 
alternatively spliced transcripts identified in this study have the capacity to affect functions 
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and dynamics of sarcoglycan complexes in the brain, which could potentially contribute to 
the requirement for ε-SG but not other sarcoglycans for normal brain function.  
Muscle-specific SGCA also exhibited key differences in alternative splicing compared to its 
more widely expressed paralogue SGCE. No alternative splicing events were shared between 
these two genes, despite highly similar exon/intron boundaries (Figure 4.13) (Ettinger et al., 
1997, McNally et al., 1998, Ritz et al., 2011). SGCE and SGCA appeared to be similar in the 
abundance of alternative splicing, though: less than half of SGCA cDNA mini-library clones 
comprised the full-length major transcript, while at least a third of SGCE transcripts in the 
brain are reported to be alternatively spliced (Figure 4.14) (Ritz et al., 2011). Both genes also 
encode alternatively spliced isoforms with extended intracellular regions, though these 
regions show minimal sequence similarity (data not shown) (Figure 4.13; Chapter 1 Figure 
1.2). Intriguingly, the transcript encoding an extended α-SG isoform was detected at low 
abundance in the skeletal muscle cDNA mini-library, and instead the most abundant 
transcript was the SGCA Δ exons 6-7 transcript, which alone constituted 27% of the mini-
library clones screened (Table 4.4). The α-SG isoform 2 encoded by this isoform is predicted 
to be secreted into the extracellular space, something not previously described for a 
sarcoglycan. This could suggest as yet unidentified function(s) for α-SG in the skeletal 
muscle extracellular spaces. Furthermore, eight of the twelve alternatively spliced SGCA 
transcripts were predicted to be unproductive, accounting for 21% of SGCA cDNA clones. 
This suggested alternative splicing could help regulate α-SG protein levels in skeletal muscle 
as predicted for SGCB, SGCD and SGCG.  
Novel exons in SGCB, SGCD, SGCZ and SGCG were identified during this study. When 
searched for similarity to transposable elements, five of these seven novel exons were found 
to be substantially similar to primate-specific transposable elements (Figure 4.6). SGCE exon 
10 is also Alu-derived, so five of the 6 sarcoglycan genes have alternatively spliced exons 
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derived from transposable elements; the exception is SGCA (McNally et al., 1998). From one 
perspective, this was entirely expected: few mutations are required to turn sequences in 
reverse-orientation Alu elements into alternatively spliced exons, and Alu elements 
preferentially insert into introns (Rebollo et al., 2012, Sela et al., 2010, Shen et al., 2011a). 
Consequently, transposable elements are frequently recruited into gene transcripts (Rebollo et 
al., 2012). Yet even though transposable element-related sequences are abundant in the 
human genome, only about 5% of known alternatively spliced exons show similarity to 
transposable elements (de Koning et al., 2011, Lev-Maor et al., 2003, Rebollo et al., 2012, 
Shen et al., 2011a, Sorek et al., 2002). By this measure, the five transposable element-derived 
novel exons identified in this study would be unusual. As a result the significance of the 
novel, transposable element-derived sarcoglycan exons remains unclear. 
Several alternatively spliced SGCB and SGCD transcripts were identified in skeletal muscle 
but not cerebellum (Tables 4.1 and 4.2). By contrast, the full-length, major transcript was 
generally more abundant in skeletal muscle cDNA mini-libraries compared to cerebellum 
cDNA mini-libraries, suggesting that alternative splicing may be less frequent in skeletal 
muscle. All muscle-specific transcripts were present at low abundance, accounting for less 
than 5% each and in most cases only 1-2% of the skeletal muscle cDNA mini-library clones 
screened. Therefore, the apparent tissue specificity of these transcripts could be due to 
insufficient sampling from each cDNA mini-library. Use of an alternate technique such as 
RNA sequencing could also help clarify the presence of the simpler muscle-only transcripts, 
but several of these were complex transcripts involving multiple splicing events that would 
not be accurately identified with this technique.  
In conclusion, this study identified a number of alternatively spliced transcripts from SGCA, 
SGCB, SGCD, SGCG and SGCZ in the first systematic screen of these genes’ splicing. 
Therefore alternative splicing is not limited to SGCE. This study also demonstrated strong 
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differences in splicing between paralogous genes, which could reflect functional differences 
in the encoded proteins. Examination of splicing in additional tissues could further clarify 
whether any of the alternatively spliced transcripts identified in this study were tissue-
specific; the SGCZ transcripts would be of particular interest as they could affect sarcoglycan 
complex composition in the brain. Additionally, use of RNA sequencing or quantitative PCR 
to determine actual abundance of alternative splicing events in different tissues would reveal 
any tissue differences in splicing. Additional alternatively spliced transcripts might also be 
identified, although the present study was expected to identify the most common transcripts. 
Further investigation of these transcripts and the novel sarcoglycan protein isoforms encoded 
therein could provide insights into dynamics and functions of sarcoglycan complexes and 
individual proteins (Chapter 5). 
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Chapter 5: Characterisation of alternatively spliced 
sarcoglycan isoforms 
5.1. Introduction 
While many of the alternatively spliced sarcoglycan gene transcripts identified in Chapter 4 
were predicted to be unproductive, several transcripts were predicted to encode novel 
sarcoglycan isoforms. Most of the alternative splicing events involved omission of an exon 
from the mature transcript, and accordingly many of the encoded isoforms were predicted to 
lack regions of the coding sequence present in the full-length protein. In addition, a few 
alternative splicing events introduced new termination codons into the transcript that should 
escape nonsense-mediated decay to encode truncated protein isoforms (Amrani et al., 2004, 
Chang et al., 2007b). Comparing the isoform’s amino acid sequence to that of the full-length 
isoform may provide some initial clues to potential differences in function, but very little is 
known about the biochemistry of sarcoglycan proteins. Therefore, in order to determine the 
functional effects of alternative splicing on sarcoglycan proteins, the isoforms needed to be 
tested in vitro. Wild-type, full-length sarcoglycans are known to be glycosylated, and 
assemble into putatively heterotetrameric complexes that traffic to the cell surface (Holt and 
Campbell, 1998, Jung et al., 1996, Noguchi et al., 2000). Isoforms generated through 
alternative splicing might exhibit changes in their ability to interact with some or all other 
sarcoglycans, as well as their trafficking. In this study I tested a panel of sarcoglycan 
isoforms for translation, stabilisation by proteasome inhibition, glycosylation, incorporation 
into sarcoglycan heterotetramers and trafficking to the cell surface in HEK293T cells.  
5.2. Results 
A series of functional assays was performed for each sarcoglycan isoform. Initially, a plasmid 
encoding the epitope-tagged isoform was transfected into HEK293T cells in triplicate. 
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Transfected cells were then either treated with the proteasome inhibitor bortezomib or mock-
treated with DMSO, and cell lysates were analysed by Western blot (Chapter 2 section 2.4.4). 
If protein signal intensity was increased in bortezomib-treated cells compared to DMSO-
treated cells, then proteasome inhibition stabilised the isoform. To determine whether 
isoforms were glycosylated, recombinant protein was treated with the endoglycosidase 
PNGase F to remove N-linked glycans and then analysed by Western blot (Chapter 2 section 
2.6.1). A reduction in mass after PNGase F treatment indicated N-glycosylation of the 
isoform. The translation, glycosylation and proteasome inhibition stabilisation of each 
sarcoglycan isoform tested are summarised in Table 5.1.  
To determine whether sarcoglycan isoforms were incorporated into sarcoglycan complexes 
and trafficked to the cell surface, sarcoglycan complex assembly was modelled in HEK293T 
cells. Isoforms were examined in the context of an εβδζ or αβδγ complex as appropriate. 
Cells were co-transfected with different combinations of plasmids encoding epitope-tagged 
sarcoglycans, and plasma membrane sarcoglycans were labelled through cell surface 
biotinylation (Chapter 2 sections 2.4.9, 2.6.9). Proteins were co-precipitated from cells using 
M2 anti-FLAG to enrich for FLAG-tagged β-SG, an anti-ε-SG antibody to enrich for ε-SG or 
NeutrAvidin (Pierce) to enrich for biotinylated protein, and analysed by Western blotting 
(Chapter 2, sections 2.6.2-3). For each sarcoglycan, the full-length isoform 1 assembled into a 
heterotetrameric complex that trafficked to the cell surface as previously described (Chapter 3 
section 3.2.2.2) (Durbeej and Campbell, 1999, Holt and Campbell, 1998, Jung et al., 1996, 
Noguchi et al., 2000, Shiga et al., 2006, Straub et al., 1999). 
Isoforms were scored on several aspects of incorporation into sarcoglycan complexes and 
trafficking to the cell surface. First, immunoprecipitation (IP) for β-SG as described above 
revealed whether the isoform of interest interacted with the βδ-SG core. Co-purification of 
other sarcoglycans in the β-SG IP alongside the isoform elucidated the composition of 
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complexes containing that isoform. If all four sarcoglycans co-purified, then the isoform was 
incorporated into a prototypical sarcoglycan heterotetramer. For β-SG and ζ-SG isoforms, IP 
using an anti-ε-SG antibody was also carried out to determine whether partial complexes 
containing ε-SG were formed as previously observed (Chapter 3, section 3.2.2.2). Finally, 
Western blotting of immunoprecipitated proteins with streptavidin-Alexa Fluor 680 to detect 
biotinylated proteins demonstrated whether the isoform of interest was trafficked to the cell 
surface as part of a sarcoglycan complex. Western blot analysis of NeutrAvidin affinity 
purifications demonstrated whether the isoform was present at the cell surface overall. All 
experiments were repeated at least twice to confirm results. 
5.2.1. Alternatively spliced β-SG isoforms 
5.2.1.1. β-SG isoform 2 is degraded by the proteasome. 
Only one alternatively spliced SGCB transcript was predicted to be translated: SGCB Δ exon 
2 transcript, encoding β-SG isoform 2. This isoform would lack residues Q12-I82 inclusive 
Figure 5.1 β-SG isoform 2 can only be detected in transfected cells with proteasome inhibition. Plasmids encoding 
isoforms 1 and 2 of β-SG were each transfected in triplicate into HEK293T cells, which were then either treated with the 
proteasome inhibitor bortezomib or mock-treated with an equal volume of the diluent DMSO. When cell lysates were 
immunoblotted for β-SG, protein could be detected in all cells transfected with the β-SG isoform 1 plasmid, although the 
amount of protein present was increased in bortezomib-treated cells compared to DMSO-treated cells as assessed by 
quantitation of the immunoblot signal. By contrast, β-SG isoform 2 could only be detected in bortezomib-treated cells; no 
isoform 2 was detected in transfected cells treated with DMSO. Abbreviations: kDa, kilodaltons; IgG, immunoglobulin. 
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relative to isoform 1, including the transmembrane domain. However, it could only be 
detected in cells treated with proteasome inhibitor (Figure 5.1).  By contrast the full-length β-
SG isoform 1 could be detected in both bortezomib-treated and DMSO-treated cells, although 
the signal intensity on Western blot was higher with proteasome inhibition (Figure 5.1, Table 
5.1). Additional protein bands were detected in bortezomib-treated cells compared to DMSO-
treated cells, reflecting partial β-SG products normally degraded by the proteasome.  
5.2.1.2. Lack of β-SG alters sarcoglycan complex assembly 
The function of β-SG isoforms was examined in the context of an εβδζ heterotetramer in 
HEK293T cells. The aim of this experiment was to determine whether co-expression with 
other sarcoglycans could stabilise β-SG isoform 2, and assess its effect on sarcoglycan 
complex assembly and trafficking. Since ε-SG/α-SG and ζ-SG/γ-SG are paralogues, results 
from the εβδζ heterotetramer should apply to other sarcoglycan heterotetramers (McNally et 
al., 1998, Shiga et al., 2006, Straub et al., 1999). The three β-SG proteins examined were full-
length isoform 1, isoform 2, and the LGMD-associated T182A mutant (described in Chapter 
3 section 3.2.2.2). β-SG isoform 1 was expected to traffic to the cell surface as part of a 
heterotetramer, while the T182A mutant would prevent trafficking of the βδ-SG core leaving 
only a residual εζ-SG complex at the cell surface. While β-SG isoform 1 and T182A mutant 
β-SG were detected in co-transfected cell lysates, β-SG isoform 2 was not (Figure 5.2, lysate 
lanes). Therefore, co-expression as part of an εβδζ heterotetramer did not stabilise β-SG 
isoform 2. As predicted, β-SG isoform 1 was incorporated into prototypical sarcoglycan 
heterotetramers present at the cell surface (Figure 5.2). By contrast, only residual εζ-SG 
complexes were present at the surface of cells transfected with T182A mutant β-SG or β-SG 
isoform 2 (Figure 5.2). 
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Protein Isoform 
Detected in 
transfected cells? 
Stabilised by 
proteasome inhibition? 
N-linked 
glycosylation sites 
N-linked 
glycosylated? 
Purify with 
other SGs? 
Cell 
surface? 
β-SG 
1 Yes Yes N158, N211, N258 Yes Yes Yes 
2 No Completely N88, N141, N188 Not tested Not tested Not tested 
δ-SG 
1 Yes Yes N61, N109, N285 Yes Yes Yes 
2 Yes Yes N61, N109 Yes Yes Yes 
Isoform 1 exon 
3 truncation 
No Completely N66, N242 Not tested Not tested Not tested 
Isoform 1 Δ 
exon 6 
Yes - weak Yes N61, N109, N245 Yes Not tested Not tested 
3 Yes No N61, N109 Yes Yes Yes 
ζ-SG 
1 Yes No N75, N123 Yes Yes Yes 
2 Yes No N75, N89 Yes Modified No 
3 Yes Yes N75, N123 Yes Modified No 
γ-SG 
1 Yes No N110 Yes Yes Yes 
2 Yes No N110 Yes Modified Yes 
3 Yes No N110 Yes Modified Yes 
α-SG 
1 Yes Yes N174, N246 Yes Yes Yes 
2 No Not tested N174 Not tested Not tested Not tested 
3 Yes Yes N174 Yes Yes No 
4 Yes Yes N174, N246 Yes Yes Yes 
Table 5.1 Translation and glycosylation of β-, δ-, ζ-, γ-, and α-SG protein isoforms. The main β-, δ-, ζ-, γ- and α-SG isoforms were each expressed in HEK293T cells, and tested for stability 
in the absence versus presence of the proteasome inhibitor bortezomib and N-linked glycosylation status via PNGase F treatment of recombinant protein. Experiments were repeated at least 
twice to ensure results were consistent. The results are tabulated here, alongside the predicted glycosylation sites derived from amino acid sequence. Whether an isoform was stabilised by 
proteasome inhibition was determined by comparing protein levels in cells treated with bortezomib to cells mock-treated with DMSO through quantitation of immunoblot signal. If an isoform 
was only detectable in cells treated with bortezomib, it was deemed completely stabilised by proteasome inhibition. If the isoform could be detected in both bortezomib- and DMSO-treated 
cells, it was deemed stabilised – “Yes” in the table. If protein levels for the isoform were unchanged between DMSO-treated and bortezomib-treated cells, then the isoform was regarded as not 
stabilised by proteasome inhibition – “No”. Abbreviations: N, asparagine. 
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Figure 5.2 Incorporation and trafficking of β-SG isoforms in εβδζ sarcoglycan heterotetramers. HEK293T cells were 
transfected with plasmids encoding full-length c-Myc-tagged ε-SG isoform 2, HA-tagged δ-SG, c-Myc-tagged ζ-SG, and 
one of three FLAG-tagged β-SG proteins: wild-type isoform 1, T182A mutant β-SG, or β-SG isoform 2. After surface 
biotinylation, protein complexes were immunoprecipitated with either anti-ε-SG antibody beads or NeutrAvidin. In cell 
lysates, β-SG isoform 1 and T182A could be detected but not isoform 2 despite co-transfection with other sarcoglycans. 
Both isoform 1 and T182A mutant β-SG co-purified with ε-SG, but biotinylation of T182A mutant β-SG was substantially 
reduced compared to isoform 1 indicating failure to traffic to the cell surface. Biotinylation of δ-SG was also reduced, but 
some εζ-SG complex could be detected at the cell surface in the presence of T182A mutant β-SG. Co-transfection of β-SG 
isoform 2 also resulted in presence of only an εζ-SG complex at the cell surface. Abbreviations: kDa, kilodaltons; 1, wild-
type β-SG isoform 1; T182A, β-SG with T182A mutation; 2, β-SG isoform 2; IP, immunoprecipitation. 
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5.2.2. Alternatively spliced δ-SG isoforms 
5.2.2.1. Some alternatively spliced SGCD transcripts were translated to produce 
glycosylated δ-SG isoforms 
There are two major δ-SG isoforms generated through use of two different transcription 
termination sites (Chapter 4 section 4.2.2). δ-SG isoform 1 has a full-length, 233aa 
extracellular region with N-linked glycans at N60, N108 and N284 plus two disulphide bonds 
(Chapter 4 Figure 4.8). By contrast, δ-SG isoform 2 has a truncated C-terminus with a unique 
sequence after amino acid residue E233, and therefore lacks the disulphide bonds and final 
N-linked glycan found in isoform 1 (Chapter 4, Figure 4.8). Both isoforms were detected in 
transfected cells, and proteasome inhibition increased protein levels compared to DMSO-
treated cells as indicated by increased signal intensity on Western blot (Figure 5.3, Table 5.1). 
Both isoforms were N-glycosylated (Figure 5.4, Table 5.1).  
Three alternatively spliced transcripts also encoded δ-SG isoforms. The SGCD exon 3 
truncation transcript encoded the isoform 1 exon 3 truncation protein lacked amino acid 
residues V22-I64 including the transmembrane domain (Chapter 4 Figure 4.8). This isoform 
could only be detected in transfected cells treated with bortezomib, indicating that it would 
normally be degraded by the proteasome (Figure 5.3, Table 5.1). The SGCD Δ exon 6 
transcript encoded an isoform lacking residues G128-L167 from the middle of the 
extracellular region, which was detected in all transfected cells although proteasome 
inhibition increased protein levels (Figure 5.3, Table 5.1). Finally, SGCD Δ exon 7 transcripts 
terminating in exon 8b encoded δ-SG isoform 3 with a unique, truncated C-terminus from 
residue G168 (Chapter 4 Figure 4.8). This isoform was detected in all transfected cells, with 
no effect from bortezomib treatment compared to DMSO treatment (Figure 5.3, Table 5.1). 
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These isoforms were also N-glycosylated, although de-glycosylated isoform 3 merged with 
the SDS-PAGE dye front and therefore was incompletely resolved (Figure 5.4, Table 5.1).  
Figure 5.3 Most alternative δ-SG isoforms were stabilised by proteasome inhibition. Plasmids encoding HA-tagged δ-
SG isoform 1, isoform 2, isoform 1 exon 3 truncation, isoform 1 Δ exon 6 and isoform 3 were transfected in triplicate into 
HEK293T cells; these cells were then either treated with the proteasome inhibitor bortezomib or mock-treated with the 
diluent DMSO. When cell lysates were immunoblotted for δ-SG, all isoforms except for isoform 3 showed an increase in 
protein levels with bortezomib treatment compared to DMSO treatment, indicating that they were stabilised by protein 
inhibition. The isoform 1 exon 3 truncation protein could only be detected in cells treated with bortezomib and not at all in 
DMSO-treated cells; this suggested full degradation of the isoform by the proteasome. Additionally, levels of isoform 1 Δ 
exon 6 were very low unless cells were treated with bortezomib. Abbreviations: kDa, kilodaltons; IgG, immunoglobulin. 
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5.2.2.2. Alternatively spliced δ-sarcoglycan isoforms do not affect assembly or 
trafficking of sarcoglycan εβδζ heterotetramers 
The effects of δ-SG isoforms on sarcoglycan complex assembly and trafficking were tested in 
the context of an εβδζ heterotetramer. Two isoforms were not tested: δ-SG isoform 1 Δ exon 
6 and δ-SG isoform 1 exon 3 truncation. The former was encoded by a rare transcript (1-3% 
of SGCD cDNA mini-libraries, Chapter 4 section 4.2.2) and poorly translated in HEK293T 
cells, while the latter required proteasome inhibition for detection in transfected cells (Table 
5.1). δ-SG isoform 1 exon 3 truncation was similar to β-SG isoform 2, and therefore co-
expression with other sarcoglycans was not predicted to stabilise δ-SG isoform 1 exon 3 
truncation either. Therefore, only isoforms 1, 2 and 3 were tested for incorporation into 
prototypical cell surface sarcoglycan heterotetramers. Complexes lacking δ-SG were also 
tested for assembly and trafficking. 
 As predicted, δ-SG isoform 1 was incorporated into a prototypical sarcoglycan 
heterotetramer that trafficked to the cell surface (Figure 5.5, isoform 1 lanes). δ-SG isoforms 
Figure 5.4 Four δ-SG isoforms were N-glycosylated as predicted. Transcripts encoding each HA-tagged δ-SG isoform – 
isoform 1, isoform 2, isoform 1 Δ exon 6, and isoform 3 – were transfected into HEK293T cells, and half of the cell lysate 
was treated with PNGase F to remove all N-linked glycans. Immunoblot of the untreated and treated lysates for δ-SG 
revealed a size shift for all four isoforms after PNGase F treatment, indicating glycosylation of the proteins. Abbreviations: 
kDa, kilodaltons; -, untreated lysate; +, PNGase F-treated lysate; Δ exon 6, δ-SG isoform 1 Δ exon 6. 
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2 and 3 also co-purified with β-SG, δ-SG and ζ-SG, indicating incorporation into prototypical 
sarcoglycan heterotetramers (Figure 5.5, isoforms 2 and 3 lanes). These complexes were 
Figure 5.5 Incorporation and trafficking of δ-SG isoforms in εβδζ sarcoglycan heterotetramers. HEK293T cells were 
transfected with plasmids encoding full-length c-Myc-tagged ε-SG isoform 2, FLAG-tagged β-SG, c-Myc-tagged ζ-SG, and 
a HA-tagged δ-SG isoform: isoform 1, isoform 2, isoform 3, or no δ-SG at all (-). After surface biotinylation protein 
complexes were immunoprecipitated with either M2 anti-FLAG antibody resin or NeutrAvidin resin. All three δ-SG 
isoforms co-purified with the other sarcoglycans, and were biotinylated i.e. at the cell surface. In the absence of δ-SG, the 
three remaining sarcoglycans co-purified and were biotinylated. Therefore δ-SG isoform did not affect sarcoglycan complex 
assembly or trafficking. Abbreviations: kDa, kilodaltons; -, no δ-SG transfected. 
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biotinylated, indicating that εβδζ heterotetramers incorporating δ-SG isoforms 2 and 3 were 
present on the cell surface (Figure 5.5, isoforms 2 and 3 lanes).  Additionally, biotinylated ε-, 
β- and ζ-SG co-purified from cells not expressing δ-SG (Figure 5.5, - lanes). Therefore in 
HEK293T cells δ-SG was not required for assembly of an εβζ complex that trafficked to the 
cell surface, and δ-SG isoforms did not affect sarcoglycan complex assembly or trafficking.  
5.2.3. Alternatively spliced ζ-SG isoforms 
5.2.3.1. ζ-SG isoforms are translated and N-glycosylated 
The alternatively spliced SGCZ transcripts SGCZ Δ exon 3 and SGCZ Δ exon 5 were 
predicted to encode ζ-SG isoforms 2 and 3 respectively (Chapter 4 section 4.2.3). Isoform 2 
lacked residues G80-D113 from the N-terminal extracellular region while isoform 3 lacked 
residues A143-G182 from the middle of the extracellular region relative to ζ-SG isoform 1 
(Chapter 4 Figure 4.11). All three ζ-SG isoforms could be detected in the lysate of transfected 
cells and were glycosylated (Table 5.1). However, only isoform 3 was stabilised by 
proteasome inhibition as demonstrated by increased signal intensity on Western blot 
compared to DMSO-treated cells (Table 5.1).  
5.2.3.2. ζ-SG isoforms 2 and 3 interfere with the assembly and trafficking of 
sarcoglycan heterotetramers 
The ζ-SG isoforms were tested in the context of an εβδζ sarcoglycan heterotetramer to 
identify differences in sarcoglycan heterotetramer assembly and trafficking. All three ζ-SG 
isoforms co-purified with β-SG and δ-SG using M2 anti-FLAG to enrich for complexes 
containing FLAG-tagged β-SG (Figure 5.6, β-SG IP lanes). However, co-purification of ε-SG 
with β-SG was reduced in the presence of ζ-SG isoforms 2 and 3, compared to ζ-SG isoform 
1 (Figure 5.6, β-SG IP lanes). Co-purification of ζ-SG isoforms 2 and 3 with the anti-ε-SG 
antibody was also reduced compared to ζ-SG isoform 1 (Figure 5.6). Neither ζ-SG isoform 2 
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nor isoform 3 could be detected at the cell surface, whereas ζ-SG isoform 1 was detected at 
the cell surface in association with the three other sarcoglycans (Figure 5.6). Therefore, ζ-SG 
isoform 1 was trafficked to the cell surface as part of a prototypical sarcoglycan 
heterotetramer, but ζ-SG isoforms 2 and 3 were not. In addition, cell surface β-SG and δ-SG 
Figure 5.6 Incorporation and trafficking of ζ-SG isoforms in εβδζ sarcoglycan heterotetramers. HEK293T cells were 
co-transfected with plasmids encoding full-length c-Myc-tagged ε-SG isoform 2, FLAG-tagged β-SG 1, HA-tagged δ-SG 1 
and a c-Myc-tagged ζ-SG isoform: isoform 1, 2 or 3. After surface biotinylation protein complexes were immunoprecipitated 
with either anti-ε-SG antibody or M2 anti-FLAG antibody resin. ζ-SG isoform 1 co-purified with all three other 
sarcoglycans, and was biotinylated indicating trafficking to the cell surface as part of a heterotetramer. By contrast, co-
purification of ζ-SG isoforms 2 and 3 with ε-SG was reduced on both IPs, and led to reduced co-purification of β-SG and δ-
SG on ε-SG IP. These isoforms were not biotinylated, but residual ε-SG, β-SG and δ-SG were biotinylated. Therefore, ζ-SG 
isoforms 2 and 3 inhibited incorporation of ε-SG into the sarcoglycan complex and did not traffic to the cell surface. 
Abbreviations: kDa, kilodaltons. 
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was reduced in the presence of ζ-SG isoforms 2 and 3 (Figure 5.6). Therefore ζ-SG isoforms 
2 and 3 interfered with the assembly and trafficking of sarcoglycan heterotetramers. 
5.2.4. Alternatively spliced γ-SG isoforms 
5.2.4.1. Alternatively spliced SGCG transcripts encode glycosylated γ-SG 
isoforms. 
Two alternatively spliced transcripts were predicted to encode γ-SG isoforms in skeletal 
muscle. The SGCG Δ exon 5 transcript was predicted to encode a γ-SG isoform 2 lacking 
amino acid residues P130-G169 from the middle of the extracellular region, while the SGCG 
exon 6b+ transcript was predicted to encode an isoform 3 with a truncated, unique C-
terminus from residue R193 (Chapter 4 Figure 4.16). All three γ-SG isoforms were expressed 
and glycosylated when transfected into HEK293T cells, but were not stabilised by 
proteasome inhibition (Table 5.1). 
5.2.4.2. γ-SG isoforms alter sarcoglycan complex assembly and trafficking 
The three γ-SG isoforms were examined for assembly and trafficking in the context of αβδγ 
heterotetramers only. While SGCE and SGCG expression overlaps in cardiac and smooth 
muscle, εβδγ heterotetramers are thought to be a minor species compared to αβδγ 
heterotetramers (Durbeej and Campbell, 1999, Lancioni et al., 2011, Noguchi et al., 1995, 
Noguchi et al., 2001). As expected, full-length γ-SG isoform 1 interacted with β-SG, δ-SG 
and α-SG to form heterotetrameric complexes that were present at the cell surface (Figure 5.7 
lane 1). Isoforms 2 and 3 also co-purified with β-SG and δ-SG using M2 anti-FLAG to enrich 
for β-SG (Figure 5.7). However, co-purification of α-SG in β-SG IPs was slightly reduced in 
the presence of γ-SG isoforms 2 and 3 (Figure 5.7). Therefore, γ-SG isoforms 2 and 3 
reduced incorporation of α-SG into the sarcoglycan complex. In the presence of γ-SG 
isoforms 2 and 3, a reduced amount of biotinylated β-SG, δ-SG and γ-SG was detected in β-
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SG IPs (Figure 5.7 isoforms 2 and 3). However, no biotinylated α-SG was present. 
NeutrAvidin affinity purification of biotinylated protein also demonstrated that no 
Figure 5.7 Incorporation and trafficking of γ-SG isoforms in αβδγ SGCs. HEK293T cells were co-transfected with full-
length c-Myc-tagged α-SG, FLAG-tagged β-SG, HA-tagged δ-SG and a c-Myc-tagged γ-SG isoform: isoform 1, 2 or 3. 
After cell surface biotinylation proteins were immunoprecipitated with either M2 anti-FLAG antibody resin or NeutrAvidin 
resin. All three γ-SG isoforms co-purified with α-SG, β-SG and δ-SG; however, co-purification of α-SG was reduced in the 
presence of γ-SG isoform 2 or 3. The full heterotetramer formed with γ-SG isoform 1 was biotinylated, indicating trafficking 
to the cell surface. In the presence of γ-SG isoforms 2 and 3, α-SG was not detected at the cell surface but residual β-SG, δ-
SG and γ-SG was present at the cell surface. Therefore, γ-SG isoforms 2 and 3 reduce incorporation of α-SG into 
sarcoglycan complexes, and prevent trafficking of tetramers. However residual complexes containing γ-SG isoforms 2 or 3 
remain trafficking competent. Abbreviations: kDa, kilodaltons. 
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biotinylated α-SG was present in cells expressing γ-SG isoforms 2 and 3 (Figure 5.7). 
Therefore, γ-SG isoforms 2 and 3 reduced incorporation of α-SG into the sarcoglycan 
complex, and interfered with the trafficking of αβδγ heterotetramers. However, a residual βδγ 
complex still trafficked to the cell surface. 
5.2.5.  Alternatively spliced α-SG isoforms 
5.2.5.1. Alternative α-SG isoforms were N-glycosylated, and stabilised by the 
proteasome 
Three alternatively spliced SGCA transcripts were predicted to be translated (Chapter 4 
section 4.2.4). The most abundant in the skeletal cDNA mini-library at 27% of clones was 
SGCA Δ exon 6-7. This transcript was predicted to encode an α-SG isoform 2 lacking 
residues V195-R319 including the transmembrane domain and extracellular juxtamembrane 
region compared to isoform 1 (Chapter 4 Figure 4.13). α-SG isoform 2 was predicted to be 
secreted, but was not examined in the present study because its predicted mass was equal to 
that of immunoglobulin light chain and therefore would be difficult to detect using the 
available reagents. The SGCA exon 6 truncation transcript was predicted to encode an α-SG 
isoform 3 lacking amino acid residues G201-V250 from the extracellular juxtamembrane 
region, while the SGCA Δ exon 9b transcript was predicted to encode an isoform 4 with a 
unique, extended intracellular region from residue T367 (Chapter 4 Figure 4.13). When 
expressed singly in HEK293T cells, α-SG isoforms 1, 3 and 4 were all substantially stabilised 
by proteasome inhibition with bortezomib, although they could be detected at very low levels 
in DMSO-treated cells (Table 5.1). All three isoforms were also N-glycosylated as predicted 
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from their amino acid sequences (table 5.1). Co-transfection with other sarcoglycans 
stabilised all α-SG isoforms, as demonstrated in the lysates lanes of Figure 5.8. 
Figure 5.8 Incorporation and trafficking of α-SG isoforms in αβδγ sarcoglycan heterotetramers. HEK293T cells were 
co-transfected with full-length c-Myc-tagged γ-SG, FLAG-tagged β-SG, HA-tagged δ-SG and a c-Myc-tagged α-SG 
isoform: isoform 1, 3 or 4. After cell surface biotinylation, protein complexes were immunoprecipitated with either M2 anti-
FLAG antibody resin or NeutrAvidin resin. All three isoforms co-purified with the other sarcoglycans. Isoforms 1 and 4 
were biotinylated (i.e. trafficked to the cell surface) as part of sarcoglycan complexes. However, isoform 3 was not 
biotinylated and reduced biotinylation of the other sarcoglycans. Therefore, α-SG isoform 3 impaired trafficking of the 
complex to the cell surface. Some residual β-SG, δ-SG and γ-SG was still biotinylated, however. Abbreviations: kDa, 
kilodaltons. 
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5.2.5.2. Alternatively spliced α-SG isoforms had different effects on the assembly 
and trafficking of the SGC. 
The α-SG isoforms were tested in the context of αβδγ heterotetramers. As expected, full-
length α-SG isoform 1 was incorporated into prototypical sarcoglycan heterotetramers that 
trafficked to the cell surface (Figure 5.8, isoform 1 lanes). Isoform 4 also co-purified with β-
SG, δ-SG and γ-SG in the β-SG IP, and all four immunoprecipitated sarcoglycans were 
biotinylated (Figure 5.8, isoform 4 lanes). Therefore, α-SG isoform 4 was incorporated into a 
prototypical sarcoglycan heterotetramer that trafficked to the cell surface. By contrast, while 
isoform 3 co-purified with the other sarcoglycans it was not biotinylated (Figure 5.8, isoform 
3 lanes). Biotinylation of β-SG and γ-SG was also reduced in the presence of α-SG isoform 3 
(Figure 5.8, isoform 3 lanes). Therefore, α-SG isoform 3 could assemble into a prototypical 
sarcoglycan heterotetramer but impaired trafficking of that heterotetramer to the cell surface.  
5.3. Discussion 
While several protein-coding alternatively spliced transcripts were identified for SGCB, 
SGCD, SGCZ, SGCG and SGCZ in Chapter 4, the functionality of the encoded isoforms was 
unknown. Therefore, the aim of this study was to examine several key attributes of those 
sarcoglycan isoforms to assess their functionality. Initially the stability and glycosylation of 
isoforms was examined and compared to the full-length isoform 1 of each sarcoglycan. 
Although β-SG isoform 2 and δ-SG isoform 1 exon 3 truncation could only be detected in 
transfected cells when the proteasome was inhibited, all other isoforms were expressed and 
N-glycosylated as predicted (Table 5.1). Subsequently, a panel of sarcoglycan isoforms were 
tested for incorporation into prototypical sarcoglycan heterotetramers and trafficking to the 
cell surface. Isoforms were tested in physiologically relevant heterotetramers: SGCZ 
expression does not overlap with SGCA so ζ-SG isoforms were tested in the context of εβδζ 
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heterotetramers, while α-SG and γ-SG isoforms were tested in the context of αβδγ 
heterotetramers (Ettinger et al., 1997, Noguchi et al., 2001, Roberds et al., 1993a, Shiga et al., 
2006, Wheeler et al., 2002, Yamamoto et al., 1994). β-SG and δ-SG are present in all 
prototypical sarcoglycan heterotetramers, so isoforms of these proteins were tested in the 
context of εβδζ heterotetramers following the premise that complexes containing paralogues 
were functionally equivalent (McNally et al., 1998, Shiga et al., 2006, Straub et al., 1999). 
The failure of wild-type and alternatively spliced δ-SG isoforms to affect trafficking of 
sarcoglycan heterotetramers was unexpected (Figure 5.5). A previous study found that 
residues 57-92 of δ-SG were required for the interaction with β-SG, while the extracellular C-
terminal disulphide bonds and N-linked glycosylation were required for trafficking to the 
plasma membrane in heterologous cells (Chen et al., 2006). δ-SG isoforms 2 and 3 lack the 
disulphide bonds and final N-linked glycan found in δ-SG isoform 1 (Chapter 4 Figure 4.7). 
Therefore, these isoforms were expected to interact normally with other sarcoglycans but not 
traffic to the plasma membrane. However, when expressed alongside ε-SG, β-SG and ζ-SG in 
HEK293T cells, δ-SG isoforms 2 and 3 were detected at the cell surface as part of εβδζ 
heterotetramers (Figure 5.5). This contradictory result may be due to the system used to 
model sarcoglycan interactions and trafficking. Importantly, the previous study examined the 
interaction and trafficking of β-SG and δ-SG in isolation, without other sarcoglycans (Chen et 
al., 2006). By contrast, in the present study I examined δ-SG isoforms in a physiologically 
relevant, heterotetrameric context. Inclusion of ε-SG and ζ-SG in the sarcoglycan complex 
alongside β-SG and δ-SG might be compensating for the loss of disulphide bonds in δ-SG 
and allow the complex to traffic to the cell surface. In particular, the high similarity between 
the paralogues δ-SG and ζ-SG could permit ζ-SG to compensate for the putative trafficking 
defect in δ-SG isoforms 2 and 3 (Shiga et al., 2006, Wheeler et al., 2002). Further research 
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will be required to determine whether this is the case, and also to examine the behaviour of 
muscle-type αβδγ heterotetramers containing δ-SG isoforms 2 and 3. 
Also unexpected were the differences in cell surface trafficking between ζ-SG and γ-SG 
isoforms. As mentioned above, ζ-SG and γ-SG are paralogues, and generally thought to be 
functionally equivalent (Ozawa et al., 2005, Shiga et al., 2006, Wheeler et al., 2002). In 
addition, both SGCZ and SGCG produce Δ exon 5 transcripts. SGCZ Δ exon 5 transcripts 
encode ζ-SG isoform 3 lacking residues A143-G182 from the middle of the extracellular 
region, while SGCG Δ exon 5 transcripts encode γ-SG isoform 2 lacking the equivalent 
residues P130-G169 (Chapter 4 Tables 4.3 and 4.5). Both ζ-SG isoforms and γ-SG isoforms 
produced through alternative splicing reduced incorporation of α-SG/ε-SG into the 
sarcoglycan complex (Figures 5.6 and 5.7). However, residual γ-SG isoforms 2 and 3 could 
still be detected at the cell surface as part of βδγ complexes, whereas ζ-SG isoforms 2 and 3 
were completely absent from the cell surface. This difference in trafficking capacity of 
directly equivalent ζ-SG and γ-SG isoforms suggested that these proteins may not be 
completely interchangeable. Inclusion of ζ-SG versus γ-SG in a sarcoglycan heterotetramer 
could affect trafficking and perhaps protein interactions in as yet unidentified ways. 
The α-SG isoforms studied had distinct effects on trafficking of sarcoglycan heterotetramers. 
As described above, the extracellular juxtamembrane region of δ-SG is thought to mediate 
interaction with other sarcoglycans (Chen et al., 2006). However, α-SG isoform 3 lacked the 
extracellular juxtamembrane domain and yet was able to assemble into a sarcoglycan 
heterotetramer (Figure 5.8). Instead, loss of amino acid residues 201-250 impaired its ability 
to traffic to the plasma membrane. By contrast the elongation of the intracellular domain in α-
SG isoform 4 did not affect sarcoglycan heterotetramer assembly or trafficking compared to 
α-SG isoform 1. This parallels the identical sarcoglycan heterotetramer assembly and 
trafficking of ε-SG isoforms with differences in the intracellular region (Chapter 3 section 
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3.2.2.2). For these paralogues, the intracellular domain does not affect assembly or 
trafficking.  
The observed effects of β-, δ-, ζ-, γ- and α-SG isoforms on sarcoglycan heterotetramer 
assembly and trafficking in HEK293T cells generally support the current model of 
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sarcoglycan complex assembly and trafficking as illustrated in Figure 5.9 (Chan et al., 1998, 
Hack et al., 2000, Noguchi et al., 2000, Shi et al., 2004, Yoshida et al., 1997, Yoshida et al., 
1994). In this model, sarcoglycan heterotetramer assembly is thought to occur sequentially: 
β-SG and δ-SG form a core dimer with which γ-SG or ζ-SG interacts and then α-SG or ε-SG 
interacts more loosely with the resultant trimer (Chan et al., 1998, Noguchi et al., 2000, 
Yoshida et al., 1997, Yoshida et al., 1994). Co-IP experiments have indicated that γ-SG/ζ-SG 
Chapter 5: Characterisation of alternatively spliced sarcoglycan isoforms 
 
 
[180] 
 
may mediate the interaction between α-SG/ε-SG and the remainder of the sarcoglycan 
complex (Chan et al., 1998, Hack et al., 2000, Noguchi et al., 2000, Shi et al., 2004). This 
would suggest a direct interaction between γ-SG/ζ-SG and α-SG/ε-SG. The specific 
disruption of α-SG/ε-SG incorporation into the sarcoglycan complex by alternative γ-SG and 
ζ-SG isoforms supports that hypothesis (Figure 5.9d, e). This implicates ζ-SG residues 80-
113, ζ-SG residues 143-182 or γ-SG residues 130-169, and the C-terminus of γ-SG in the 
association with α-SG/ε-SG, as described below. 
Based on the data presented in this study, δ-SG seems to be non-essential in assembly of the 
sarcoglycan complex (Figure 5.5, 5.9c). Even in the absence of δ-SG, ε-SG, β-SG and ζ-SG 
interacted to form a complex that trafficked to the cell surface (Figure 5.5). However humans 
and mice carrying SGCD mutations develop muscular dystrophy with loss of the entire SGC 
from the sarcolemma, indicating a requirement for δ-SG in vivo (Coral-Vazquez et al., 1999, 
Duggan et al., 1997b). While the reasons for this apparent contradiction are unclear, one 
possibility is that in vivo additional mechanisms ensure partial complexes lacking δ-SG 
cannot traffic to the plasma membrane. These mechanisms may not be captured in 
experiments carried out using heterologous cells and might involve δ-SG-specific protein 
interactions, or conformation of the sarcoglycan complex as a whole.  
Figure 5.9 Summary of the proposed model for sarcoglycan complex assembly and trafficking, with the effects of 
different alternative sarcoglycan isoforms. A) Model of canonical sarcoglycan complex assembly. On the ER membrane, 
β-SG and δ-SG interact first to form the βδ-SG core. Either γ-SG or ζ-SG then interacts with the βδ-SG core. Finally, either 
α-SG or ε-SG interact with the complex – apparently directly through γ-SG/ζ-SG – to complete the heterotetramer. This 
complex then traffics to the plasma membrane via the Golgi apparatus (not shown on this model). B) β-SG isoform 2, which 
lacks a transmembrane domain, is degraded by the proteasome and so the βδ-SG core cannot form. However, ε-SG and ζ-SG 
can still interact to form a residual complex that traffics to the plasma membrane. C) The alternative δ-SG isoforms 2 and 3 
still interact with the other sarcoglycans to form a heterotetramer that traffics to the cell surface despite lacking the 
disulphide bonds of isoform 1. D) ζ-SG isoforms 2 and 3 lack sections of the extracellular domain, and interact with the βδ-
SG core to form a βδζ complex. However, ε-SG is not incorporated into this complex and the complex does not traffic to the 
cell surface. ε-SG traffics independently to the cell surface, though. E) Alternative γ-SG isoforms 2 and 3 have alterations to 
the extracellular domain compared to isoform 1, and interact with the other sarcoglycans. However, the full tetramer with α-
SG does not traffic to the cell surface; instead, partial complexes containing β-SG, δ-SG and γ-SG isoform 2/3 can be 
detected at the cell surface. F) α-SG isoform 3 lacks the extracellular juxtamembrane domain compared to isoform 1, and 
interacts with the βδγ sub-complex. However, the resultant heterotetramer does not traffic to the cell surface. G) α-SG 
isoform 4 has an extended intracellular domain but incorporates into a cell surface complex as in A. 
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The sarcoglycan isoforms also provide additional insight into the protein regions required for 
interactions between sarcoglycans. Chen et al. (2006) identified residues 57-92 in mouse δ-
SG as required for the interaction with β-SG. None of the δ-SG isoforms studied affected this 
region, and accordingly they all interacted normally with β-SG (Figure 5.5). However, Chen 
et al. (2006) also found that γ-SG residues 94-194 were required for the interaction with the 
βδ-SG core. γ-SG isoform 2 lacked amino acid residues P130-P169, whereas ζ-SG isoform 2 
removed amino acid residues G80-D113 that correspond to γ-SG residues G69-D100 
(Chapter 4 Figure 4.10). Both of these isoforms still interacted with the βδ-SG core, and 
therefore the interaction between γ-SG and the βδ-SG core most likely requires γ-SG residues 
101-129 or a more distal region (Figures 5.6-5.7). This assumes that γ-SG and ζ-SG interact 
with the βδ-SG core in the same way. However, all three regions of γ-SG and ζ-SG affected 
in alternatively spliced isoforms were found to modulate the interaction with α-SG/ε-SG, 
however. This suggested the overall extracellular conformation may be more important for 
the interaction with α-SG/ε-SG than any specific region, since most of the γ-SG/ζ-SG 
extracellular region was altered in at least one isoform. Finally, Chen et al. (2006) proposed 
that the extracellular juxtamembrane region of α-SG might be important for its interaction 
with γ-SG based on clustering of LGMD 2D-associated mutations in that region. This region 
is lost in α-SG isoform 3, but the isoform can be incorporated into a prototypical sarcoglycan 
heterotetramer (Figure 5.8). Instead, trafficking of the complex to the cell surface was 
impaired. This suggested that the α-SG extracellular juxtamembrane region may be required 
for trafficking rather than sarcoglycan complex interactions.  
The prevalence of sarcoglycan isoforms described in this study also have implications for the 
molecular pathogenesis and treatment of sarcoglycan-associated LGMD and MD. A recent 
proof-of-concept study examined the use of induced exon skipping as a means to treat LGMD 
2C, which is caused by autosomal recessive SGCG mutations as covered in Chapter 1 section 
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1.3.2 (Gao et al., 2015). Although the “Mini-Gamma” protein generated through skipping 
exons 4-7 improved the phenotype of Sgcg knockout mice, mice still had signs of muscular 
dystrophy (Gao et al., 2015). Based on the observed effects of γ-SG isoforms 2 and 3 
described in this study, which like “Mini-Gamma” lacked sections of the extracellular 
domain, “Mini-Gamma” is likely to interfere with inclusion of α-SG into muscle sarcoglycan 
complexes and this could contribute to the incomplete phenotype rescue observed in mice 
(Gao et al., 2015). The observed differences between similar γ-SG and ζ-SG also demonstrate 
that sarcoglycan heterotetramer composition may be more important for function than 
previously thought. Paralogous sarcoglycans may be able to replace each other in some 
functions but not others, and incorporation of ζ-SG versus γ-SG in brain complexes could 
impact trafficking of those complexes. As discussed in Chapter 4 (section 4.2.3), transcripts 
encoding ζ-SG isoforms 2 and 3 were relatively abundant in the cerebellum SGCZ cDNA 
mini-library. ζ-SG isoforms 2 and 3 impair sarcoglycan complex assembly and trafficking to 
the cell surface, so their presence in the brain could lead to cell surface ε-SG that is not 
associated with a sarcoglycan complex. Distinct functions of this pool of sarcoglycan 
complex-independent ε-SG could contribute to the specifically neurological phenotype of 
SGCE mutations. Since this independent cell surface ε-SG would not be affected by LGMD-
associated sarcoglycan mutations, it could also contribute to the absence of neurological signs 
in LGMD. 
In conclusion, the sarcoglycan isoforms produced from alternatively spliced transcripts 
described in Chapter 4 had a range of effects on the assembly and trafficking of the 
sarcoglycan complex. One potentially abundant isoform could not be studied, however: α-SG 
isoform 2. This isoform is approximately the same size as mouse immunoglobulin light 
chain, and so could not be resolved from immunoglobulin on Western blots using the 
available reagents. Production of additional antibodies raised in non-mouse species would 
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facilitate the study of this isoform. Another outstanding question is whether the sarcoglycan 
isoforms studied here are actually present in vivo. Due to the sarcoglycan complex-disrupting 
effects of several isoforms, novel antibodies against the sarcoglycans would also resolve this 
question. However, tissue source may be a difficulty: the transcripts encoding these isoforms 
were identified in human tissue, and it is not clear whether they are also present in mice 
which would be the most accessible animal model. Indeed, previous research suggested that 
overall alternative splicing is less abundant in mice compared to humans (Kim et al., 2007). 
This could complicate efforts to detect these isoforms in vivo. However, the present study 
does provide a basic characterisation of several novel sarcoglycan isoforms, and highlights 
the potential importance of ζ-SG isoforms in the brain that may be relevant to the molecular 
pathogenesis of MD.  
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Chapter 6: General discussion 
6.1. Introduction 
The overall aim of this study was to identify proteins interacting with ε-SG in the brain, and 
from that gain insight into the molecular pathogenesis of SGCE mutation-positive MD. To 
achieve this aim, three major objectives were pursued: 
 To determine whether the ubiquitous and brain-specific ε-SG isoforms are part of 
DGC-like complexes in the brain. 
 To identify additional, non-DGC proteins with which ε-SG interacts in the brain. 
 To systematically examine alternative splicing of SGCA, SGCB, SGCD, SGCG and 
SGCZ to identify transcripts encoding novel sarcoglycan isoforms that could affect 
sarcoglycan complex function. 
Mutations in SGCE were first identified as a cause of MD in 2001, but little is known about 
the function of the encoded ε-SG protein even now. Most pathogenic SGCE mutations result 
in cell surface ε-SG deficiency, suggesting cell surface ε-SG is essential for normal brain 
function (Carecchio et al., 2013, Esapa et al., 2007, Grunewald et al., 2008, Waite et al., 
2011). In addition, the contrast between the neurological phenotype of ε-SG deficiency and 
the muscle-only LGMD phenotype induced by deficiency of the related α-, β-, δ- and γ-SG 
proteins remains unexplained. A unique function for the brain-specific ε-SG isoform 2, 
generated through alternative splicing, has been proposed to underlie the specifically 
neurological phenotype of SGCE mutations (Nishiyama et al., 2004, Ritz et al., 2011, Yokoi 
et al., 2005). In smooth muscle and peripheral nerve, ε-SG interacts with β-SG, δ-SG and γ-
SG or ζ-SG to form heterotetrameric sarcoglycan complexes that are part of the DGC or 
DGC-like complexes (Cai et al., 2007, Durbeej and Campbell, 1999, Imamura et al., 2000, 
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Straub et al., 1999). Immunoaffinity purification of ε-SG, including of isoform 2 specifically, 
from mouse brain tissue resulted in co-purification of β-SG, δ-SG and ζ-SG (Chapter 3). This 
co-purification indicated that in the brain both ε-SG isoforms 1 and 2 are part of prototypical 
sarcoglycan complexes comprising εβδζ (Chapter 3). Brain ε-SG also interacts with 
dystroglycan and Dp71, suggesting that it contributes to DGC-like complexes. Finally, the 
extracellular matrix proteoglycan tenascin-R co-purified specifically with ε-SG isoform 2 
from mouse brain. 
Alternatively spliced SGCA, SGCB, SGCD, SGCG and SGCZ transcripts encoding novel 
sarcoglycan protein isoforms may also contribute to differences in sarcoglycan complexes 
between tissues. A systematic screen for alternatively spliced transcripts from these genes in 
human cerebellum and skeletal muscle was performed using RT-PCR (Chapter 4). All five 
genes produced alternatively spliced transcripts, some of which encoded novel sarcoglycan 
isoforms which differentially affected assembly and/or trafficking of sarcoglycan complexes 
in heterologous cells (Chapter 5).  
6.2. ε-SG protein interactions in the brain 
Chapter 3 describes experiments designed to capture protein complexes containing ε-SG from 
mouse brain. IAPs using antibodies that bound to either all ε-SG isoforms or only ε-SG 
isoform 2 were performed and then analysed by Western blotting and mass spectrometry. ε-
SG co-purified with β-SG, δ-SG and ζ-SG using both antibodies. Based on previous studies 
of sarcoglycan complexes, this pattern of co-purification would support the presence of εβδζ 
complexes including either ε-SG isoform 1 or isoform 2 in the brain (Chan et al., 1998, Holt 
and Campbell, 1998, Jung et al., 1996, Noguchi et al., 2000, Shiga et al., 2006). However, ε-
SG isoforms 1 and 2 would be part of different complexes based on the absence of ε-SG 
isoform 1 from esg2-1358 IAPs that specifically enriched ε-SG isoform 2. Intriguingly, γ-SG 
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did not co-purify with ε-SG from mouse brain using either antibody despite its co-purification 
with an antibody against all ε-SG isoforms from rat brain in a previous study (Waite et al., 
2016). This most likely reflects the low abundance of γ-SG in the brain (Chapter 3).  
The identification of ε-SG-containing prototypical sarcoglycan complexes in the brain was 
unexpected given the absence of LGMD-like features in MD and vice versa. Both disorders 
are caused by loss-of-function mutations resulting in cell surface deficiency of the individual 
sarcoglycan or entire sarcoglycan complex, yet β-SG or δ-SG deficiency affects only muscle 
function and not the CNS (Esapa et al., 2007, Sandona and Betto, 2009, Waite et al., 2011). 
Modelling of sarcoglycan complex assembly in heterologous cells demonstrated that residual 
εζ-SG complexes could traffic to the cell surface despite the presence of LGMD-associated 
mutant β-SG that impeded trafficking of the βδ-SG core; residual cell surface ε-SG and ζ-SG 
have also been identified in the brain of δ-SG-deficient BIO14.6 hamsters (Waite et al., 
2016). Residual sarcoglycans are functional in muscle, so residual cell surface ε-SG and ζ-SG 
in the brain could be sufficient for normal brain function in sarcoglycan-deficient LGMD 
patients (Bianchini et al., 2014, Esapa et al., 2007, Gastaldello et al., 2008, Li et al., 2009, 
Soheili et al., 2012, Waite et al., 2011, Waite et al., 2016). Differential trafficking of partial 
sarcoglycan complexes in different tissues may contribute to the distinct phenotypes of 
sarcoglycan-associated LGMD and MD. 
Under mild tissue lysis conditions, Dp71 and β-dystroglycan were also found to co-purify 
with ε-SG from brain (Chapter 3 section 3.2.3). If tissue was lysed using harsher RIPA 
buffer, this co-purification was lost; a similar result was observed using lung tissue in which 
ε-SG is known to be a component of DGCs (Chapter 3). Therefore, ε-SG was part of DGC-
like complexes in the brain but the protein interactions required for these complexes were 
disrupted by RIPA buffer. By extension, RIPA buffer may also disrupt other protein 
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interactions of ε-SG and other sarcoglycan proteins, which could have contributed to previous 
failed attempts at identifying ε-SG interactors.  
Incorporation of ε-SG into DGC-like complexes in the brain suggests that perturbation of 
DGC-like complexes may contribute to the SGCE mutation-positive MD phenotype. DGC-
like complexes in the brain are thought to have a number of functions, including organisation 
of neurotransmitter receptors at the synapse and calcium homeostasis (Brünig et al., 2002, 
Knuesel et al., 1999, Krasowska et al., 2014, Waite et al., 2012). In particular, DGC-like 
complexes help organise GABA receptors on the postsynaptic membrane; as previously 
discussed, GABAergic signalling may contribute to surround inhibition which is impaired in 
dystonia (Chapter 1 section 1.2.3.1) (Garibotto et al., 2011, Herath et al., 2010, Levy and 
Hallett, 2002, Waite et al., 2012). As part of DGC-like complexes, ε-SG might contribute to 
neurotransmitter receptor clustering at the synapse. Deficiency of ε-SG might perturb DGC-
like complexes, resulting in aberrant synapse organisation. Specific effects of disrupting 
DGC-like complexes on GABAergic signalling could contribute to the molecular 
pathogenesis of dystonia. 
As part of DGC-like complexes, ε-SG may also contribute to calcium homeostasis. 
Numerous lines of evidence support a role for the DGC generally and sarcoglycans 
specifically in maintaining normal calcium levels in muscle, and abnormal brain calcium 
levels have also been described in patients with DMD mutations (Chapter 1 section 1.4.3) 
(Allen et al., 2016, Anderson et al., 2002, Andersson et al., 2012, Waite et al., 2012). 
Therefore, as part of DGC-like complexes ε-SG could contribute to maintenance of normal 
intracellular calcium levels. Three other monogenic dystonia genes (ANO3, PRRT2 and 
HPCA) are thought to directly perturb calcium signalling/homeostasis: the ANO3 protein is 
calcium activated, PRRT2 protein is regulated through binding to calcium sensor proteins, 
and hippocalcin is itself a calcium sensor (Charlesworth et al., 2015, Huang et al., 2013, 
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Valente et al., 2016). More recently, mutations in CACNA1B which encodes a calcium 
channel pore-forming subunit have been linked to dystonia as well (Ament et al., 2015, 
Groen et al., 2015a). Mutations in these genes are thought to contribute to dystonia by 
altering the cellular response to calcium fluctuations or by directly changing intracellular 
calcium concentration. If ε-SG deficiency led to disruption of DGC-like complexes, SGCE 
mutations could also affect calcium homeostasis. 
In addition, the extracellular matrix protein tenascin-R co-purified with ε-SG from brain 
(Chapter 3). This was not a consequence of non-specific interactions or direct binding of 
tenascin-R to an anti-ε-SG antibody, as a reciprocal IAP using an anti-tenascin-R antibody 
resulted in co-purification of ε-SG. Surprisingly, only ε-SG isoform 2 and not isoform 1 was 
detected in the tenascin-R IAP. A functional difference between the widespread (isoform 1) 
and brain-specific (isoform 2) ε-SG isoforms has previously been proposed to contribute to 
the brain-specific effects of ε-SG deficiency, but to date no such differences between 
isoforms have been identified (Ritz et al., 2011). As described above, both isoforms are 
incorporated into prototypical sarcoglycan heterotetramers and interact with other DGC 
proteins. Furthermore, when examined in heterologous cells all ε-SG isoforms exhibited 
identical sarcoglycan complex assembly and trafficking (Chapter 3 section 3.2.2.2). Co-
purification of only ε-SG isoform 2 with tenascin-R is the first sign there might be a genuine 
functional difference between ε-SG isoforms, and provides addition evidence in favour of 
independent localisation of the two major ε-SG isoforms in the brain (Chan et al., 2005, 
Nishiyama et al., 2004). 
Although the co-purification of ε-SG isoform 2 and tenascin-R does not provide conclusive 
evidence of an interaction between these proteins, the specificity of the co-purification is 
suggestive. In addition, there are similarities in the phenotypes of tenascin-R deficient mice 
and ε-SG-deficient mice. Mice deficient in tenascin-R have no gross abnormalities, but 
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display several neurological phenotypes including increased anxiety, impaired motor learning 
and impaired coordination (Freitag et al., 2003, Montag-Sallaz and Montag, 2003). ε-SG-
deficient mice also have an anxiety-like behavioural phenotype, and impaired motor 
coordination (Chapter 1 section 1.3.2.4) (Yokoi et al., 2006, Zhang et al., 2012). Recently, an 
exome sequencing study identified several rare TNR variants in familial Parkinson disease; 
this provides additional support for dysfunction of tenascin-R in movement disorders (Farlow 
et al., 2016). As a central organiser of perineuronal nets (PNNs), tenascin-R contributes to 
normal clustering of neurotransmitter receptors and ion channels at the synapse (Anlar and 
Gunel-Ozcan, 2012, Geissler et al., 2013, Oohashi et al., 2015). Therefore, an interaction 
between ε-SG and tenascin-R could further implicate the former in synapse organisation.  
6.3. Alternative splicing of SGCA, SGCB, SGCD, SGCG and SGCZ pre-mRNA 
The experiments described in chapter 4 identified alternatively spliced transcripts from 
human SGCA, SGCB, SGCD, SGCG and SGCZ using PCR-based screening of cDNA mini-
libraries derived from adult human skeletal muscle and cerebellum. Chapter 5 described 
initial characterisation of novel sarcoglycan isoforms encoded by some of these alternatively 
spliced transcripts. While SGCE alternative splicing has already been described in depth, this 
was the first systematic study of alternative splicing in transcripts from the other five 
sarcoglycans (Ritz et al., 2011). All five genes were found to produce alternatively spliced 
transcripts with varying effects on protein synthesis, but there were substantial differences in 
alternative splicing between paralogous sarcoglycans. No alternative splicing events were 
shared between SGCE and SGCA at all, despite highly similar genes and encoded proteins 
(Chapter 4 section 4.2.4) (Dickens et al., 2002, Ettinger et al., 1997, McNally et al., 1998, 
Ritz et al., 2011). By contrast, paralogues SGCG and SGCZ shared one alternative splicing 
event, omission of exon 5; this was substantially more common in SGCZ cDNA than SGCG, 
however (Chapter 4 sections 4.2.3 and 4.2.5). The γ-SG and ζ-SG isoforms 2 and 3 encoded 
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by Δ exon 5 transcripts from SGCG and SGCZ respectively both reduced incorporation of α-
SG/ε-SG into the sarcoglycan complex in heterologous cells, but showed a strong difference 
in cell surface trafficking (Chapters 4 and 5). While γ-SG isoform 3 was detectable at the cell 
surface, ζ-SG isoform 2 was not (Chapter 5 sections 5.2.3.2 and 5.2.4.2). Therefore, these 
similar alternatively spliced isoforms of paralogous sarcoglycans had very different 
trafficking despite similar effects on sarcoglycan complex assembly. 
The distinct alternative splicing of paralogous sarcoglycans and the different effects of 
identical alternative splicing events on different sarcoglycans suggest hitherto unappreciated 
divergence between sarcoglycans. In particular, a SGCA transcript encoding a potentially 
secreted α-SG isoform was abundant in the skeletal muscle SGCA cDNA mini-library at 27% 
of clones, but no equivalent for SGCE has been described (Chapter 4 Figure 4.12). This 
difference could indicate a unique function for α-SG in the extracellular matrix not shared by 
its paralogue ε-SG. Additionally, the different effects on sarcoglycan complex trafficking of 
highly similar alternatively spliced γ-SG and ζ-SG isoforms hint that composition could 
strongly affect sarcoglycan complex functionality. Since SGCZ expression is enriched in the 
brain whereas SGCG is enriched in muscle, this might contribute to the different sarcoglycan 
requirements in brain versus muscle (Chapter 1 section 1.4.1) (Barresi et al., 2000b, Shiga et 
al., 2006, Yamamoto et al., 1994). Moreover, transcripts encoding ζ-SG isoforms that impair 
sarcoglycan complex assembly accounted for a quarter of SGCZ cerebellum cDNA mini-
library clones (Chapter 4 section 4.2.3). If accurate, these data suggest a substantial 
proportion of ζ-SG in the brain may be assembled into ε-SG-deficient partial complexes that 
do not traffic to the cell surface. This would leave a pool of cell surface ε-SG not associated 
with other sarcoglycans, which might have a distinct function(s) important for MD 
pathogenesis that is not affected in sarcoglycan-deficient LGMD. 
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6.4. Future directions 
This thesis provided evidence for incorporation of brain ε-SG into DGC-like complexes. 
However, these experiments did not reveal whether ε-SG is a component of all brain DGC-
like complexes or only certain subtypes, and what effect ε-SG deficiency might have on these 
complexes. Of particular interest might be whether ε-SG alone is part of brain DGC-like 
complexes, or whether the entire prototypical sarcoglycan complex participates in these. This 
would in turn provide additional insight into the similarities and differences between brain 
and muscle prototypical sarcoglycan complexes. Clarification of ε-SG deficiency’s effects on 
DGC-like complex function would further extend our understanding of ε-SG’s function in the 
brain. IAPs performed as part of this study also identified co-purification between ε-SG and 
the extracellular matrix proteoglycan tenascin-R; as described in Chapter 3 (section 3.3) 
further experiments are required to determine whether ε-SG isoform 2 genuinely interacts 
with tenascin-R. There are also likely to be additional proteins that interact with ε-SG in the 
brain. Finally, the novel alternatively spliced sarcoglycan isoforms described in Chapters 4 
and 5 were only studied in heterologous cells and total RNA from human tissue. They will 
need to be identified in vivo before their effect on sarcoglycan complex function can be 
understood. Of particular interest for MD will be the ζ-SG alternatively spliced isoforms, 
which based on the experiments performed in heterologous cells were unlikely to co-purify 
with ε-SG. Verification of these isoforms and confirmation that they do not interact with cell 
surface ε-SG as observed in heterologous cells could reveal a sarcoglycan complex-
independent role for ε-SG in the brain. Overall, these data could further contribute to our 
understanding of the molecular pathogenesis of MD, and the different phenotypes of 
sarcoglycan-associated LGMD and MD.
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Appendix I: Oligonucleotide primers 
All primer sequences are written 5’ to 3’, and were obtained from Sigma-Aldrich. 
Species Gene Exon Name Purpose Restriction 
site 
Epitope 
tag 
Sequence 
Human SGCE 2 HESGMYCPFUSE-F RT-PCR NcoI c-Myc CGGCCATGGTTGAGCAAAAGCTCATTTCTGAAGAGGACTTGG
ATCGGAGTGTATACCCATC 
Human SGCE 12 HESGMYCPFUSE-R RT-PCR NcoI - TAACCATGGTGTGATGTAACTGCTATATTGTC 
Mouse Kcna3 1 cmKcna3F RT-PCR SalI - AGTTGTCGACGCCAGACATGACCGTGGTGC 
Mouse Kcna3 1 cmKcna3R RT-PCR NotI - ATGAGCGGCCGCTCAGCACAGAATTGGCAACCGTA 
Mouse Tnr 1 cmTnR_F RT-PCR SalI - AGTTGTCGACATGCTGGCTACCACTGAGAG 
Mouse Tnr 21 cmTnR_R RT-PCR NotI FLAG ATGAGCGGCCGCTCACTTGTCGTCATCGTCTTTGTAGTCGAAT
TTCAAGGCTCGCCGT 
Human SGCB 1 hSGCB_cF RT-PCR SalI - AGTTGTCGACGCGGGAAGATGGCGGCA 
Human SGCB 6 hSGCB_cR RT-PCR NotI FLAG ATGAGCGGCCGCTCACTTGTCGTCATCGTCTTTGTAGTCATGA
GTGTTTCCACAGGGGTTG 
Human SGCB 1 hSGCB_Ex1F Colony PCR - - GCGGGAAGATGGCGGCA 
Human SGCB 4 hSGCB_Ex3R Colony PCR - - GCTTTGTTGTCCCTTGCTGA 
Human SGCB 2 hSGCB_Ex2aF Colony PCR - - GAAGTCCATGCGTGAGAAGG 
Human SGCB 5 hSGCB_Ex4R Colony PCR - - ACACCTTCATTTCCACGCAC 
Human SGCB 4 hSGCB_Ex3F Colony PCR - - GCAAGGGACAACAAAGCTCA 
Human SGCB 6 hSGCB_Ex5R Colony PCR - - CCAGTCACCACTACCCAACT 
Human SGCD 1a.3 hSGCD_164F RT-PCR SalI - AGTTGTCGACGTGTGAAGGCTGAGACAACC 
Human SGCD 1b hSGCD_476F RT-PCR SalI - AGTTGTCGACTTTCATCGGCCGGTTTGTGA 
Human SGCD 8b hSGCD_475R RT-PCR NotI HA ATGAGCGGCCGCTCAAGCGTAATCTGGAACATCGTATGGGTA
ACCAGTTATGGGAAGGGTTGG 
Human SGCD 9 hSGCD_388R RT-PCR NotI HA ATGAGCGGCCGCTCAAGCGTAATCTGGAACATCGTATGGGTA
GAGGCAGACACTTGTGTTTATCTG 
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Human SGCD 8 hSGCD_7skR Recloning for 
HA tag 
NotI HA ATGAGCGGCCGCTCAAGCGTAATCTGGAACATCGTATGGGTA
GAGACCGGGTTGGGGACTCCAAC 
Human SGCD 3 hSGCD_Ex3R Colony PCR - - TCCTCAGGTTTCCCATTCCA 
Human SGCD 2 hSGCD_Ex2aF Colony PCR - - GTTGAGTGAAGGGACCAGGT 
Human SGCD 5 hSGCD_Ex4R Colony PCR - - GGCAGACTTGAAGTACAGGG 
Human SGCD 4 hSGCD_Ex3F Colony PCR - - TCTTACAACCTCTCTACGCCA 
Human SGCD 7 hSGCD_Ex6R Colony PCR - - AGATTTAGGGAACACTGTGCC 
Human SGCD 6 hSGCD_Ex5F Colony PCR - - TGAAGTGGTAGTAGGAGCTGA 
Human SGCD 8b hSGCD_Ex7aR Colony PCR - - TCTCATCCCTCACCTCTCCA 
Human SGCD 9 hSGCD_Ex7bR Colony PCR - - AGGCGTGTAGGATCCATGAG 
Human SGCZ 1 hSGCZ_cLNF RT-PCR SalI - AGTTGTCGACAGTTGCGCTCCATGGACAG 
Human SGCZ 8 hSGCZ_cR RT-PCR NotI c-Myc ATGAGCGGCCGCTCACAAGTCCTCTTCAGAAATGAGCTTTTG
CTCGCTCCACAGGCAGATGTTG 
Human SGCZ 1 hSGCZ_ex1aF Colony PCR - - AGTTGCGCTCCATGGACAG 
Human SGCZ 5 hSGCZ_ex4R Colony PCR - - GCCATCTTCACTGGCTCTCA 
Human SGCZ 4 hSGCZ_ex3F Colony PCR - - ATCACATGGGGCAGTTAACC 
Human SGCZ 7 hSGCZ_Ex6R Colony PCR - - CTTGAAGTCTCCTGCAGCAG 
Human SGCZ 5 hSGCZ_Ex5F Colony PCR - - ACATCAGAGCAGAGCCATCC 
Human SGCZ 8 hSGCZ_Ex7R Colony PCR - - TGAGGAGCTGGGTGAAGAAG 
Human SGCZ 2 hSGCZ_2nR Colony PCR - - GCATTCTCAGTCCTTGGCAG 
Human SGCZ 2 hSGCZ_2nF Colony PCR - - CCAAGGACTGAGAATGCACA 
Human SGCZ 4 hSGCZ_4nR Colony PCR - - GCCCCATGTGATTTCTTGCA 
Human SGCZ 6 hSGCZ_6nR Colony PCR - - CACAGAGTGCCCAAATACGG 
Human SGCA 1 hSGCA_cF RT-PCR SalI - AGTTGTCGACCTCTGTCACTCACCGGGC 
Human SGCA 10 hSGCA_cR RT-PCR NotI - ATGAGCGGCCGCCCCCTCTCCCTGCTTGTTTA 
Human SGCA 4 hSGCA_4R Colony PCR - - TGGTATCAAAGCTGTCCCGA 
Human SGCA 3 hSGCA_3F Colony PCR - - TGGGCTCCAGGTCATTGAG 
Human SGCA 7 hSGCA_7R Colony PCR - - CTCCGGCACTGACTTATCCA 
Human SGCA 6 hSGCA_6F Colony PCR - - CGTTGACTGGTGCAATGTGA 
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Human SGCA 8 hSGCA_8R Colony PCR - - TAGCCAGGTCTCTCTTCAGC 
Human SGCA 8 hSGCA_8F Colony PCR - - GCTGAAGAGAGACCTGGCTA 
Human SGCA 5 hSGCA_5F Colony PCR - - CTTCAGCTGCTCAACGTCAC 
Human SGCA 9 hSGCA_9cR Recloning for 
c-Myc tag 
NotI c-Myc ATGAGCGGCCGCTCACAAGTCCTCTTCAGAAATGAGCTTTTG
CTCGTGCTGGTCCAGAATGAGGG 
Human SGCA 10 hSGCA_9bR Recloning for 
c-Myc tag 
NotI c-Myc ATGAGCGGCCGCTCACAAGTCCTCTTCAGAAATGAGCTTTTG
CTCCCCCACCCCACCCCCTCTCCCTGCTTGTTTA 
Human SGCG 1 hSGCG_cF RT-PCR SalI - AGTTGTCGACCCAGCTGTAGTTCATTCGCC 
Human SGCG 8 hSGCG_cR RT-PCR NotI c-Myc ATGAGCGGCCGCTCACAAGTCCTCTTCAGAAATGAGCTTTTG
CTCGAGGCAGATGTGGCTGTG 
Human SGCG 5 hSGCG_5R Colony PCR - - CCGTCGTTGGAGTTGATCTG 
Human SGCG 4 hSGCG_4F Colony PCR - - TCACAGGCAGGTTAAAAGTCG 
Human SGCG 7 hSGCG_7R Colony PCR - - CATCCATGCTTAGACTCCGAG 
Human SGCG 5 hSGCG_5F Colony PCR - - CAGATCAACTCCAACGACGG 
Human SGCG 2 hSGCG_2cF Recloning into 
pCMV-myc 
SalI - AGTTGTCGACGTTGCGCATGGTGCGTGAGCAGTAC 
Human SGCG 8 hSGCG_2Rcmv Recloning into 
pCMV-myc 
NotI - ATGAGCGGCCGCTCAGAGGCAGATGTGGCTGTG 
Human SGCZ - hZlnP267S_F Mutagenesis 
for PCR error 
- - TTCTTCACCCAGCTCCTCAAGTTCTCGACAGAC 
Human SGCZ - hzlnP267S_R - - GTCTGTCGAGAACTTGAGGAGCTGGGTGAAGAA 
Human SGCZ - hZlnN113D_F Mutagenesis 
for PCR error 
- - AAGAAATTCATTCTCGAAAGGATAGTCCGCTGGTCTTACAG 
Human SGCZ - hZlnN113D_R - - CTGTAAGACCAGCGGACTATCCTTTCGAGAATGAATTTCTT 
Human SGCZ - hZlnT304S_F Mutagenesis 
for PCR error 
- - TAGGTTCCACTTGTCAGTCCAGTAGCAACATCTGC 
Human SGCZ - hZlnT304S_R - - GCAGATGTTGCTACTGGACTGACAAGTGGAACCTA 
Human SGCD - hD2A8T_F Mutagenesis 
for PCR error 
- - CTCAGGAGCAGTACACTCACCACCGGAGC 
Human SGCD - hD2A8T_R - - GCTCCGGTGGTGAGTGTACTGCTCCTGAG 
Human SGCD - hD2A220T_F Mutagenesis 
for PCR error 
- - GGCAATATGGAAGCCACCTGCAGGACAGAGC 
Human SGCD - hD2A220T_R - - GCTCTGTCCTGCAGGTGGCTTCCATATTGCC 
Human SGCD - hD3R9H_F Mutagenesis 
for PCR error 
- - GAGCAGTACACTCACCACCGGAGCACC 
Human SGCD - hD3R9H_R - - GGTGCTCCGGTGGTGAGTGTACTGCTC 
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Human SGCD - hD3R176K_F Mutagenesis 
for PCR error 
- - GAGGGCACAGTGTTCCCTAAATCTATAGAAACACCTAA 
Human SGCD - hD3R176K_R - - TTAGGTGTTTCTATAGATTTAGGGAACACTGTGCCCTC 
Human SGCA - hA237tc_F Mutagenesis 
for PCR error 
- - TGCCTCCCCGCGTGGACAGCGCCCAG 
Human SGCA - hA237tc_R - - CTGGGCGCTGTCCACGCGGGGAGGCA 
Human SGCA - hA34ex5ct_F Mutagenesis 
for PCR error 
- - CGGAGGAGGTGCTGCCCTCAACACCTGCC 
Human SGCA - hA34ex5ct_R - - GGCAGGTGTTGAGGGCAGCACCTCCTCCG 
Human SGCA - hA34_ex7_tc_F Mutagenesis 
for PCR error 
- - CCTGGTGCCCCTGCTGGTGGCCCT 
Human SGCA - hA34_ex7_tc_R - - AGGGCCACCAGCAGGGGCACCAGG 
Human SGCA - hAT3_ex10_ct_F Mutagenesis 
for PCR error 
- - CTGATTCCAGCTCCTGGCCCTCCTGG 
Human SGCA - hAT3_ex10_ct_R - - CCAGGAGGGCCAGGAGCTGGAATCAG 
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Appendix II: Pre-immune immunoglobulin IAP, CD-1 mice 
Table of proteins identified in the pre-immune immunoglobulin IAP from digitonin-solubilised wild-type CD-1 mouse brain. Proteins are ranked 
by protein identity score, an output of the SEQUEST algorithm that provides the likelihood that the protein in question was genuinely present in 
the sample. Also provided are the percent of the protein covered by peptides identified in the sample (Coverage), the number of distinct peptides 
identified for that protein in the sample (Number of unique peptides), the number of mass spectra corresponding to that protein (Spectral count), 
and the molecular weight of the protein in kilodaltons (Molecular weight (kDa)). 
Gene 
symbol 
Protein name 
Protein identity 
score 
Coverage 
(%) 
Number 
of unique 
peptides 
Spectral 
count 
Molecular 
weight 
(kDa) 
Cltc Clathrin heavy chain 1  261.93 44 50 87 191.4 
Tuba1a Tubulin alpha-1A chain 260.42 64.3 3 76 50.1 
Tubb2b Tubulin beta-2B chain 228.72 75.96 1 84 49.9 
Tubb2a Tubulin beta-2A chain 227.69 75.96 2 85 49.9 
Tubb4b Tubulin beta-4B chain 220.09 77.75 1 82 49.8 
tuba Tubulin alpha chain 219.85 64.37 1 64 49.8 
Tubb4a Tubulin beta-4A chain 215.56 78.83 4 80 49.6 
Gapdh Glyceraldehyde-3-phosphate dehydrogenase 212.71 69.97 15 66 35.8 
Tubb5 Tubulin beta-5 chain 203.45 77.93 4 76 49.6 
Tuba4a Tubulin alpha-4A chain 166.71 62.28 4 52 49.9 
Atp5b ATP synthase subunit beta, mitochondrial 121.2 48.39 16 37 56.3 
Tubb3 Tubulin beta-3 chain  117.2 50.89 5 42 50.4 
Syn1 Synapsin-1 115.32 47.88 17 39 74.1 
Dpysl2 Dihydropyrimidinase-related protein 2  109.22 66.26 18 35 62.2 
KRT1 Keratin, type II cytoskeletal 1 101.02 45.34 17 27 66 
Actb Actin, cytoplasmic 1  99.78 57.07 1 33 41.7 
ACTB Actin, cytoplasmic 1  93.6 57.6 1 31 41.7 
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Hspd1 60 kDa heat shock protein, mitochondrial 88.28 34.03 13 24 60.9 
Syn2 Synapsin-2 86.42 38.05 11 28 63.3 
Eef1a2 Elongation factor 1-alpha 2  85.7 30.24 4 26 50.4 
Eef1a1 Elongation factor 1-alpha 1 85.2 30.3 4 25 50.1 
Atp1a3 Sodium/potassium-transporting ATPase subunit alpha-3 81.75 25.27 8 25 111.6 
Mb21d2 Protein MB21D2 (Mab-21 domain-containing protein 2) 79.22 39.71 12 25 55.6 
Slc1a3 Excitatory amino acid transporter 1  73.11 15.1 5 20 59.6 
Cnp 2',3'-cyclic-nucleotide 3'-phosphodiesterase 71.52 41.9 12 24 47.1 
Atp5a1 ATP synthase subunit alpha, mitochondrial 67.95 38.17 14 24 54.6 
Nsf Vesicle-fusing ATPase 66.67 36.16 19 26 82.6 
Dnm1 Dynamin-1 62.77 23.99 11 20 97.7 
Hsp90aa1 Heat shock protein HSP 90-alpha 60.95 26.47 9 22 84.7 
Ighg2b Immunoglobulin gamma heavy chain 59.99 47.62 2 18 36.7 
Stxbp1 Syntaxin-binding protein 1 58.94 34.68 12 17 67.5 
Hspa8 Heat shock cognate 71 kDa protein 54.69 42.05 11 17 50.4 
Ighg Immunoglobulin gamma-3 50.41 33.83 1 18 51.9 
Atp1a1 Sodium/potassium-transporting ATPase subunit alpha-1 48.7 16.62 4 15 112.9 
HSP90AB1 Heat shock protein HSP 90-beta 48.16 26.24 8 19 83.2 
Ighg Immunoglobulin gamma-3 46.61 38.3 1 19 25.8 
KRT1 Keratin, type II cytoskeletal 1 46.37 27.8 11 14 66 
Ina Alpha-internexin  46.07 27.15 9 14 55.3 
Igkv8-30 Immunoglobulin kappa light chain 45.46 34.58 1 19 26.6 
Igkc Immunoglobulin kappa light chain 45.26 39.73 1 19 24.1 
Ap2b1 AP-2 complex subunit beta 45.17 16.43 8 13 101.3 
Atp1a2 Sodium/potassium-transporting ATPase subunit alpha-2 44.09 15.21 2 14 103.5 
Nefm Neurofilament medium polypeptide 43.33 22.17 10 14 95.9 
Ighg1 Immunoglobulin heavy chain 43.18 46.6 2 16 35.7 
Tcp1 T-complex protein 1 subunit alpha 43 24.82 7 14 60.4 
Actbl2 Beta-actin-like protein 2  40.74 26.33 1 12 42 
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Idh3a Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial  40.73 21.04 5 12 39.6 
Ighg1 Immunoglobulin heavy chain 39.1 46.6 1 14 35.7 
Hnrnpk Heterogeneous nuclear ribonucleoprotein K  38.14 25.91 8 17 48.5 
Pkm Pyruvate kinase PKM  35.8 12.05 4 10 57.8 
Ncdn Neurochondrin  34.87 24.01 11 12 78.8 
Vdac1 Voltage-dependent anion-selective channel protein 1 34.15 56.08 9 12 32.3 
Gls Glutaminase kidney isoform, mitochondrial  34 14.54 5 9 73.9 
Pfkp 6-phosphofructokinase 33.77 15.18 5 9 85.5 
Prss1 Trypsin-1 33.08 12.2 2 13 26.1 
Hspa12a Heat shock 70 kDa protein 12A 32.72 23.41 11 11 74.8 
Sirt2 NAD-dependent protein deacetylase sirtuin-2 31.64 25.07 6 8 39.4 
Ywhaz 14-3-3 protein zeta/delta 31.37 28.98 5 9 27.8 
Eno1 Alpha-enolase 30.02 22.35 5 7 47.1 
Nefl Neurofilament light polypeptide 29.51 19.02 5 9 57.8 
Ap2a2 AP-2 complex subunit alpha-2 28.57 18.66 5 10 104 
Crmp1 Dihydropyrimidinase-related protein 1  28.26 20.28 5 8 62.1 
Rap1gds Rap1 GTPase-GDP dissociation stimulator 27.7 17.83 5 7 59.1 
Arf3 ADP-ribosylation factor 3 27.62 54.7 1 10 20.6 
Slc1a2 Excitatory amino acid transporter 2 27.24 13.82 4 7 60.6 
Cfl1 Cofilin-1  26.11 50.6 6 7 18.5 
Pygb Alpha-1,4 glucan phosphorylase 25.39 14.71 7 11 96.6 
Sh3glb2 Endophilin-B2 24.94 23.51 6 11 44.9 
Hnrnpl Heterogeneous nuclear ribonucleoprotein L 24.71 7.17 2 6 63.9 
Sept6 Septin-6 24.66 19.59 5 7 49.6 
Atp6v1b2 V-type proton ATPase subunit B, brain isoform 24.14 20.94 6 7 56.5 
Dnm3 Dynamin-3 22.87 5.01 1 6 92.8 
Cpsf7 Cleavage and polyadenylation specificity factor subunit 7  22.82 5.31 1 5 52 
Uba1 Ubiquitin-like modifier-activating enzyme 1 22.7 9.07 5 10 117.7 
Tmod2 Tropomodulin-2 21.42 16.52 2 5 39.5 
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Ddx3x ATP-dependent RNA helicase DDX3X 21.36 8.32 3 6 73 
Tubb1 Tubulin beta-1 chain 21.25 13.75 1 9 50.4 
Rab3a Ras-related protein Rab-3A 21.22 35 4 7 25 
Atp6v1a V-type proton ATPase catalytic subunit A  21.21 9.4 4 6 68.3 
Ppp2r1a Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit 
A alpha isoform 
21.15 16.47 6 8 65.3 
Sept8 Septin-8 21.11 18.88 4 7 49.8 
Gfap Glial fibrillary acidic protein 21.11 21.86 7 8 49.9 
Sept7 Septin-7 20.88 19.69 4 7 45 
Ywhag 14-3-3 protein gamma 20.56 25.1 3 5 28.3 
Ddx1 ATP-dependent RNA helicase DDX1 20.3 5.14 2 6 82.4 
Sept5 Septin-5 20.01 26.29 5 9 42.7 
Acat1 Acetyl-CoA acetyltransferase, mitochondrial 19.94 15.57 4 6 44.8 
Snap91 Clathrin coat assembly protein AP180 19.8 13.25 5 6 86 
Ckmt1 Creatine kinase U-type, mitochondrial 19.68 11.24 2 5 47 
Acly ATP-citrate synthase 19.4 8.03 2 5 47.9 
Psmd2 26S proteasome non-ATPase regulatory subunit 2 19.24 6.67 2 6 66.8 
Matr3 Matrin-3 19.09 7.09 3 5 94.6 
Rmdn3 Regulator of microtubule dynamics protein 3 18.96 4.89 1 4 52 
Atp2b4 Plasma membrane calcium-transporting ATPase 4 18.28 6.59 1 9 122.2 
Ogdh 2-oxoglutarate dehydrogenase, mitochondrial 18.06 7.56 2 7 116 
Cct5 T-complex protein 1 subunit epsilon 18.06 14.6 4 6 59.6 
Ogdhl 2-oxoglutarate dehydrogenase-like, mitochondrial 17.8 9.6 2 8 114.5 
Xpnpep1 Xaa-Pro aminopeptidase 1 17.49 13.01 5 6 66 
Mbp Myelin basic protein 17.38 32.64 6 7 20.9 
Slc4a4 Electrogenic sodium bicarbonate cotransporter 1 17.14 2.34 1 4 115.1 
Etfa Electron transfer flavoprotein subunit alpha, mitochondrial 17.06 13.21 3 5 35 
Atp2b2 Plasma membrane calcium-transporting ATPase 2 16.92 5.63 3 5 127.2 
Stip1 Stress-induced-phosphoprotein 1 16.92 10.5 4 5 62.5 
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Gnao1 Guanine nucleotide-binding protein G(o) subunit alpha 16.85 22.88 5 6 40.1 
Kpnb1 Importin subunit beta-1 16.84 4 2 4 97.1 
Pi4ka Phosphatidylinositol 4-kinase alpha 16.83 2.89 3 5 231.2 
Amph Amphiphysin 16.56 5.45 2 4 69.6 
Hadha Trifunctional enzyme subunit alpha, mitochondrial 16.44 9.57 3 4 82.6 
Gpd1 Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic 16.4 9.17 1 3 37.5 
Gda Guanine deaminase 16.39 7.27 2 4 50.9 
Arf4 ADP-ribosylation factor 4 16.32 38.89 1 6 20.4 
Park7 Protein deglycase DJ-1 16.29 18.52 2 4 20 
Ap2a1 AP-2 complex subunit alpha-1 16.21 9.11 2 6 107.6 
Cse1l Exportin-2 15.95 8.2 4 5 103.8 
ARF1 ADP-ribosylation factor 1 15.83 43.65 1 6 20.6 
Ppp3ca Serine/threonine-protein phosphatase 2B catalytic subunit alpha 
isoform 
15.27 14.97 4 7 58.6 
Eef2 Elongation factor 2 14.96 5.22 3 4 93.5 
Cct6a T-complex protein 1 subunit zeta 14.91 23.39 5 5 42.9 
PLP1 Myelin proteolipid 14.9 20.22 5 6 30.1 
Nono Non-POU domain-containing octamer-binding protein 14.83 4.86 1 8 54.4 
Add1 Alpha-adducin  14.82 13.79 5 5 72.9 
Actr1a Alpha-centractin  14.65 16.49 1 4 42.6 
Pfkl ATP-dependent 6-phosphofructokinase, liver type 14.53 6.41 2 4 85.3 
Vps35 Vacuolar protein sorting-associated protein 35 14.4 6.16 3 4 83.9 
Dpysl3 Dihydropyrimidinase-related protein 3 14.4 10.74 1 4 61.7 
Ctbp1 C-terminal-binding protein 1  14.25 14.29 3 4 47.7 
Ahsg Alpha-2-HS-glycoprotein 14.21 15.36 2 5 37.3 
Ak1 Adenylate kinase isoenzyme 1 14.17 19.07 3 4 21.5 
Ywhab 14-3-3 protein beta/alpha  14.07 19.92 2 4 28.1 
Gad2 Glutamate decarboxylase 2 14.01 7.35 2 3 65.2 
Osbpl10 Oxysterol-binding protein-related protein 10 13.95 7.11 2 4 65.8 
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Ywhae 14-3-3 protein epsilon 13.68 16.08 3 4 29.2 
Map6 Microtubule-associated protein 6 13.56 15.32 5 5 54.7 
Hspa9 Stress-70 protein, mitochondrial  13.55 10.6 5 5 73.4 
Vdac2 Voltage-dependent anion-selective channel protein 2  13.3 28.98 6 6 30.4 
Try10 MCG140784 13.21 14.63 1 8 26.2 
Acaa1a 3-ketoacyl-CoA thiolase A, peroxisomal 13.12 20.41 1 4 10.2 
Actr1b Beta-centractin 12.86 45.4 2 4 19.6 
Ap1b1 AP-1 complex subunit beta-1 12.83 8.52 2 4 101.1 
Camk2a Calcium/calmodulin-dependent protein kinase type II subunit alpha 12.77 9.21 3 4 54.1 
Ahcyl1 Putative adenosylhomocysteinase 2 12.72 15.09 4 7 58.9 
C1qb Complement C1q subcomponent subunit B 12.67 15.02 2 4 26.7 
Hspa1L Heat shock protein 1-like protein 12.62 6.86 1 4 70.6 
Dnm1l Dynamin-1-like protein 12.62 6.88 2 3 79.5 
Cadps Calcium-dependent secretion activator 1 12.59 5.39 5 5 153 
Sars Serine--tRNA ligase, cytoplasmic 12.51 8.61 2 3 58.2 
Pdhb Pyruvate dehydrogenase E1 component subunit beta, mitochondrial  12.4 16.43 3 4 38.9 
Dnajc6 Putative tyrosine-protein phosphatase auxilin 12.09 6.93 2 5 102.2 
Sept11 Septin-11 12.06 12.06 2 4 49.7 
Igh Immunoglobulin H 12.03 8.81 1 4 52.2 
Gpd1l Glycerol-3-phosphate dehydrogenase 1-like protein 12 9.12 1 3 38.2 
Rasal1 RasGAP-activating-like protein 1 11.76 3 1 3 89.3 
Idh3b Isocitrate dehydrogenase [NAD] subunit, mitochondrial 11.7 8.07 2 3 42.2 
Tomm70a Mitochondrial import receptor subunit TOM70 11.66 2.95 1 3 67.5 
Cand1 Cullin-associated NEDD8-dissociated protein 1  11.57 4.63 4 4 136.2 
C1qa Complement C1q subcomponent subunit A 11.51 14.29 2 3 26 
Cpsf6 Cleavage and polyadenylation-specificity factor subunit 6 11.49 13.74 1 3 21.2 
Tufm Elongation factor Tu 11.48 13.05 4 4 49.5 
Slc25a5 ADP/ATP translocase 2  11.35 25.84 2 5 32.9 
ACT1 Actin 1 11.3 15.92 1 6 41.7 
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Acadsb Short/branched chain specific acyl-CoA dehydrogenase, 
mitochondrial 
11.26 6.18 1 3 37.7 
Cct2 T-complex protein 1 subunit beta 11.11 9.35 3 4 57.4 
Atp2b1 Plasma membrane calcium-transporting ATPase 1 11.05 5.33 1 4 134.7 
Tubal3 Tubulin alpha chain-like 3 11.03 7.4 1 5 50 
Calb1 Calbindin 10.73 13.03 2 3 30 
Git1 ARF GTPase-activating protein GIT1 10.71 5.52 2 3 84.1 
Nefh Neurofilament heavy polypeptide 10.65 3.92 2 4 112.5 
Sfpq Splicing factor, proline- and glutamine-rich 10.63 30.33 2 3 13.9 
Tppp Tubulin polymerization-promoting protein  10.43 13.76 2 3 23.6 
Sccpdh Saccharopine dehydrogenase-like oxidoreductase 10.4 17.06 1 3 18.6 
Hspa5 78 kDa glucose-regulated protein 10.39 5.77 1 3 56.9 
Atp5c1 ATP synthase subunit gamma, mitochondrial 10.22 26.32 2 3 18.7 
Eif3f Translation initiation factor-3 subunit 5 10.14 12.84 1 2 16.1 
Krt5 Keratin, type II cytoskeletal 5 10.06 6.03 2 3 61.7 
Hnrnph1 Heterogeneous nuclear ribonucleoprotein H  10.05 10.47 3 3 49.2 
Prss1 Trypsin-1 10.04 8.13 1 4 26.1 
Vdac3 Voltage-dependent anion-selective channel protein 3 9.87 12.01 2 4 30.7 
Snrpd1 Small nuclear ribonucleoprotein Sm D1 9.75 16.81 1 2 13.3 
Slc25a12 Calcium-binding mitochondrial carrier protein Aralar1 9.75 2.51 1 2 74.5 
Atp2b3 Plasma membrane calcium-transporting ATPase 3 9.73 4.81 1 5 125.6 
Pde1b Calcium/calmodulin-dependent 3',5'-cyclic nucleotide 
phosphodiesterase 1B 
9.67 9.17 3 3 52.5 
Dlat Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial 
9.64 3.74 2 3 67.9 
Cct7 T-complex protein 1 subunit eta 9.58 10.66 3 3 59.6 
Prss2 Anionic trypsin-2 9.51 15.45 1 3 26.5 
Ipo9 Importin-9 9.28 4.27 1 2 72.7 
Ttc7b Tetratricopeptide repeat protein 7B 9.22 2.37 1 3 94.1 
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Napb Beta-soluble NSF attachment protein 9.19 10.4 2 2 33.5 
Kpna4 Importin subunit alpha-3 9.09 3.26 1 2 57.9 
Map2 Microtubule-associated protein 2 8.98 6.65 1 2 49.2 
Add2 Beta-adducin 8.93 7.12 4 4 77.8 
Sh3gl2 Endophilin-A1 8.92 11.36 3 3 39.9 
Capzb Capping protein beta 3 8.87 27.78 1 2 10 
Krt10 Keratin, type I cytoskeletal 10 8.76 6.42 3 3 57 
Acsl6 Long-chain-fatty-acid--CoA ligase 6 8.63 6.96 2 3 39.8 
Serpinh1 Serpin H1 8.57 6.24 1 3 46.5 
Dclk1 Serine/threonine-protein kinase DCLK1 8.56 11.29 3 3 40.3 
Cyfip2 Cytoplasmic FMR1-interacting protein 2 8.51 3.99 4 5 145.6 
Hnrnpa2b1 Heterogeneous nuclear ribonucleoprotein A2/B1  8.5 12.02 3 3 35.9 
Sv2a Synaptic vesicle glycoprotein 2A 8.45 6.2 2 2 82.6 
Picalm Phosphatidylinositol-binding clathrin assembly protein 8.34 6.53 1 3 64.6 
Slc25a4 ADP/ATP translocase 1 8.27 21.48 1 4 32.9 
Pfkm ATP-dependent 6-phosphofructokinase, muscle type 8.22 11.54 6 6 85.2 
Plcxd3 PI-PLC X domain-containing protein 3 8.19 8.72 1 2 36.3 
Slc25a3 Phosphate carrier protein, mitochondrial 8.16 7.56 2 3 39.6 
Atp2a2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 7.97 5.61 4 4 109.7 
Krt42 Keratin, type I cytoskeletal 42 7.91 7.3 1 2 50.1 
Atp1b1 Sodium/potassium-transporting ATPase subunit beta-1  7.84 12.5 3 4 35.2 
Eif4g1 Eukaryotic translation initiation factor 4 gamma 1 7.82 4.8 1 3 54.4 
Osbpl9 Oxysterol-binding protein-related protein 9 7.67 4.15 2 3 70.1 
Vsnl1 Visinin-like protein 1  7.6 14.14 2 2 22.1 
Gpr37l1 G protein-coupled receptor 37-like 1  7.59 4.89 1 2 38.3 
Rph3a Rabphilin-3A 7.58 6.31 2 2 75.4 
Krt14 Keratin, type I cytoskeletal 14 7.56 7.02 1 2 52.8 
Psmc4 26S protease regulatory subunit 6B 7.53 16.24 2 2 35.2 
Gnb1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1  7.36 8.53 2 2 37.4 
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Actr10 Actin-related protein 10  7.3 4.32 1 2 46.2 
Eif4b Eukaryotic translation initiation factor 4B 7.28 6.2 1 2 46.5 
Aak1 AP2-associated protein kinase 1  7.22 5.53 2 2 103.3 
Pcmt1 Protein-L-isoaspartate(D-aspartate) O-methyltransferase (PIMT)  7.19 15.82 2 2 18.9 
Nup155 Nuclear pore complex protein Nup155 7.18 2.72 1 3 88.8 
Rab10 Ras-related protein Rab-10 7.01 16.5 2 3 22.5 
Actn1 Alpha actinin 1a 7 2.48 2 2 102.7 
Sv2b Synaptic vesicle glycoprotein 2B 7 10.93 1 2 20 
Pygm Alpha-1,4 glucan phosphorylase  6.96 7.03 1 4 87.5 
Map2k4 Dual specificity mitogen-activated protein kinase kinase 4  6.94 8.56 2 3 44.1 
Dazap1 DAZ-associated protein 1  6.93 9.36 1 2 19.4 
Arhgef2 Rho guanine nucleotide exchange factor 2 6.93 3.03 1 4 108.5 
Pdia6 Protein disulfide-isomerase A6 6.88 6.14 1 2 42.9 
Prdx2 Peroxiredoxin-2 6.87 22.73 3 3 21.8 
Ighv1-31 Immunoglobulin heavy chain 6.86 33.67 1 3 11 
Ddx5 Probable ATP-dependent RNA helicase DDX5 6.82 13.79 3 4 46 
Synj1 Synaptojanin-1  6.75 2.37 2 2 144.5 
Krt79 Keratin, type II cytoskeletal 79 6.73 2.26 1 2 57.5 
Cul5 Cullin-5 6.61 4.77 1 2 65.5 
Ptk2b Protein-tyrosine kinase 2-beta 6.59 4.03 2 2 111 
Atad3 ATPase family AAA domain-containing protein 3  6.44 3.72 2 2 66.7 
Arhgap44 Rho GTPase-activating protein 44  6.41 2.33 1 2 88.9 
Fus RNA-binding protein FUS 6.4 19.23 2 3 14 
Atad1 ATPase family AAA domain-containing protein 1 6.34 8.21 1 2 22.1 
Aldh6a1 Methylmalonate-semialdehyde dehydrogenase [acylating], 
mitochondrial 
6.3 7.44 2 3 49.6 
Prps1l3 Ribose-phosphate pyrophosphokinase 1 6.27 5.98 1 2 27.5 
Uggt1 UDP-glucose:glycoprotein glucosyltransferase 1  6.27 2 2 2 176.3 
Aldh2 Aldehyde dehydrogenase, mitochondrial 6.27 5.78 2 2 56.5 
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Pdha1 Pyruvate dehydrogenase E1 component subunit alpha, somatic form, 
mitochondrial  
6.15 8.97 2 2 43.2 
EZR Ezrin 6.01 4.44 2 2 69.4 
Sucla2 Succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial 6.01 7.13 2 2 50.1 
Vps52 Vacuolar protein sorting-associated protein 52 homolog 5.95 6.36 2 3 82 
Clasp2 CLIP-associating protein 2 5.92 3.67 2 2 119.4 
Atp5f1 ATP synthase F(0) complex subunit B1, mitochondrial 5.87 5.86 1 2 28.9 
Syt1 Synaptotagmin-1 5.85 8.31 3 3 47.4 
Opa1 Dynamin-like 120 kDa protein, mitochondrial 5.81 14.19 2 3 33.9 
Caprin1 Caprin-1 5.79 6.53 1 2 37.6 
Gstp2 Glutathione S-transferase P 2 5.77 19.15 2 2 21.1 
Ctnnb1 Catenin beta-1 5.75 12.07 1 2 19.1 
Prkce Protein kinase C epsilon type 5.69 3.39 1 3 83.5 
Atp5o ATP synthase subunit O, mitochondrial 5.56 11.74 2 2 23.3 
Pdcd6ip Programmed cell death 6-interacting protein 5.52 1.96 1 2 96 
Fh Fumarate hydratase, mitochondrial 5.5 6.71 2 2 54.3 
Stx1b Syntaxin-1B 5.47 9.72 2 2 33.2 
Acsf2 Acyl-CoA synthetase family member 2, mitochondrial 5.35 4.72 1 1 67.9 
Trim21 E3 ubiquitin-protein ligase TRIM21 5.35 5.19 2 2 53.3 
Anxa7 Annexin A7 5.31 6.02 2 2 44.4 
Nceh1 Neutral cholesterol ester hydrolase 1  5.24 6.86 1 1 45.7 
Cct3 T-complex protein 1 subunit gamma 5.23 4.73 2 2 56.5 
Lphn3 Latrophilin-3  5.15 2.52 1 2 97.1 
Phgdh D-3-phosphoglycerate dehydrogenase 5.12 10.32 4 4 56.5 
Pcbp2 Poly(rC)-binding protein 2 5.11 10.43 2 2 29.6 
Ppp1cc Serine/threonine-protein phosphatase PP1-gamma catalytic subunit  5.01 5.26 1 1 37 
Ndufs1 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial 4.85 4.13 1 1 79.6 
Sec23a Protein transport protein Sec23A 4.82 3.67 1 5 82.9 
Hnrnpd Heterogeneous nuclear ribonucleoprotein D0 4.75 20.56 2 2 12.1 
Appendix II: Pre-immune immunoglobulin IAP, CD-1 mice 
 
 
[241] 
 
Pura Transcriptional activator protein Pur-alpha  4.74 7.17 1 1 34.9 
Josd2 Josephin-2 4.74 13.7 1 1 16.1 
Khsrp Far upstream element-binding protein 2 4.73 3.21 2 2 76.7 
Ldha L-lactate dehydrogenase 4.73 7.17 1 1 26 
Ehd3 EH domain-containing protein 3 4.67 5.05 1 1 60.8 
Enpp6 Ectonucleotide pyrophosphatase/phosphodiesterase family member 
6 
4.65 25.33 1 1 8.8 
Nudt21 Cleavage and polyadenylation specificity factor subunit 5  4.53 12.78 1 2 26.2 
Ogt UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 
110 kDa subunit 
4.51 1.91 1 1 116.9 
Iars2 Isoleucine--tRNA ligase, mitochondrial 4.49 6.43 1 1 62.4 
Prkar1a cAMP-dependent protein kinase type I-alpha regulatory subunit 4.34 9.34 1 1 28.8 
Hbb Beta-globin 4.34 25.85 3 3 15.7 
Tom1l2 TOM1-like protein 2 (Target of Myb-like protein 2) 4.24 2.56 1 1 55.6 
Dnaja2 DnaJ homolog subfamily A member 2 4.2 3.64 1 1 45.7 
Lgi3 Leucine-rich repeat LGI family member 3  4.17 2.74 1 1 61.8 
Krt79 Keratin, type II cytoskeletal 79 4.11 2.26 1 1 57.5 
Ganab Neutral alpha-glucosidase AB  4.01 3.39 1 1 106.8 
Vat1L Synaptic vesicle membrane protein VAT-1 homolog-like 3.95 3.89 1 1 36.8 
SDH1-2 Succinate dehydrogenase [ubiquinone] flavoprotein subunit 2, 
mitochondrial 
3.89 2.22 1 1 69.3 
Mms19 MMS19 nucleotide excision repair protein homolog 3.88 9.79 1 4 30.9 
Dpysl4 Dihydropyrimidinase-related protein 4  3.88 3.5 1 1 61.9 
Stk39 STE20/SPS1-related proline-alanine-rich protein kinase  3.85 2.52 1 1 60.3 
Ppp2r2a Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit 
B alpha isoform 
3.84 5.69 1 1 28.9 
Ikbkap Elongator complex protein 1 3.81 1.73 1 1 149.5 
Trim2 Tripartite motif-containing protein 2 3.81 3.94 1 1 61.6 
Rabgef1 Rab5 GDP/GTP exchange factor 3.79 3.87 1 1 56.8 
Pfas Phosphoribosylformylglycinamidine synthase 3.79 1.42 1 1 144.5 
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Dpp9 Dipeptidyl peptidase 9 3.79 2.44 1 1 97.9 
Fam49a Protein FAM49A 3.74 7.43 1 1 37.3 
Aars Alanine--tRNA ligase, cytoplasmic 3.74 4.15 1 1 49.6 
Vamp3 Vesicle-associated membrane protein 3 3.63 16.5 1 1 11.5 
Ctsb Cathepsin B 3.62 9.28 1 1 20.9 
Hk1 Hexokinase-1 3.61 2.24 1 1 74.3 
Map2k1 Dual specificity mitogen-activated protein kinase kinase 1 3.59 5.33 1 1 33.4 
Hpcal4 Hippocalcin-like protein 4 3.57 7.74 1 1 18 
Eif5a Eukaryotic translation initiation factor 5A-1 3.57 31.58 1 1 8.4 
Krt2 Keratin, type II cytoskeletal 2 epidermal 3.56 1.98 1 1 70.9 
Slc6a1 Sodium- and chloride-dependent GABA transporter 1 3.56 8.2 1 1 28.6 
Snca Alpha-synuclein  3.56 11.43 1 1 14.5 
Trim3 Tripartite motif-containing protein 3  3.54 3.07 1 1 78.2 
2210010C04
Rik 
Protein 2210010C04Rik 3.5 4.86 1 1 26.4 
Atp6v1h V-type proton ATPase subunit H 3.48 3.31 1 1 55.8 
Igkv3-7 Immunoglobulin kappa light chain 3.46 18 1 1 10.9 
Xpo7 Exportin-7 3.46 1.47 1 1 123.7 
Nptn Neuroplastin 3.44 14.75 1 1 13.2 
Arfip2 Arfaptin-2 (ADP-ribosylation factor-interacting protein 2) 3.43 6.45 1 1 37.7 
Canx Calnexin 3.4 2.71 1 1 67.2 
Ppp3r1 Calcineurin subunit B type 1 3.39 16.47 1 1 19.3 
Wdr7 WD repeat-containing protein 7  3.37 1.54 1 1 163.3 
Prkcb Protein kinase C beta type 3.27 1.79 1 1 76.7 
Dnaja3 DnaJ homolog subfamily A member 3, mitochondrial 3.26 5.08 1 1 49.5 
Mtch2 Mitochondrial carrier homolog 2 3.25 4.76 1 1 32.3 
Ptbp1 Polypyrimidine tract-binding protein 1 3.23 7.02 1 1 32.3 
Comtd1 Catechol O-methyltransferase domain-containing protein 1 3.21 9.92 1 2 28.9 
Rnf14 E3 ubiquitin-protein ligase RNF14 3.18 6.13 1 1 40.7 
Appendix II: Pre-immune immunoglobulin IAP, CD-1 mice 
 
 
[243] 
 
Krt77 Keratin 77  3.16 4.95 1 1 25.8 
mt-Nd4 NADH-ubiquinone oxidoreductase chain 4  3.14 7.14 1 1 28.5 
Rgs7 Regulator of G-protein signaling 7 3.07 3.41 1 1 54.8 
Diras2 GTP-binding protein Di-Ras2 3.07 5.53 1 1 22.5 
Rpl23 60S ribosomal protein L23 3.06 33.33 1 1 6.2 
Cryzl1 Quinone oxidoreductase-like protein 2 3.04 8.29 1 1 37.8 
Ckb Creatine kinase B-type 3.03 3.41 1 1 42.7 
Gnaq Guanine nucleotide-binding protein G(q) subunit alpha 3.03 5.29 1 1 42.1 
Pde2a cGMP-dependent 3',5'-cyclic phosphodiesterase 3.02 2.29 1 1 103.2 
Necab2 N-terminal EF-hand calcium-binding protein 2  2.98 12.5 1 1 25.2 
Hba Alpha globin 2.98 25.86 1 1 6.2 
Inpp4a Type I inositol 3,4-bisphosphate 4-phosphatase 2.97 1.92 1 1 76.3 
Ndufs7 NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, 
mitochondrial 
2.93 12.05 1 1 24.7 
Rtn1 Reticulon-1  2.92 4.36 2 2 83.5 
Dsp Desmoplakin (DP) 2.91 0.42 1 1 332.7 
Rap1gap Rap1 GTPase-activating protein 1 2.91 4.2 1 1 43.4 
Psmd12 26S proteasome non-ATPase regulatory subunit 12  2.91 6.31 1 1 23.6 
Dhx9 ATP-dependent RNA helicase A 2.88 2.29 1 1 59.2 
Nsfl1c NSFL1 cofactor p47 (p97 cofactor p47) 2.87 5.01 1 1 37.4 
Atp6v1c1 V-type proton ATPase subunit C 1 2.86 4.19 1 1 43.8 
Dync1li1 Cytoplasmic dynein 1 light intermediate chain 1 2.85 9.36 1 1 21 
Actr3 Actin-related protein 3 2.85 5.09 1 1 24.1 
Ywhaq 14-3-3 protein theta 2.84 4.9 1 1 27.8 
Sept4 Septin-4 2.82 6.57 1 1 24.2 
Syncrip Heterogeneous nuclear ribonucleoprotein Q 2.81 6.63 1 1 21.6 
Ctnnd2 Catenin delta-2 2.79 2.68 1 1 41.6 
Mpst 3-mercaptopyruvate sulfurtransferase 2.73 4.38 1 1 33.1 
Syngr1 Synaptogyrin-1 2.72 6.28 1 1 21.3 
Appendix II: Pre-immune immunoglobulin IAP, CD-1 mice 
 
 
[244] 
 
CPK21 Calcium-dependent protein kinase 21 2.71 5.08 1 1 59.9 
4930544G1
1Rik 
Testis specific expressed protein 5 2.69 12.44 1 1 21.6 
Mgst3 Microsomal glutathione S-transferase 3 2.68 8.5 1 1 16.9 
Cap1 Adenylyl cyclase-associated protein 2.66 11.59 1 1 17.9 
Rufy3 Protein RUFY3  2.65 5.12 2 2 53 
Cttn Src substrate cortactin 2.64 2.55 1 1 57.1 
Map1b Microtubule-associated protein 1B 2.64 3.09 1 1 34.9 
Hivep1 Zinc finger protein 40 2.62 3.42 1 1 92.9 
Npepps Puromycin-sensitive aminopeptidase 2.61 1.37 1 1 98.5 
Lasp1 LIM and SH3 domain protein 1 2.6 23.21 1 1 6.5 
Hadhb Trifunctional enzyme subunit beta, mitochondrial 2.59 9.25 1 1 19 
Syp Synaptophysin 2.57 7.88 1 1 18.1 
Abat 4-aminobutyrate aminotransferase, mitochondrial 2.55 6.47 1 1 26.2 
Cct8 T-complex protein 1 subunit theta 2.54 9.09 1 1 14.5 
Pacsin1 Protein kinase C and casein kinase substrate in neurons protein 1 2.54 5.22 1 1 50.5 
Dagla Sn1-specific diacylglycerol lipase alpha 2.51 1.63 1 1 115.2 
Sec24b Protein transport protein Sec24B 2.51 1.08 1 1 112 
Vcp Transitional endoplasmic reticulum ATPase 2.48 2.35 1 1 80.1 
Capza2 F-actin-capping protein subunit alpha-2  2.47 5.75 1 1 20 
Echs1 Enoyl-CoA hydratase, mitochondrial 2.46 5.76 1 1 20.9 
Cct4 T-complex protein 1 subunit delta 2.46 5.7 2 2 54.8 
Bdh1 3-hydroxybutyrate dehydrogenase 2.45 19.05 1 1 12.1 
Padi2 Protein-arginine deiminase type-2 2.45 6.48 1 1 36.9 
Gpd2 Glycerol-3-phosphate dehydrogenase, mitochondrial 2.39 1.24 1 1 80.9 
Suclg1 Succinyl-CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial 2.38 4.62 1 1 36.1 
Smap1 Stromal membrane-associated protein 1 2.37 3.38 1 1 37.8 
Rab11b Ras-related protein Rab-11B 2.34 10.4 1 1 14.3 
Ncald Neurocalcin-delta 2.33 4.6 1 1 20.2 
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Rab2a Ras-related protein Rab-2A 2.32 15.48 2 2 19.1 
Krt15 Keratin, type I cytoskeletal 15 2.28 3.98 1 1 49.1 
Aldoc Fructose-bisphosphate aldolase C 2.28 4.41 1 1 39.4 
Gtf2i General transcription factor II-I 2.25 8.12 1 1 40.5 
Pmpca Mitochondrial-processing peptidase subunit alpha 2.24 3.85 1 1 48.4 
Ipo5 Importin-5 2.24 2.51 1 1 90 
Gnb5 Guanine nucleotide-binding protein subunit beta-5 2.22 9.31 1 1 22 
Dctn1 Dynactin subunit 1 2.22 2.28 1 1 126.7 
Mapt Microtubule-associated protein tau 2.2 10.75 2 2 38.9 
Ppp2cb Serine/threonine-protein phosphatase 2A catalytic subunit beta 
isoform 
2.2 3.96 1 1 32 
Nap1l1 Nucleosome assembly protein 1-like 1 2.18 3.82 1 1 33.5 
Sncb Beta-synuclein 2.18 10.53 1 1 14 
Mtfr1l Mitochondrial fission regulator 1-like 2.17 11.88 1 1 22.4 
Atl1 Atlastin-1 2.11 2.57 1 1 49.2 
Krt10 Keratin, type I cytoskeletal 10 2.11 2.14 1 1 57 
Vps51 Vacuolar protein sorting-associated protein 51 homolog 2.1 2.69 1 1 86.1 
Igk12f2 Immunoglobulin kappa light chain 2.07 9.4 1 1 12.3 
Immt MICOS complex subunit Mic60 2.03 6.34 1 1 30.4 
C2cd4cC2CD
4 family 
C2 calcium-dependent domain-containing protein 4C 2.02 4.3 1 1 44.6 
C1qc Complement C1q subcomponent subunit C 2.02 7.32 1 3 26 
cdk5 Cyclin-dependent kinase 5  2.02 4.97 1 1 18.5 
Dlst Dihydrolipoyllysine-residue succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, mitochondrial 
1.99 2.42 1 1 49 
Pdhx Pyruvate dehydrogenase protein X component, mitochondrial 1.94 1.8 1 1 54 
Ighm Immunoglobulin M 1.9 3.08 1 1 49.9 
Rab18 Ras-related protein Rab-18 1.85 5.34 1 1 23 
Atp5i ATP synthase subunit e, mitochondrial 1.83 16.9 1 1 8.2 
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Prdx1 Peroxiredoxin-1  1.83 4.71 1 1 18.9 
Plaa Phospholipase A-2-activating protein 1.79 2.14 1 1 87.2 
Pcbp1 Poly(rC)-binding protein 1 (Alpha-CP1) 1.76 3.93 1 1 37.5 
Fubp1 Far upstream element (FUSE) binding protein 1 1.68 2.03 1 1 67.2 
Tanc2 Protein TANC2 1.64 0.4 1 1 220.1 
Usp5 Ubiquitin carboxyl-terminal hydrolase 1.62 1.56 1 1 93.3 
Gpm6a Neuronal membrane glycoprotein M6-a 1.6 4.12 1 1 29.8 
Ran GTP-binding nuclear protein Ran 0 6.48 1 1 24.4 
Mpp2 MAGUK p55 subfamily member 2 0 3.62 1 1 61.5 
Mycb Protein B-Myc 0 21.76 1 3 18.5 
Phyhipl Phytanoyl-CoA hydroxylase-interacting protein-like 0 4.27 1 1 42.3 
Rtn3 Reticulon-3 0 1.17 1 1 101.5 
Rtn4 Reticulon-4 0 1.03 1 1 126.5 
Igh Immunoglobulin heavy chain 0 16.24 1 1 12.9 
Prkcg Protein kinase C gamma type 0 2.32 1 1 72.9 
Gna14 Guanine nucleotide-binding protein subunit alpha-14 0 6.13 1 1 36.4 
Bin1 Myc box-dependent-interacting protein 1 0 3.77 1 1 52.7 
Rab5c Ras-related protein Rab-5C 0 31.43 1 1 3.4 
Plekhg5 Pleckstrin homology domain-containing family G member 5 0 3.94 1 1 115.7 
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Appendix III: Pre-immune immunoglobulin IAP, C57BL/6J mice 
Table of proteins identified in the pre-immune immunoglobulin IAP from digitonin-solubilised wild-type C57BL/6J mouse brain. Proteins are 
ranked by protein identity score, an output of the SEQUEST algorithm that provides the likelihood that the protein in question was genuinely 
present in the sample. Also provided are the percent of the protein covered by peptides identified in the sample (Coverage (%)), the number of 
distinct peptides identified for that protein in the sample (Number of unique peptides), the number of mass spectra corresponding to that protein 
(Spectral count), and the molecular weight of the protein in kilodaltons (Molecular weight (kDa)). 
Gene 
symbol 
Protein name 
Protein 
identity 
score 
Coverage 
(%) 
Number of 
unique 
peptides 
Spectral 
count 
Molecular 
weight 
(kDa) 
Tubb4b Tubulin beta-4B chain 44.8 31.24 1 15 49.8 
Tubb2a Tubulin beta-2A chain 41.07 34.61 5 15 49.9 
Tubb4a Tubulin beta-4A chain 35.72 28.38 2 12 49.6 
Tuba1a Tubulin alpha-1A chain 31.6 22.39 5 11 50.1 
Mb21d2 Protein MB21D2 (Mab-21 domain-containing protein 2) 31.39 21.79 9 10 55.6 
Atp5a1 ATP synthase subunit alpha, mitochondrial 31.09 21.16 9 11 59.7 
Krt14 Keratin, type I cytoskeletal 14  29.04 17.98 3 10 52.8 
Atp5b ATP synthase subunit beta, mitochondrial 28.72 25.9 9 11 56.3 
Gapdh Glyceraldehyde-3-phosphate dehydrogenase 25.09 21.62 5 8 35.8 
Krt42 Keratin, type I cytoskeletal 42  24.19 14.82 2 8 50.1 
Krt5 Keratin, type II cytoskeletal 5 22.97 14.31 3 9 61.7 
Atp1a3 Sodium/potassium-transporting ATPase subunit alpha-3 20.73 11.35 7 7 111.6 
Krt77 Keratin 77  20.61 7.53 1 11 61.3 
Igh Immunoglobulin H 19.98 14.88 3 5 52.2 
Ighm Immunoglobulin mu 19.62 13.88 5 6 49.9 
Dpysl2 Dihydropyrimidinase-related protein 2  19.52 15.56 6 7 62.2 
Krt1 Keratin, type II cytoskeletal 1 17.82 5.02 1 10 65.6 
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Krt14 Keratin, type I cytoskeletal 14 16.89 11.16 1 5 52.8 
Hspa8 Heat shock cognate 71 kDa protein 16.77 14.47 6 6 60.8 
Actb Actin, cytoplasmic 1 16.6 25.87 2 8 41.7 
Igkc Immunoglobulin kappa light chain 16.37 23.4 1 6 25.8 
Krt10 Keratin, type I cytoskeletal 10 15.92 7.66 4 6 57 
Actb Actin, cytoplasmic 1 15.37 22.4 1 7 41.7 
Igkc Immunoglobulin kappa light chain 15.26 23.74 1 6 24.1 
Krt6a Keratin, type II cytoskeletal 6A  14.92 12.3 1 6 59.3 
Krt2 Keratin, type II cytoskeletal 2 epidermal 14.73 4.53 2 6 70.9 
Krt42 Keratin, type I cytoskeletal 42 14.4 9.73 1 4 50.1 
Tuba4a Tubulin alpha-4A chain 14.15 10.71 1 5 49.9 
Krt10 Keratin, type I cytoskeletal 10 12.96 9.45 5 7 57 
Krt5 Keratin, type II cytoskeletal 5 12.66 5.52 3 4 61.7 
Nefl Neurofilament light polypeptide 12.59 10.59 3 4 57.8 
Trim21 E3 ubiquitin-protein ligase TRIM21 12.11 9.52 4 5 53.3 
4732456N
10Rik 
Uncharacterised protein 11.82 7.62 1 5 58.2 
Krt73 Keratin, type II cytoskeletal 73 11.72 4.27 2 3 58.9 
Krt14 Keratin, type I cytoskeletal 14 11.49 35.48 1 3 10.7 
Ighg2b Immunoglobulin gamma heavy chain 11.48 14.85 4 5 44.2 
Krt16 Keratin, type I cytoskeletal 16 10.85 6.61 1 4 51.6 
C1qb Complement C1q subcomponent subunit B 10.84 16.6 4 6 26.7 
Plp1 Myelin proteolipid protein 10.23 17.33 4 4 30.1 
Krt16 Keratin, type I cytoskeletal 16 9.9 10.23 1 4 51.6 
Dlat Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial 
9.83 9.35 4 5 67.9 
Krt79 Keratin, type II cytoskeletal 79 9.67 5.84 1 4 57.5 
Krt15 Keratin, type I cytoskeletal 15 9.35 9.73 1 5 49.1 
Krt76 Keratin, type II cytoskeletal 76 9.09 4.88 1 4 62.8 
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Cnp 2',3'-cyclic-nucleotide 3'-phosphodiesterase 8.25 11.25 4 4 44.6 
Prss1 Trypsin-1 8.21 8.13 1 2 26.1 
Krt2 Keratin, type II cytoskeletal 2 epidermal 8.15 4.95 3 3 70.9 
IgK Immunoglobulin kappa 8.05 16.22 1 4 12 
C1qc Complement C1q subcomponent subunit C 7.95 13.01 3 3 26 
Syn1 Synapsin-1 7.59 5.81 2 3 74.1 
Krt14 Keratin, type I cytoskeletal 14  7.4 33.33 1 2 10.7 
Syn2 Synapsin-2 7.09 5.97 1 2 63.3 
Ighg3 Immunoglobulin gamma-3 7.03 10.3 3 3 43.9 
Ighg1 Immunoglobulin heavy chain 6.94 8.21 3 3 51 
Ighv Immunoglobulin heavy chain 6.86 23.89 2 3 12.7 
Xpnpep1 Xaa-Pro aminopeptidase 1 6.85 9.47 2 3 31.6 
Rab3d Ras-related protein Rab-3D 6.67 20.75 2 3 12 
Pcmt1 Protein-L-isoaspartate(D-aspartate) O-methyltransferase (PIMT)  6.6 17.39 2 2 22.4 
C1qa Complement C1q subcomponent subunit A 6.58 10.2 2 3 26 
Prss1 Trypsin-1 6.54 8.13 1 3 26.1 
Ina Alpha-internexin  6.02 4.19 1 2 55.3 
Ighv Immunoglobulin heavy chain 5.93 10.92 1 2 13.5 
Krt79 Keratin, type II cytoskeletal 79 5.87 4.14 1 2 57.5 
Cfl1 Cofilin-1  5.72 15.06 2 2 18.5 
Sirt2 NAD-dependent protein deacetylase sirtuin-2 5.56 7.12 2 2 39.4 
Nefm Neurofilament medium polypeptide 5.46 4.89 1 2 53.5 
Acot13 Acyl-coenzyme A thioesterase 13 5.28 21.43 2 2 15.2 
Hspa9 Stress-70 protein, mitochondrial  5.25 3.68 2 2 73.4 
Igha Immunoglobulin A heavy chain 4.96 26.67 1 2 9.7 
Gnao1 Guanine nucleotide-binding protein G(o) subunit alpha 4.87 7.34 2 2 40.1 
Igk Immunoglobulin kappa 4.83 23.68 2 2 12.6 
Atp5c1 ATP synthase subunit gamma, mitochondrial 4.81 14.94 2 2 16.8 
Igkv Immunoglobulin kappa light chain 4.78 21.5 1 2 11.6 
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Ighv Immunoglobulin heavy chain 4.7 20 1 2 13.3 
Igkc Immunoglobulin kappa light chain 4.37 21.5 1 2 11.7 
Eef1a1 Elongation factor 1-alpha 1 4.18 4.11 2 2 50.1 
Tuba1b Tubulin alpha-1B chain 3.96 15.15 1 1 10.9 
Dsp Desmoplakin (DP) 3.9 0.66 1 1 261.3 
Sncb Beta-synuclein 3.65 10.53 1 1 14 
C1qa Complement C1q subcomponent subunit A 3.64 6.12 1 1 26 
Ighv Immunoglobulin heavy chain 3.33 27.97 1 2 12.9 
Sh3glb2 Endophilin-B2 3.28 3.48 1 1 41.8 
Krt78 Keratin, type II cytoskeletal 78 3.21 2.85 1 1 54.7 
Ubc Polyubiquitin-C 3.17 23.88 1 1 22.6 
Ighm Immunoglobulin M heavy chain 3.17 13.83 1 1 10.6 
Hsp90ab1 Heat shock protein HSP 90-beta 3.16 7.41 1 1 22.5 
Nsf Vesicle-fusing ATPase 3.14 1.75 1 1 82.6 
Eno1 Alpha-enolase 2.99 26.87 1 1 7.4 
Actb Actin, cytoplasmic 1 (Beta-actin) 2.94 14.88 1 1 13.5 
Camk2a Calcium/calmodulin-dependent protein kinase type II subunit alpha 2.92 6.35 1 1 21.3 
Plp1 Myelin proteolipid 2.88 5.35 1 1 26.5 
Jup Junction plakoglobin 2.84 1.61 1 1 81.7 
Gnb1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1  2.79 10.19 1 1 12.3 
Igkv5-39 Immunoglobulin heavy chain 2.62 6.11 2 2 27.8 
Mbp Myelin basic protein 2.57 8.2 1 1 13.8 
Gapdh Glyceraldehyde-3-phosphate dehydrogenase 2.54 9.72 1 1 15.5 
Krt78 Keratin, type II cytoskeletal 78 2.54 2.44 1 1 54.7 
Mbp Myelin basic protein 2.35 9.84 1 1 13.8 
Pdha1 Pyruvate dehydrogenase E1 component subunit alpha, somatic form, 
mitochondrial  
2.2 3.33 1 1 43.2 
C1qc Complement C1q subcomponent subunit C 2.1 4.07 1 1 26 
Arf3 ADP-ribosylation factor 3 2.04 22.45 1 1 5.3 
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Igkv Immunoglobulin kappa light chain 1.94 11.4 1 1 12.4 
Sugp1 SURP and G-patch domain-containing protein 1 1.6 1.71 1 1 72.6 
Sdk2 Protein sidekick-2 0 1.47 1 1 239.8 
Pemt Phosphatidylethanolamine N-methyltransferase  0 10.16 1 1 14.2 
Ccdc171 Coiled-coil domain-containing protein 171 0 1.13 1 2 152.2 
Atp1b1 Sodium/potassium-transporting ATPase subunit beta-1  0 3.62 1 1 35.2 
Arvcf Armadillo repeat protein deleted in velo-cardio-facial syndrome homolog 0 0.94 1 1 105 
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